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Abstract 
Once the blood supply is restored after heart attack by opening up the coronary artery, 
the heart is insulted by ischemia-reperfusion (I/R) injury. Direct ischaemic 
preconditioning has the ability to protect the heart against this injury for a brief period 
of time. Direct ischaemic preconditioning involves cycles of non-lethal occlusion of 
the coronary artery and releasing. Preconditioning other organs remote to the heart 
such as the limbs can protect the heart from I/R injury. This new therapeutic 
technique, known as remote ischaemic preconditioning (RIPC) is non-invasive and 
easy to apply compared to direct ischaemic preconditioning. However, we still do not 
know the mechanism through which RIPC protects the heart. This thesis explores the 
underlying mechanism of RIPC-induced cardioprotection from myocardial I/R injury, 
in experimental in vitro and in vivo models.  
 
Both intrinsic and extrinsic pathways of apoptosis contribute to cell death during heart 
attack. This thesis explores the relative contribution of the apoptotic pathways in I/R 
injury. Moreover, autophagy is associated with myocardial I/R injury sparing effect of 
direct ischaemic preconditioning and postconditioning. It is hypothesized that 
autophagy plays a key role in RIPC-mediated cardioprotection and autophagy 
stimulation provides therapeutic benefit.  
 
There is evidence that preconditioning can decrease the level of early growth 
response-1 (Egr-1), a master regulator highly expressed in heart tissue followed by 
heart attack. Once Egr-1 is highly expressed, a number of downstream inflammatory 
signalling molecules get expressed, which are well known to cause myocardial 
damage. It is shown that Egr-1 downregulation in the hind limb prior RIPC abolishes 
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RIPC-induced cardioprotection. In addition, it augmented certain a number of process 
that are attenuated by RIPC including apoptosis, cytokine expression.  
 
This work identifies a key role for Egr-1 in the signalling mechanism of RIPC 
through its regulation of a number of crucial downstream genes and cardioprotective 
pathways. In addition, it identifies IL-6 as a potential mediator of RIPC to mitigate 
myocardial I/R injury.  
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1.1 Introduction 
 
Coronary heart disease (CHD) is the leading cause of mortality in Australia claiming 
20,173 lives in 2014 or 13% of all death. CHD kills almost one Australian in every 26 
minutes and affects around 1.2 million Australians (1).  CHD is associated with 
atherosclerosis and accounts for almost 31% of the total expenditure on 
cardiovascular diseases (CVD) in Australia. According to World Health Organization 
(WHO), CHD is the major cause of deaths and disability, and in 2008 alone, caused 
7.25 million deaths worldwide (12.8% of all deaths).   
One of the main contributions of mortality and morbidity in CHD patients is acute 
myocardial infarction (AMI) (2). Acute-ST segment elevation myocardial infarction 
(STEMI), which is the result of abrupt occlusion of an epicardial coronary artery due 
to a sudden rupture of atherosclerotic plaque, most commonly affects left anterior 
descending artery (LAD) (50%), right coronary artery (30%) and left circumflex 
artery (20%) (3). Delay in the restoration of the coronary blood flow leads to cardiac 
cell death. If acute myocardial ischaemia is prolonged more than 20 minutes, 
cardiomyocyte death begins in the sub-endocardium and over time, spreads towards 
the epicardium (4).  
Most effective therapeutic intervention for these patients to reduce the myocardial 
ischaemic injury and limit the myocardial infarction (MI) size is to promptly 
revascularize the blocked coronary artery using either thrombolytic therapy or 
primary percutaneous coronary intervention (PPCI) (5). Subsequent treatment options 
focuses on reducing the modifiable risk factors such as smoking, diabetes, 
hypertension, high cholesterol, alcohol, obesity and stress (3). Despite these efforts to 
improve the mortality and morbidity rate, a large number of patients experience 
complications after AMI including contractile dysfunction, myocardial rupture, 
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arrhythmias, ventricular chamber dilation, ventricular aneurysm, mitral valve 
insufficiency due to papillary muscle dysfunction and progressive heart failure (6). 
Each year almost 1 million people in the USA suffer from MI (one MI case in every 
34 seconds) with 15% mortality rate and within the next 5 years after the onset of the 
first MI, 36% of men and 47% women over 45 years of age will die, and almost one if 
every five men and women will develop heart failure (7).  
Although restoration of the blood flow is mandatory to avoid irreversible ischaemic 
cardiomyocyte death, sudden flow of oxygenated blood to the ischaemic cardiac 
tissue increase tissue injury in excess of that caused by ischaemia alone (8-10). 
Reperfusion injury may aggravate the final infarct size by 50% (10). 
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Figure 1.1 Individual role of myocardial ischaemic injury and myocardial 
reperfusion injury to the final infarct size in STEMI patients within 24 h after 
PPCI. Black solid line and green dashed line show the contribution of myocardial 
reperfusion injury and speculative MI size following PPCI in absence of reperfusion 
injury respectively. Red dashed line shows predicted MI size without PPCI. 
Reproduced with permission from (11).  
 
1.2 Pathophysiology of myocardial ischaemic injury 
In the initial stage of myocardial ischaemia, lack of oxygen and nutrient supply results 
in biochemical and metabolic changes within the myocardium. Depletion of oxygen 
switches the aerobic cellular metabolism to anaerobic metabolism and impairs the 
oxidative phosphorylation pathway leading to mitochondrial membrane potential loss 
and subsequently decreases in production and inhibits the contractile function of the 
cardiomyocytes. This process is exacerbated by the hydrolysis of the available 
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Adenosine triphosphate (ATP) due to the reverse function of F1F0 ATPase to 
maintain the mitochondrial membrane potential. Anaerobic glycolysis results in the 
accumulation of lactic acid, which increases the intracellular acidity by reducing the 
pH (to <7.0) and leads to ionic imbalances (12). Acidic environment damages the 
mitochondria and ATP production eventually ceases (13). Accumulation of 
intracellular protons activates Na+-H+ ion exchanger and it drives the protons out of 
the cell in exchange for Na+.  The intracellular Na+ overload in conjunction with cell 
membrane depolarization reverses the Na+-Ca2+ exchanger function and expels Na+ 
out of the cell for Ca2+ into the cell (14). Eventually cellular membrane ion pumps 
such as Na+/K+  ATPase, sarcoplasmic reticulum ATPase Ca2+ (SERCA), and active 
Ca2+ excretion fail due to drop in ATP level and ion gradients across the cell 
membranes collapse leading to cell to death (15).      
 
1.3 Pathophysiology of myocardial reperfusion injury 
Timely myocardial reperfusion is indispensable to protect the viable myocardium 
from ischaemic damage, limit MI size, preserve left ventricular (LV) systolic function 
and prevent the onset of heart failure. Paradoxically, reperfusion of the ischaemic 
myocardium exacerbates cell death. Though reperfusion injury has been known since 
the 1960s, however its existence was debatable until post conditioning was proved to 
minimize the MI size when applied at the beginning of the reperfusion (13).  
1.3.1 Forms of reperfusion injury 
The inflow of fresh oxygenated blood has several detrimental consequences on the 
heart among which the first two are reversible and the second two are irreversible.  
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1.3.1.1 Reperfusion induced arrhythmias 
Reperfusion does not necessarily homogenously restore the nutrient and ATP content 
across the ischaemic zone.  Restoration of the oxygenated blood flow can cause 
differential excitability, rapid and sudden change in ion concentrations within the 
affected tissue leading to arrhythmias. In humans, reperfusion-induced arrhythmias 
are usually relatively benign in nature and easily treatable in hospitals however, can 
be a life threatening condition outside hospital(16). 
 
1.3.1.2 Myocardial stunning  
Myocardial stunning occurs in the post-ischaemic mechanically dysfunctional 
myocardium despite no irreversible damage and adequate blood flow. It is totally 
reversible and usually recovers over a couple of days to weeks. This type of 
reperfusion injury is caused by oxidative stress and/or transient calcium overload on 
the myocardial contractile apparatus (17).  
 
1.3.1.3 Microvascular obstruction 
Microvascular obstruction (MVO) is a no-flow phenomenon where blood flow to the 
previously ischaemic region cannot be fully re-established despite opening of the 
epicardial vessel(18). The major causative factors are capillary damage, reduced 
vasorelaxation, increased vasoconstriction by both swelling of the endothelial cell and 
cardiomyocytes, microcirculatory obstruction due to platelet-leukocyte aggregation an 
friable part of the atherosclerotic plaque, release of soluble thrombogenic and 
vasomotor factors (19-22).  Importantly, MVO is quite common in PPCI patients than 
previously thought. Almost 50% of the PPCI patients who appeared to have normal 
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coronary blood flow in coronary angiography have evidence of MVO as detected by 
myocardial contrast echocardiography (23, 24), myocardial perfusion nuclear 
scanning (25), or contrast enhanced cardiac magnetic resonance imaging (MRI) (26, 
27).  MVO is associated with larger MI size, lower LV ejection fraction, adverse LV 
remodelling and poor clinical outcomes (24, 28, 29). In severe MVO cases, major 
injury to the endothelium leaks blood into the interstitial space resulting in 
intramyocardial haemorrhage within the infarcted area (30). Currently there is no 
effective treatment for reducing MVO in PPCI patients. Whether MVO is an 
independent contributing factor of reperfusion induced cell death or a feature of 
severe myocardial reperfusion injury is a topic of further debate.    
 
1.3.1.4 Lethal myocardial reperfusion injury 
Reperfusion to the severely ischaemic tissue itself cause further cardiomyocyte death 
that is termed as lethal reperfusion injury (9). The major contributing factors to lethal 
myocardial reperfusion injury include oxidative stress, calcium overload, 
mitochondrial membrane potential pore (mPTP) opening, and hypercontracture (10). 
Lethal myocardial reperfusion injury may account for up to 50% of the final MI size. 
There is currently no effective treatment to minimize the reperfusion injury in PPCI 
patients.  
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1.4 Mediators of reperfusion injury  
The exact cause of myocardial reperfusion injury is elusive despite extensive research 
on this field over the decades. This is mostly because of the involvement of multiple 
complex events at reperfusion. In addition, during reperfusion there is some sort of 
interplay between cardiomyocytes and endothelial cells. As such, several theories 
have been proposed to explain the root cause of reperfusion injury.  
 
1.4.1 Oxidative stress  
Upon reperfusion, a burst of reactive oxygen species (ROS) is produced by variety of 
sources. Highly reactive ROS including hydrogen peroxide (H2O2), superoxide (O2-
), hydroxyl radical (OH-) as well as nitrate and nitrites can oxidize most of the 
biomolecules in the cell, leading to cellular injury and cell death.  Under normal 
physiological condition, ROS can be produced as part of many mechanisms. For an 
example, oxidative phosphorylation in the mitochondria produces ROS as a by-
product of normal cellular aerobic metabolism. During tissue ischaemia, a reduction 
in the ATP level occurs as a result of the degradation of adenosine diphosphate 
(ADP), adenosine monophosphate (AMP) (31), adenosine, inosine, and hypoxanthine. 
Normally, hypoxanthine is oxidized to xanthine by xanthine dehydrogenase in the 
presence of oxygen. However, during ischaemia, this oxidation process ceases 
resulting in the build-up of excess tissue level of hypoxanthine and xanthine 
dehydrogenase is converted to xanthine oxidase. In addition, xanthine dehydrogenase 
is converted to xanthine oxidase by two mechanisms: (i) oxidation of sulfhydryl 
groups on xanthine dehydrogenase (ii) calcium dependent proteolysis of xanthine 
dehydrogenase (32). Paradoxically, when oxygenated blood is reintroduced during 
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reperfusion, conversion of excess hypoxanthine to by xanthine oxidase produces 
overwhelming toxic ROS.  
ROS can be produced in cardiomyocytes, endothelial cells and neutrophils mostly by 
the mitochondria and xanthine oxidase enzyme, a major source of superoxide. 
Xanthine oxidase is not found in human and rabbit cardiomyocytes however, in these 
species superoxide can still be formed by endothelial cells and neutrophils. 
Superoxide is converted to hydrogen peroxide, which produces highly toxic hydroxyl 
radical (OH-) by the Haber-Weiss and Fenton reactions, catalysed by the increased 
level of free iron during ischaemia. During reperfusion, nitric oxide is produced in 
large burst, which coincides with superoxide burst and form the reactive 
nitrates/nitrites such as peroxynitrite (ONOO-), peroxynitrous acid (ONOOH) and 
nitrogen dioxide (12). Physiological level of ROS is controlled by endogenous anti-
oxidative enzymes such as catalase and superoxide dismutase (SOD).  However, 
overwhelming level of ROS surpasses the anti-oxidative capacity of these enzymes, 
leading to oxidative stress and can target the cellular components non-specifically. 
Uncontrolled oxidative stress may inactivate enzymes, halt protein synthesis, change 
the function of membrane transport proteins by disrupting SERCA, NA+/K+ ATPase, 
NA+/Ca2+ exchanger activity and disrupt cellular signalling (15). In addition, 
oxidative stress can damage the cell membranes by oxidizing the polyunsaturated 
fatty acids of the membrane phospholipids initiating lipid peroxidation, which affects 
the membrane fluidity and contributes to cardiomyocyte death (12).  
 
1.4.2 Calcium overload 
Intracellular calcium overload begins at the time of myocardial ischaemia. However, 
during reperfusion, intracellular and mitochondrial calcium level increases 
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dramatically. This is associated to the sarcolemmal-membrane damage, oxidative-
stress-mediated damage to the sarcoplasmic reticulum and recovery of the 
mitochondrial membrane potential. Highly selective calcium uniporter then drives the 
calcium into the energized mitochondria and subsequently opens the mPTP (33). 
Previous studies attempting to block the sarcolemmal calcium channel (34) and 
mitochondrial calcium uniporter (35), or Na+/H+ exchanger at the onset of reperfusion 
reported success with minimizing the infarct size by almost 50% (36-38), however 
multiple clinical studies did not show a similar positive outcome (39-41). Consistent 
with this finding, Avkiran’s group demonstrated that, inhibiting the Na+/H+  
exchanger at the time of PCI or reperfusion did not confer any cardioprotection (14) 
suggesting that, Na+/H+ exchanger plays its cardioprotective role specifically during 
ischaemia but not reperfusion.  
 
1.4.3 pH paradox 
Reperfusion rapidly restores ischaemia induced acidic pH to physiological level by 
washing out the lactic acid and activates the Na+/H+ exchanger and the Na+/HCO- 
symporter. This sudden pH adjustment opens mPTP and subsequently lead to rigor 
hypercontracture which can increase the fragility of the cytoskeleton and plasma 
membrane of the cardiomyocytes contributing to lethal reperfusion injury (42), 
whereas reperfusion of neonatal rat cardiomyocytes  with acidic buffer ameliorate the 
damage (43).  This effect is likely to be mediated by the inhibition of mPTP opening 
(44).  Therefore, a potential therapeutic approach would be to slow down the pH 
adjustment or after myocardial reperfusion, however, clinical studies focusing on 
inhibiting the Na+/H+ exchanger  did not show any cardioprotection (14, 41). 
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However, slowing down the reperfusion process as adopted by myocardial ischaemic 
post-conditioning has been effective is limiting the MI size (45).  
 
1.4.4 Inflammation 
Myocardial ischaemia stimulates acute inflammatory response that is amplified upon 
reperfusion.  Polymorphonuclear leukocytes  (PMN) are integral into this acute 
response to tissue injury (46). PMN adhere to the Microvascular endothelial cells and 
migrate through the endothelial cells. PMN has the capacity to produce oxygen-
derived free radicals (OFRs) when activated by proper stimuli (47, 48).  PMN is 
accumulated into the infarct zone during first 6 h after AMI and start migrating into 
the cardiac tissue during the next 24 h. This transmigration process is facilitated by 
the cell adhesion molecules specially the selectin family which are expressed on 
endothelial cells within the first few min of reperfusion and reaches the maximum 
level by 20 min.   Leukocytes express CD-11 and CD-18, which aid its adhesion to 
the endothelium (13). Other molecules such as intercellular cell adhesion molecules 
(ICAM-1, ICAM-2), Endothelial leukocyte adhesion molecule-1 (ELAM-1), 
thromboxane A2 (TXA2), leukotriene B4, endothelin, platelet activating factor (PAF), 
cytokines (Tumour necrosis factor alpha  (TNF-α), Interleukin (IL)-1, IL6, IL-10)), 
complement system (C3a and C5a) play significant roles in the leukocyte-endothelial 
cell interaction (49). Activation of the complement pathways cleaves C5 to pro-
inflammatory protein fragments C5a and C5b. C5a is associated with 
vasoconstriction, vascular leakage and leukocyte activation while C5b-9 is associated 
with cell lysis (50). Inhibiting neutrophils by depleting leukocytes from the blood 
(51), using antibodies against P-selectin (52), CD-11 and CD-18 (53), ICAM-1 (54) 
and pharmacologically blocking the complement activation (55) reduced the 
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myocardial infarct size by up to 50%.  However, therapeutic benefits of neutrophil 
inhibition could not be replicated in clinical studies (56-60).  It is not clear why there 
was lack of efficacy in clinical setting, nonetheless, it is possible that the almost 
instantaneous activation of the complement pathway in STEMI limited the efficacy of 
the clinical studies that intervene few hours after the onset of reperfusion (50). In the 
initial 24 h post MI neutrophils accumulate in the infarct zone to digest infarcted 
tissue and remove dead cells and promote extracellular matrix (ECM) degradation. 
Subsequently, monocytes and macrophages regulate the inflammatory response to 
heal the injury in the weeks post MI (61). Monocytes can express two CD markers, 
CD-14 and CD-16. Almost 85% of the monocytes are CD-14+ (classical monocytes) 
and CD-14+/CD-16- monocytes have myeloperoxidase (MPO) releasing 
inflammatory properties and it also expresses monocyte chemotactic protein 1 (MCP-
1) binding receptor, C-C chemokine receptor type 2 (CCR2). Though CD-14+/CD-
16- monocytes also express CCR2 but at a lower level and these subset of monocytes 
has reduced phagocytic capacity and produces less ROS (62).  Increased level of 
circulating CD14+/CD-16- monocyte is an indication of adverse LV remodelling and 
impaired cardiac function (63). Biphasic monocyte response is observed after AMI 
with circulating CD-14+ monocytes reaching its peak level by day 3, followed by 
CD-16+ monocytes peaking on day 5 (64).   
The ideal therapeutic strategy would be to modulate the timing and extent of 
inflammatory cell recruitment to emphasize tissue repair and also to keep 
inflammation to an optimum level to remove necrotic cells, while setting the 
framework for collagen synthesis and angiogenesis without compromising tissue 
integrity.  
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Figure 1.2 Mediators of myocardial ischaemia-reperfusion (I/R) injury. During 
AMI, several biochemical and metabolic changes occur in the heart.  These changes 
include mitochondrial re-energization, overwhelming production of ROS, intracellular 
calcium overload, rapid pH adjustment and inflammation, all of which interact with 
each other to mediate cardiomyocyte death through mPTP opening and 
hypercontracture of the myofibrils. Reproduced with permission from (10), copyright 
Massachusetts Medical Society.  
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1.5 Modes of cell death in I/R injury 
The major form of death in myocardial ischaemic injury is necrosis. However, in I/R 
injury, apoptotic and autophagic cell death is also documented.  
 
1.5.1 Apoptosis 
Apoptosis or programmed cell death is a tightly regulated energy dependent process. 
Apoptosis is different from other types of cell death based on its biochemical and 
morphological features. Morphological features of apoptosis are cell shrinkage, 
plasma membrane blebbing, hypercondensation of chromatin. Biochemical 
alternations of apoptosis includes cleavage of chromosomes into nucleosomal 
fragments, packaging of cellular components into membrane bound ‘apoptotic bodies’ 
(65). Apoptotic bodies containing processed organelles are removed by macrophages 
via phagocytosis, and therefore does not generally stimulate an inflammatory 
response (66).     
 
1.5.1.1 Mechanism of apoptosis 
Apoptosis is the major form of cell death and its molecular mechanism is well 
documented. Identification of the apoptotic pathway and apoptotic stimuli is critical 
and facilitates better understanding of the pathogenesis of disease. This may aid in the 
development of new therapeutic strategy targeting specific pathways or genes. 
Mammals have two key apoptotic pathways: intrinsic (mitochondrial) pathway and 
extrinsic (death receptor) pathway (67). Apoptosis requires active caspases. Caspases 
are a family of cysteine proteases that usually cleave after an aspartate residue in their 
substrates (68). The family of caspases can be divided into two groups: initiator 
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caspase and executioner caspase. Initiator caspases (caspase 8, caspase 9, and caspase 
10) exist in an inactive monomer form in cells and are not activated by cleavage. 
Instead, initiator caspases can auto-cleave and gets activated under apoptotic 
conditions (69). For an example, caspase 9 gets activated by apoptosome formation 
(70).  Adaptor molecules recruit these caspases into the caspase-activation platforms 
and brings the monomers into close proximity, causing a structural change to create 
active sites.  
 
The executioner caspases (caspase 3, caspase 6, and caspase 7) execute cellular 
destruction and are mostly responsible for the phonotypical changes during apoptosis. 
Executioner caspases exist as dimer in cells and are activated by the initiator caspases 
through an internal cleavage into large and small subunits, leading to caspase cascade. 
Caspase 6 is cleaved by caspase 3 and caspase 7, whereas caspase 3 and caspase 7 are 
activated by the initiator caspases (71). Once activated, executioner caspases can 
cleave over 1000 proteins that modulates the function of these proteins and promotes 
cellular changes associated with apoptosis (72). Though cleavage of executioner 
caspases activates them, cleavage of initiator caspases do not always indicate its 
activation (73).  
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Figure 1.3 Intrinsic and extrinsic pathways of apoptosis. Intrinsic apoptotic stimuli 
such as DNA damage, endoplasmic reticulum (ER) stress cause apoptosis via 
mitochondrial outer membrane permeabilization while extrinsic pathway is initiated 
by death receptor ligands. Reprinted by permission from Macmillan Publishers Ltd: 
Nature Reviews Molecular Cell Biology  (74), copyright (2010). 
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1.5.1.1.1 Intrinsic pathway of apoptosis 
The intrinsic or mitochondrial pathway of apoptosis is the most common mechanism 
of apoptosis in vertebrates. Various non-receptor mediated stimuli including DNA 
damage, ER stress, and lack of growth factors produce intracellular signals that act 
directly on various targets in the cell and initiate intrinsic pathway.  
Several intracellular proteins recognize the stress signal and transfer these signals to 
the mitochondria (75). These stimuli change the inner mitochondrial membrane and 
open the mPTP leading to the mitochondrial membrane potential loss and 
mitochondrial outer membrane permeabilization (MOMP) (75). MOMP is a tightly 
regulated process and controlled by the three broad classes of Bcl2 family proteins: 
proapoptotic (Bax and Bak), anti-apoptotic (Bcl2, Bcl-xl, Mcl1), and BH3 only 
proteins (Bid, Bim, Bad, and Noxa). Without activation of Bax and Bak, activation of 
BH3 only proteins or suppression of anti-apoptotic proteins alone is not sufficient for 
apoptotic cell death (76) suggesting Bax and Bak are regulators of apoptosis. 
Following apoptotic stimuli, Bax translocates from the cytosol to the mitochondrial 
outer membrane, whereas Bak does not require translocation as it constantly resides in 
the mitochondria outer membrane (77, 78). MOMP releases proteins such as 
cytochrome C (Cyt C), apoptosis inducing factor (AIF) and endonuclease G from the 
mitochondrial intermembrane space into the cytosol (75, 79). In the cytosol, Cyt C 
binds to Apoptotic protease activating factor 1 (Apaf-1) and forms apoptosome (80). 
This interaction changes the conformation of Apaf-1 and exposes its caspase 
activating and recruitment domain (CARD) facilitating the activation of caspase 9. 
Activated caspase 9 in turn activates executioner caspase 3 and caspase 7, and 
initiates caspase cascade leading to apoptosis (81).  
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1.5.1.1.2 Extrinsic pathway 
Extrinsic pathway signalling is initiated by the transmembrane receptor-extracellular 
ligand interaction. These ligands and their best correspond receptors include tumour 
necrosis factor (TNF-α)/TNF-R1, Fas ligand (Fas-L)/Fas (also called CD-95/Apo-1), 
and TNF-related apoptosis inducing ligand (TRAIL)/TRAIL-R1/2 (82-89).  These 
ligands contain cysteine rich extracellular domain and a cytoplasmic domain of 80 
amino acids, known as Death Domain (DD), in their intracellular region. Death 
domain helps to transmit the death signal from the cell surface to the intracellular 
signalling pathways. When the receptors bind to their ligand, clustering of the 
receptors recruit death domain containing adaptor proteins. For an example, Fas-L 
binding to Fas receptor recruits adapter protein Fas-associated death domain (FADD) 
and TNF ligand binding to TNF receptor recruits TNF receptor associated death 
domain (TRADD) (90, 91). The adaptor proteins contain another interaction domain, 
Death Effector Domain (DED). The DED of pro-caspase 8 binds to the DED of 
FADD and brings the caspase 8 monomers in close proximity for protease activity. At 
this time, a death inducing signalling complex (DISC) is formed and pro-caspase 8 is 
autocleaved via two-step mechanism. Pro-caspase 8 is first cleaved between large and 
small subunits and this cleavage stabilizes active dimer, which is essential for the 
homodimer activity in extrinsic pathway. The second cleavage occurs between large 
subunit and prodomain and it facilitates its release from DISC (82, 92, 93).  
 
Active caspase 8 can promote apoptosis by cleaving and activating caspase 3 and 
caspase 7 in type I cells. In contrast, in type II cells, mature caspase 3, caspase 9 and 
caspase 7 are regulated by X-linked inhibitor of apoptosis (XIAP) through its 
ubiquitination domain, which signals for proteosomal degradation of active 
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executioner caspases, and block apoptosis (94-96).  In these cells, BH3-only protein 
Bid is activated by cleaved caspase 8, which in turn activates Bax and Bak to promote 
MOMP. MOMP releases IAP antagonists, SMAC and Omi (also known as Diablo 
and HtrA2 respectively) to neutralize XIAP to allow the proceeding of apoptosis.   
 
1.5.2 Autophagy 
Autophagy is an evolutionary conserved process from yeast to human involved in 
degradation of long-lived proteins and dysfunctional organelles. It maintains 
intracellular homeostasis and also contributes to the adaptive response to extrinsic and 
intrinsic stresses. A key feature of autophagy is the dynamic membrane restructuring 
that forms double membrane autophagosomes. The autophagosome formation process 
is rapid. In yeast, it is estimated to take around 4-5 min and one autophagy cycle from 
autophagosome formation to its degradation takes 7-9 min (97). In mammals, 
autophagosome formation is estimated to take 5-10 min (98) (99). The diameter of 
autophagosome is around 0.3-0.9 µm in yeast (100) and 0.5-1.5 µm in mammals 
(101).   
 
Autophagic cell death is considered as a form of programmed cell death, which is 
morphologically distinct from apoptosis and caused by excessive cellular autophagy. 
Autophagic cell death is accompanied by formation of double membrane autophagic 
vacuole, autophagosome. One of the key morphological difference between 
autophagy and apoptosis is the early degradation of organelles while preserving the 
cytoskeletal elements till late stages in autophagy whereas during apoptosis, 
cytoskeletal elements collapse in the early stage while preserving the organelles till 
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late stages. In addition, autophagic cell death is associated with very late caspase 
activation and DNA fragmentation without causing any inflammatory response (102).  
It has been widely considered that, autophagy has both pro-death and pro-survival 
mechanism. Depending on the nature and extent of stress, autophagy can mediate cell 
survival or cell death signalling.  
 
Autophagic activity has been reported in each of the diverse and complex tissue and 
cell types of the circulatory system. In normal physiological conditions, autophagy 
functions at low levels in the heart contributing to myocardial homeostasis through 
cleaning up misfolded, long-lived, damaged proteins and organelles. During 
ischaemia, nutrient and oxygen supply to the myocardium drops, resulting in 
cardiomyocyte dysfunction and accumulation of metabolic by-products such as lactic 
acid, which causes intracellular acidosis (103, 104). In normal physiological 
condition, mitochondria produce ATP via oxidative phosphorylation. However, 
during ischaemia, lack of oxygen and glucose supply impairs oxidative 
phosphorylation mechanism resulting in decrease in ATP production and increase in 
AMP/ATP ratio. Energy depletion activates the cellular energy sensor Adenosine 
monophosphate-activated protein kinase (AMPK). Activation of AMPK 
phosphorylates TSC2, leading to the suppression of mTOR (mammalian target of 
rapamycin), activity, followed by indirect activation of ULK1, there by up-regulating 
activation of autophagy pathway (105-108). Recent studies suggest that, AMPK 
activates autophagy through directly phosphorylating ULK1, rather than through 
mTOR inhibition (109). Autophagy recycled free fatty acids and amino acids to 
generate ATP through tricarboxylic acid cycle (TCA cycle) during cardiac ischaemia. 
Matsui and colleagues showed that, myocardial ischaemia-induced autophagy 
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activation was inhibited in dominant negative AMPK overexpressing transgenic mice. 
In addition, absence of AMPK caused a larger infarct size in mouse hearts after 
ischaemia. They also showed that, glucose deprivation led to strong activation of 
AMPK and inactivation of mTOR correlating with induction of autophagy, whereas 
inhibition of autophagy in glucose deprived cells decreased ATP production and 
aggravated cell death suggesting that AMPK is required for autophagy activation in 
cardiomyocytes (110). During reperfusion phase, AMPK is no longer activated and 
autophagosomes formed during reperfusion is unlikely to be regulated by AMPK. 
During reperfusion, enhanced autophagy is correlated with dramatic increase in 
Beclin-1 protein expression in the myocardium, indicating that Beclin-1 plays a 
pivotal role in autophagy in the reperfusion phase. Overexpression of Beclin-1 
increased autophagic activity during I/R in vitro (111) where as Beclin-1 silencing by 
siRNA transfection and Beclin-1+/- mice significantly attenuated I/R-mediated 
autophagy up-regulation (110, 112). Matsui and colleagues suggested that, Beclin-1 is 
a rate-limiting factor of autophagosome formation from the available LC3-II in 
cardiomyocytes (110). The signaling mechanism by which I/R upregulates beclin-1 
expression remains elusive, however Beclin-1 localizes to the ER in mammalian cells, 
therefore ER stress during I/R might be an inducer of Beclin-1-mediated autophagy 
(113). In addition, TNF-α upregulates Beclin-1 expression and subsequent autophagy 
through JNK (c-Jun N-terminal kinase) pathway in vascular smooth muscle cells 
(114). As JNK is activated during reperfusion (115-118), Beclin-1 may be 
upregulated by JNK during reperfusion in the heart. Conversely, cardioprotective 
peptide, Urocortin, reduced the expression of Beclin-1 through PI3K-Akt dependent 
mechanism while suppressing autophagy in cultured cardiomyocytes (112).  
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Figure 1.4 Steps of autophagy machinery. Phagophore expands and sequesters 
cytoplasm and forms a double membrane autophagosome. Autophagy fuses with acid 
hydrolases (AH) containing lysosomes. The fused compartment degrades its contents.  
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Drug 
Discovery (119), copyright (2007). 
 
1.5.2.1 Autophagosome formation 
Autophagy pathways can be divided into series of steps: Induction, cargo selection, 
nucleation, expansion, maturation and degradation.  Genetic analyses in yeast have 
identified a family of Atg genes termed as Atg1 to Atg35 and one subset of these Atg 
proteins are essential for one or more steps in the autophagy process denoted as the 
‘core’ autophagic machinery (120).  
 
1.5.2.1.1 Induction 
In both yeast and mammals, the formation of autophagosome starts with phagophore, 
a double membrane structure at phagophore assembly sites (PAS). The sources of this 
double membrane is not clear, however several sources of autophagosome membrane 
` 
 
 
Page | 23  
 
have been suggested including endoplasmic reticulum (121-123), golgi apparatus 
(124, 125), mitochondria (126) and plasma membrane (127, 128). Phagophore 
formation requires activation of phosphoinositide 3-kinase (PI3K) Vps34 which is 
part of a large macromolecular complex along with Beclin-1 (mammalian Atg6), 
Atg14, Vps 15 and form PI 3-phosphate (PI(3)p) (129). Mammalian Atg1 orthologues 
ULK1 and ULK2, Atg13 and focal adhesion kinase (FAK)-family interacting protein 
of 200 KDa (FIP200) regulates the activity of this complex (129).  Most Atg proteins 
are cytosolic where as Atg9 is the only conserved transmembrane protein and is 
essential for autophagosome formation (130). Atg9 is one of the first proteins 
associating with PAS and most of the Atg proteins require Atg9 for their localization 
at PAS (131) in yeast. Atg9 also localizes to the peripheral sites of PAS and can cycle 
between the two sites. This cycling relies on upon the Atg1 kinase complex (132) and 
also on the capacity of Atg9 to multimerize (133). Atg11, Atg23, and Atg27 manage 
the anterograde transport of Atg9 to PAS (134-137), and the Atg1-Atg13 complex, 
Atg2, Atg18, and PidIns3K complex are included in its retrograde transport (132). 
Self-interaction of Atg9 is essential for its retrograde transport to Atg9 as mutants are 
defective in cycling and multimerization and cannot function as a carrier in supplying 
membrane for autophagosome formation (132, 133). In mammals, Atg9 partially 
localizes to the trans-Golgi network (TGN) and endosomes, and transports from TGN 
to late endosomes. In mammalian cells, ULK1 and Atg13 regulate its redistribution 
from the TGN to late endosomes (138, 139).  
 
1.5.2.1.2 Elongation of isolation membrane 
A key step of autophagy is the elongation of the membrane sac, called isolation 
membrane. Many Atg proteins are involved in this process. Elongation of the 
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isolation membranes into autophagosomes is regulated by two ubiquitylation-like 
reactions. In the first reaction, ubiquitin like molecule Atg12 is activated by Atg7, 
which works as a E1 ubiquitin-activating enzyme and transferred to Atg5 in an E2-
like reaction by Atg10. The Atg12-Atg5 protein conjugation system, though 
discovered in yeast, is well conserved in eukaryotes (140-143).  Atg5-Atg12 Is mostly 
present in the conjugated form in mammals and unconjugated form is almost absent in 
mammalian cells (98).  The Atg5-Atg12 complex covalently binds to Atg16L, 
dimerizes and forms a complex with the exterior membrane of the phagophore (142, 
144), but detaches from the completed autophagosomes (145).The second 
ubiquitylation-like reaction conjugates microtubule-associated protein 1 light chain 3 
(MAP1-LC3; also known as Atg8 and LC3) to the lipid phosphatidylethanolamine 
(PE). Atg4 cysteine protease cleaves LC3 at its C-terminus to form the cytosolic form 
of LC3, LC3-I, which is then activated by Atg7 in an E-1 like reaction. The activated 
LC3-I is conjugated to PE in an E2-like reaction by Atg3 to form the autophagosome 
bound LC3-II (146).  There is evidence that the Atg5-Atg12-Atg16L dimer complex 
modulates the LC3-I conjugation to PE in an E-3 like fashion (147) and also directs 
the location of LC3 lipidation (148).  LC3-II is located in both exterior and the lumen 
of the autophagosome.  Luminal LC3-II is degraded by the fusion of autophagosome 
with lysosomes, while LC3-II on the cytoplasmic surface can be delipidated and 
recycled. LC3-II is only associated with autophagosomes and not with any other 
vesicular structures. Therefore, LC3-II levels correlate with the autophagic vacuole 
numbers (149). LC3-II can also facilitate membrane tethering and hemifusion to 
expand the autophagosome membranes, which suggest that LC3 may support the final 
fusion of the pre-autophagosomal double-membrane ‘cups’ into fused vesicles (150).  
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1.5.2.1.3 Fusion with the lysosome 
 
After completion of the fusion of the expanding ends of phagophore membrane, the 
autophagosomes fuse with lysosomes forming the ‘autolysosome’ (151).  It has been 
suggested that, autophagosomes fuse with early and late endosomes before fusing 
with the lysosomes to deliver cargo and components of the membrane fusion 
machinery. It also changes the autophagic vesicle environment into acidic 
environment by lowering +its pH prior distributing the lysosomal acid proteases (152) 
and this process is dependent on the GTP-bound small G protein, Rab7 (153, 154). 
Lysosomal protein cathepsin proteases B and D are required for both autophagosomal 
turnover and autolysosome maturation (155).  
 
1.5.3 Necrosis 
Necrosis can simply occur as a result of unrepairable and excessive damage that the 
cell integrity is compromised. High temperature, freeze-thaw, infarction, toxins or 
mechanical stress can cause excessive stress. Morphogical features of necrosis 
includes cell swelling, plasma membrane rupture followed by cytoplasmic leakage 
and condensation of chromatin (156). This type of cell death is not energy   dependent 
and does not activate any particular cell death signaling pathways. Necrotic tissue is 
rapidly infiltrated by leukocytes, mostly neutrophils followed by accumulation of 
monocytes. Necrotic cell death stimulates inflammation (157). It is important to note 
that, ruptured plasma membrane can be observed in late stage of apoptosis or 
autophagic cell death when phagocytosis fail to clear the dead cells from the system. 
This type of necrosis is called secondary necrosis and is a natural outcome of 
complete apoptosis (158).  
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1.6 Cardiovascular pathobiology of Early growth response (Egr)-1 
 
Cardiovascular disease progression involves multiple critical pathways and can be 
regulated by a number of genes that gets activated or deactivated in response to 
external or internal stimuli. Among the early set of rapidly expressed genes Egr-1, c-
myc and c-fos (159-162) are crucial and act as transcriptional regulators of different 
biological pathways. 
 
Egr-1, also known as NGFI-A, Zif268, Krox24, TIS8, is a zinc finger transcription 
factor (163). This 80-82kDa nuclear phosphoprotein is a product of Egr gene located 
on human chromosome 5q23-q31. This locus codes for two exons and one intron, 
covering approximately 3.6 kb (164). The domain of Egr-1 is made of three Cys2-
His2 zinc fingers, located between amino acids 332 to 4116 towards the carboxyl 
terminus. Egr-1 preferentially binds to GC-rich elements, and the DNA bound Egr-1 
regulates gene expression through different mechanisms involving co-activators and 
corepressors. Structural analysis of Egr-1 gene has identified a resilient 
transactivation zone spanning between amino acids 1 and 281 towards the amino 
terminus (165). Egr-1 contains an inhibitory domain of 34 amino acid residues long, 
located at the 5’ zinc finger-binding domain (3). Egr-1 is promptly and transiently 
expressed in different cells by a variety of extracellular stimuli. In cultured 
cardiomyocytes, a number of hormonal stimuli such as norepinephrine (166-168), 
angiotensin II, endothelin-1 (169), transforming growth factor beta (TGF-) (170), 
fibroblast growth factors (171) can mediate the expression of different transcriptional 
factors through binding to membrane receptor and facilitate morphological changes 
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and regulate the activation of different genes (166, 172). Transcriptional regulators 
of Egr-1 can bind to repression or transactivation site and regulate the gene 
expression in either negative or positive way respectively (173).  
 
Egr-1 plays a crucial role in cardiovascular pathology as a master regulator of 
multiple genes. Multiple stimuli, growth factors and cytokines upregulate Egr-1 
and facilitate the formation of atherosclerosis, cardiac hypertrophy, neointimal 
hyperplasia of injured blood vessel, coronary allograft vasculopathy and 
transplant rejection, angiogenesis. Egr-1 null mice and rabbit models as well as 
Egr-1 inhibitors such as antisense oligonucleotides, siRNAs, DNAzymes have 
helped to understand Egr-1 regulated pathways to some extent. However, our 
understanding of how Egr-1 links to the cellular level and initiates pathological 
changes is not clear yet. Knowledge on Egr-1 linked positive and negative 
feedback loop controlled by NAB-1, NAB-2 and a possible regulator Atf-3 is 
limited. Further studies are mandatory especially in larger animal models to 
pinpoint the specific roles of Egr-1 in cardiovascular pathological processes. 
Once the molecular process of Egr-1 regulation is well understood, better clinical 
options can be implemented for Egr-1 mediated cardiovascular diseases.  
 
1.6.1 Atherosclerosis 
Atherosclerosis is a multifactorial progressive disease of the arterial wall and 
demonstrated by focal development of atherosclerotic lesion or plaque within 
the arterial wall.  Smooth muscle cells (SMCs) and mononuclear phagocytes 
(MPs) as well as inflammatory cells such as macrophages, T cells, dendritic cells, 
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and mast cells accumulate in the lesions as the disease progresses(174). Multiple 
risk factors including dyslipidemia, incriminated vasoconstrictor hormones, 
hyperglycemia, pro-inflammatory cytokines and smoking facilitate the 
progression of almost 50% of the arterial lesions. In the absence of systemic 
hypercholesterolemia, stimulated T lymphocytes, certain heat shock proteins, 
plasma lipoprotein induces inflammation that help the atherosclerotic plaque 
formation (175, 176). Chronic inflammation can rupture the plaque and may 
lead to ischemia and myocardial infarction(177, 178). 
 
Evis Harja and colleagues(179) provided mechanistic insight into the link 
between Egr-1 and chronic vascular inflammatory disease in vivo. The 
atherosclerotic lesion area and complexity is a progressive process and largely 
depends on Egr-1. Dramatic reduction of 2.5-fold in atherosclerotic area has 
been observed in Egr-1 and apoE deficient mice at 14 weeks compared to apoE 
alone deficient mice. The area of the lesion decreased by almost 7-fold at 28 
weeks. However, the level of total cholesterol and triglyceride were not different.  
 
Egr-1 is expressed in the areas of macrophage infiltration, as well as in 
endothelial cells and smooth muscle cells of the fibrous cap. OxLDL use a variety 
of molecular pathways to induce vascular stress and atherogenic mechanism, 
which in turn may upregulate Egr-1 expression in MP through MEK-ERK1/2 
MAP kinase pathway(179). Moreover, increased level of isoprostane has been 
detected in atherosclerotic lesions and 8-iso-PGE2, an isoprostane, has been 
found to stimulate the binding of monocyte to endothelial cells via Egr-1 
dependent mechanisms(180). Approximately five-fold increase in Egr-1 
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expression in human atherosclerotic tissue compared to adjacent media has 
been reported by genome expression array conducted by McCafffrey and 
colleagues(181). They also found that, fat fed LDL receptor deficient mice shows 
high expression of Egr-1 in atherosclerotic lesions. Previously, Brand and 
colleagues indicated towards the role of Egr-1 in lipid metabolism. They 
identified two polymorphism of Egr-1 gene, one of which helps to lower plasma 
levels of total cholesterol, LDL cholesterol and apolipoprotein B(182).  
 
Claudia Albrecht and colleagues studied the role of bone marrow derived 
hematopoietic macrophage to atherogenesis and found Egr-1 to play a significant 
role. Transplanting bone marrow from Egr-1 deficient mice into lethally 
irradiated LDL receptor null mice presented significant reduction in the necrotic 
core size of the atherosclerotic lesion and increased thickness of the fibrous cap 
when compared with the wild type control mice. Apart from this, VCAM-1 
expression, an immunoglobulin like adhesion molecule highly expressed by 
activated endothelial cells of the vessel and initiates atherosclerotic lesion 
development by recruiting monocytes(183-185) and prompts the 
transformation of monocytes to macrophages within the vessel wall(186), was 
reduced within the atherosclerotic lesions of the aortic sinus and thoracic aortas. 
Microarray analysis has previously proved that VCAM-1 is regulated by Egr-
1(187). VCAM-1 expressed by macrophages contributes to the formation of foam 
cell aggregates, which help to develop the lipid core of the lesion in early 
atherosclerosis(178, 188).   Finding of Dansky et al(183) strengthens the 
contribution of VCAM-1 to atherogenesis as partial VCAM-1 disruption leads to 
decreased fatty streak formation in vivo. 
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Pro-inflammatory genes such as TNF(189), IL-2(190, 191), IL-1(179), 
TF(179), PAI-1(179), MCP-1 and ICAM-1(192) have been identified to be as Egr-
1 target genes. MCP-1 is a strong chemotactic factor for monocytes and initiates 
and facilitates the development of atherosclerotic lesions in hyperlipidemic 
mice(193, 194). Tissue factor (TF) plays a key role in the milieu of plaque 
stability and rupture(195). CD40 ligand induced expression of tissue factor in 
human endothelial cells is mediated by Egr-1(196-198). However, elevated 
expression of Egr-1 in human atherosclerotic cells suppress vascular repair 
mechanism by down regulating transforming growth factor- type II 
receptor(199). Some studies have been previously conducted to establish a link 
between post-infectious Egr-1 expression and atherosclerosis. Bea et al(200) 
previously showed that Chlamydia pneumoniae infection could induce tissue 
factor (TF) expression by activating Egr-1 in macrophages within 1 h via MEK-
ERK1/2 MAP kinase pathway. Similar type of experiment was conducted by 
Maass et al(201), who observed significant increase of vascular endothelial 
growth factor (VEGF) mRNA expression in healthy human blood monocytes 
infected with Chlamydia strain CV-6, isolated from a 68 year old man with 
coronary restenosis(202). Increased VEGF expression within the blood vessel is 
associated with increased recruitment of mononuclear cells and facilitates the 
development of atherosclerotic lesion formation(203). In line with this, Maass et 
al(201) showed that post-infection Egr-1 expression is not limited to Chlamydia 
pneumoniae, but can also be distinctively upregulated at a rapid rate by 
Salmonella enterica enteritidis and Staphylococcus auerus once co-incubated with 
blood monocytes. However, more evidence is required to prove the predisposing 
role of multiple pathogens in the development of atherosclerosis in humans.  
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1.6.2 Cardiac hypertrophy 
Three known hypertrophic stimuli endothelin-1, angiotensin-II and norepinephrine 
(204-207) are distinctively recognized to induce Egr-1 expression at mRNA and 
protein level (208) in rat cardiac myocytes. In addition, loss of Egr-1 expression 
inhibits hypertrophic changes (209). Consistent with this, inhibition of angiotensin 
generating enzyme ACE (angiotensin converting enzyme) in spontaneously 
hypertensive rats have also shown to decrease cardiac hypertrophy(210, 211). 
Similarly, use of antisense oligonucleotide against Egr-1 mRNA has proved to be 
effective against adult cardiomyocytes growth(212) and indicates towards the 
potential role of Egr-1 in cardiac hypertrophy(208). Endothelin 1 (ET-1) exposure 
results in multiphasic gene expression in cardiomyocytes and ET-1 induced ERK1/2 
pathway is involved in cardiomyocyte hypertrophy(213, 214). Atf3, a member of the 
ATF/CREB [CRE (cAMP –response element)- binding protein] family   proteins is a 
transcription repressor of Egr-1 in ET-1 induced pathway. Co-ordinated Atf3 
expression along with Egr-1 is necessary for ET-1 induced hypertrophic growth of 
cardiomyocytes as absence of Atf3 results in abnormal hypertrophic growth(215). 
Interestingly, overexpression of Atf3 has been reported to be associated with 
hypertrophic changes in vivo(216). Hence, Atf3-Egr-1 negative feedback loop might 
be of broad importance in terms of physiological growth of cardiomyocytes and in 
vivo growth response. Egr-1 expression is also negatively regulated by NGFI-A 
binding protein 1 (NAB-1)(217). NAB-1 binds to the R1 domain of Egr-1 and 
negatively regulates Egr-1 induced pathologic cardiac hypertrophy(218). Buitrago et 
al. engineered 1- adrenergic receptor overexpressing transgenic mice and gene array 
analysis showed inducible expression of transcriptional corepressor NAB-1 in the LV 
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of the myocardium of these mice. Even normal mice showed upregulation of NAB-1 
in the left ventricle upon pressure overload. Though activated adregenic receptor 
stimulates Egr-1 interaction with DNA in normal mice, NAB-1 overexpressing mice 
did not show similar interaction(219). Egr-1 is minimally expressed in left ventricular 
myocardium of normal mice but expression in stimulated upon adrenergic stress and 
pressure overload. Adrenergic stimulation is associated with ventricular 
hypertrophy(220). But, Buitrago et al. reported that, -adrenergic stimulation did not 
cause hypertrophy in NAB-1 transgenic mice as well as in Egr-1 null mice.  
 
1.6.3 Neointimal hyperplasia of injured blood vessel 
SMC and endothelial cells of the injured blood vessel produce excess amount of 
extracellular matrix(221). These SMCs also proliferate at a rapid rate and migrate to 
the intimal layer of the blood vessel, which in turn promote neointimal 
hyperplasia(221). 
 
Egr-1 is normally expressed weakly in the arterial wall. However, its expression in the 
vascular SMC and endothelial cells can be stimulated by mechanical injury, fluid 
shear stress, hypoxia, and by growth factors such as PDGF, FGF-1, FGF-2, and by 
coagulation factors like angiotensin-II and thrombin (163),(222).  Egr-1 is associated 
with cell proliferation and controls the expression of different proliferation related 
genes (163). Possible role of Egr-1 as a mediator of SMC proliferation and neointimal 
hyperplasia formation has been demonstrated by using ED5, a DNA based 
catalytically active molecule with Egr-1 mRNA specific catalytic core. Transfection 
of rat aortic SMC with phosphorothioate linked ED5 showed significant reduction in 
cell proliferation and cell cycle controlling switch-cyclin D1 level and arrest of 
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G0/G1 phase at 24 h (221). cDNA chip analysis by McCaffrey et al proved the 
dependency of cyclin D1 expression on Egr-1 gene(181). TGF-β1, a proliferation-
associated gene, has a specific recognition site for Egr-1 binding near the promoter 
region(223). TGF-β1 promoter bound Egr-1 can regulate its expression (221) and 
once expressed, TGF-β1 can work in a positive feedback loop to stimulate Egr-1 
expression(224). Increased activity of TGF- β1 following restenosis in both animal 
(225) and human blood vessels(226) has been previously confirmed. Interestingly, 
antibodies against TGF- β1 inhibited neointimal hyperplasia in rat balloon injury 
model(227), which further indicates the role of Egr-1 in neointima formation.  
1.6.4 Coronary allograft vasculopathy and transplant rejection 
Total organ transplantation is most often the only therapeutic option for end-stage 
organ disease patients. However, one of the major limitations behind the long-term 
survival of allograft function and survival depends on the chronic rejection of the 
transplanted organ. In cardiovascular transplantation, this disease process is known as 
cardiac allograft vasculopathy (CAV). Almost half of the transplant recipients 
develop CAV within five years of the transplant (228). Not only vascular injury but 
also I/R injury and prolonged preservation of donor organ can trigger or accelerate the 
CAV development process (229),(230). CAV pathogenesis involves immune, non-
immune and autoimmune mechanisms(231, 232). However, immune factors are the 
most important causes as CAV occurs within the donor’s arteries, but not in the 
recipient’s arteries(233). In allograft chronic rejection, alloimmune response attacks 
the epithelium, arteries and capillaries and replaces the normal parenchymal tissue of 
the allograft with fibrous scar tissue(231). Though CAV resembles atherosclerosis, 
the pathological features are markedly distinct(234).  Intimal hyperplasia is a 
pathologic characteristic of chronically rejected cardiac allograft(235). However, the 
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intimal proliferation in CAV is concentric rather than eccentric and is diffused into 
both proximal and distal epicardial coronary trees(236-238). Apart from this, calcium 
deposition in blood vessel and disruption of the elastic lamina are common features of 
atherosclerosis, which are uncommon for CAV(239). But, the Adult SMCs are in a 
contractile state and maintains the tension and tone in the smaller blood vessels. 
These SMCs have little secretory function, whereas fetal arterial cells secrete various 
cytokines and growth factors, which help these cells to proliferate and migrate(235). 
Egr-1 is an early transcription factor that regulates inflammatory and thrombotic 
cascades in ischaemic blood vessels(230, 240, 241). Egr-1 also initiates 
dedifferentiation of SMCs and vascular remodeling following cardiac 
transplantation(235). Egr-1 expression in endothelial cells and medial layer of SMCs 
precedes the neointimal thickening of the vessel. Egr-1 expression is stimulated by 
multiple stimuli including the shear and mechanical stress evident following vein 
graft bypass (242) and is highly expressed in endothelial and smooth muscle cells of 
the injured aorta(223) and carotid artery(243). Vascular injury activates endothelial 
cells and expresses the fetal isoforms of the smooth muscle myosin heavy chain 
molecule, SMemb(244-246). Basic transcriptional-element binding protein 2 
(BTEB2) is a crucial transcriptional factor that regulates the expression of 
SMemb(247). Interestingly, transcriptional activation of BTEB2 is under direct 
regulation of Egr-1 through MAPK pathways in vascular SMCs (248). Activation of 
endothelial cells and SMemb expression upregulates transcription factor, cytokines, 
adhesion molecules, which initiates mononuclear cell infiltration, extracellular matrix 
proliferation, and SMCs migration(235).  
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Egr-1 expression in the SMCs of rejected heterotopic cardiac allograft of Japanese 
monkey also suggests a link between Egr-1 and CAV(235). Allograft coronary artery 
transplantation in transiently immunosuppressed mice showed marked elevation of 
Egr-1 and it’s down stream gene PDGF-A, a strong mitogenic inducer of SMCs, in 
endothelial cells and SMCs compared to isograft or naïve heart at day 60 post-
transplantation (230). In the same study, Egr-1+/+ cardiac allograft showed prominent 
expression of ICAM-1 and VCAM-1 on the coronary artery endothelial cells, whereas 
in Egr-1-/- allografts ICAM-1, VCAM-1 and PDGF-A level were almost 
undetectable. Egr-1 plays a significant role in cardiac allograft parenchymal rejection 
and it is supported by previous findings where Egr-1-/- allografts exhibited 
significantly reduced lesion and mononuclear cell infiltration compared to Egr-1+/+ 
controls. In addition, genetic absence of Egr-1 gene resulted in reduced expression of 
macrophage inflammatory protein (MIP)-2, JE/MCP-1, IL-1β cytokines, cell adhesion 
molecules like ICAM-1 and prothrombic genes like tissue factor and plasminogen 
activator inhibitor-1 after ischaemia. These genes are involved in leukocyte 
trafficking and chronic rejection of the transplanted organ(230).   
 
In addition, the neointimal lesion formed after vein graft implantation is inflammatory 
and is characterized by mononuclear cell infiltration in the early stages of the 
pathogenesis(249). Previous vein graft implantation studies with ICAM-1 knockout 
mouse model have reported 30%-50% reduction in the neointimal lesion formation. In 
addition, leukocyte adhesion and infiltration to the graft also decreased in the ICAM-1 
knock out mice compared to the wild type controls (250). Inhibition of Egr-1 mRNA 
expression with DNA enzymes (DNAzymes) have shown to reduce neointimal 
hyperplasia formation in both rat (251), (252) and rabbit model (253) of balloon 
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injury. The intra-operative pressure-mediated transfection of the vein segment with an 
Egr-1 decoy oligonucleotide prior to bypass implantation resulted in a 50 % reduction 
in neointima hyperplasia compared to control when measured at 6 weeks post-
implantation in rabbit model(242). 
 
1.6.5 Angiogenesis 
Angiogenesis is the process of new blood vessel formation from existing vasculature. 
Angiogenesis has a critical role in the context of several physiological and 
pathological processes such as wound healing, perfusion of infarcted area in the heart 
and tumor growth. The complex process of angiogenesis is regulated by multiple pro-
angiogenic and anti-angiogenic factors(254). Egr-1 is involved in the angiogenic 
process and highly expressed by the endothelial cells in the injured site(255). 
Antisense oligonucleotide targeted to Egr-1 mRNA demonstrated the role of Egr-1 in 
endothelial cell repair after mechanical injury in vitro (256). Moreover, Egr-1 down 
regulation by DNAzymes inhibits endothelial cell proliferation, migration and inhibits 
the tubule formation. In addition to it, Matrigel plug analysis of sub-dermal implant in 
Egr-1 deficient mice and VEGF-soaked disks in rat cornea found analogous results 
(254).  
Apart from this, Egr-1 is found to be involved in tumor angiogenesis and tumor 
solidification. Inhibition of Egr-1 by DNAzymes demonstrated encouraging results in 
tumor angiogenesis study. DNAzymes reduced blood vessel density in tumors and 
slowed down its growth by inhibiting expression of FGF-2, an Egr-1 regulated pro-
angiogenic factor(257).  
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1.7 Remote ischaemic preconditioning  
Impaired coronary circulation resulting in prolonged myocardial ischaemia can lead 
to lethal hypoxic injury. Rapid restoration of coronary blood flow through either 
thrombolytic therapy or percutaneous coronary intervention (PCI) is essential to limit 
MI size, preserving LV ejection fraction and preventing (LV) remodeling. 
Revascularisation via either thrombolytic therapy or PCI reduces the mortality rate of 
patients suffering a heart attack by almost 50% (258). Paradoxically, a restoration of 
oxygenated blood to the ischaemic heart after revascularization aggravates the tissue 
damage, a phenomenon known as I/R injury mediated by calcium overload, oxidative 
stress and inflammation (10). This prompted a search for novel therapeutic strategies 
to protect the heart against I/R injury to improve clinical outcomes of the patients 
presenting with AMI. One of the current therapeutic strategies to limit I/R injury is 
ischaemic conditioning, which is an endogenous approach to protect the heart against 
acute I/R injury. Murry et al. (259) used a canine model to provide the first 
demonstration that brief episodes of non-lethal I/R to the heart prior to sustained 
ischaemia can dramatically reduce MI size, an endogenous cardioprotective 
phenomenon termed ischaemic preconditioning (IPC). IPC has been well studied over 
the last 30 years and found to reduce I/R associated damage to other organs including 
the lung (260), kidney (261), liver (262), skeletal muscle (263), intestine (264), brain 
(265) and improve post-operative recovery from cardiac surgeries (266). The clinical 
application of IPC is restricted to elective cardiac surgeries, where the timing of 
ischaemic insult is well controlled. However, patients with AMI present with blocked 
coronary arteries, making it impossible to precondition the heart. Ischaemic 
postconditioning (IPost), where a non-lethal I/R is performed to the heart by 
interrupting the PCI-induced reperfusion, delivers a similar outcome to IPC making it 
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a better strategy to treat patients with AMI. Both IPC and IPost require interventional 
approaches, which limit its application in clinical settings. In contrast to directly 
preconditioning the target organ, Przyklenk and Whittaker in 1993 made the 
intriguing discovery that preconditioning the heart does not limit its efficacy to the 
perfused area of the coronary artery, but was extended to the remote myocardial tissue 
(267).   Similarly, Liauw et al. (268) showed that skeletal muscle can be protected 
against I/R by preconditioning the contralateral skeletal muscle. This discovery 
facilitated the extension of preconditioning techniques to protect other organs beyond 
the heart. This approach of remotely protecting a target organ through ischaemic 
preconditioning is known as remote ischaemic preconditioning (RIPC). A major 
advance in myocardial RIPC came with the use of skeletal muscle as the origin of 
RIPC stimulus and brief I/R produced with a tourniquet applied to one of the hind 
limbs of pig (269). This lead to a blood pressure measuring cuff around the arm to 
achieve the RIPC stimulus making it possible to accommodate most of the clinical 
settings of acute I/R injury. In a non-invasive approach, RIPC has the capacity to 
protect the organ or tissue whether applied prior to I/R (RIPC), after ischaemia but 
prior to reperfusion (PerC) (270) or during reperfusion (remote ischaemic 
postconditioning, RIPost) (271). However, the clinical effectiveness of RIPC is 
controversial and lack of protection has been observed in many clinical settings. 
Table 1.1 summarizes the key clinical trials on the effect of RIPC prior to coronary 
artery bypass graft (CABG) and PCI. 
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Table 1.1: Key clinical trials of RIPC 
Study Nature of 
trial 
Number of 
participants 
analysed (RIPC / 
Control) 
RIPC protocol Cardioprotection 
Coronary artery bypass graft 
Hong et al. 
(272) 
RCT 35/35 4 cycles of 5 min I/R on lower limb Yes 
Lucchinetti et 
al. (273) 
RCT 27/28 4 cycles of 5 min I/R of leg No 
Hausenloy et 
al. (274)  
RCT 27:30 3 cycles of 5 min I/R of right upper 
limb 
Yes  
Candilio et al. 
(275) 
RCT 89/89 2 cycles of simultaneous 5 min I/R on 
upper arm and upper thigh  
Yes 
Venugopal et 
al. (276) 
RCT 23/22 3 cycles of 5 min I/R of right forearm  Yes 
Hausenloy et 
al. (277) 
Multicenter 
RCT 
801/811 4 cycles of 5 min I/R of upper arm No   
Krogstad et 
al. (278) 
RCT 45/47 3 cycles of 5 min I/R of upper arm No 
Percutaneous coronary intervention 
Pryds et 
al.(279)  
Post-hoc 
analysis of 
RCT 
166:167 4 cycles of 5 min I/R of upper arm Yes 
Sloth et al. 
(280) 
Post-hoc 
analysis of 
RCT 
71:68 4 cycles of 5 min I/R of upper arm Yes 
Pryds et al. 
(281) 
Post-hoc 
analysis of 
RCT 
71:68 4 cycles of 5 min I/R of upper arm Yes 
Botker et al. 
(282) 
 
RCT 126: 125 4 cycles of 5 min I/R of upper arm Yes 
 
 
Prasad et al. 
(283) 
RCT 47:48 3 cycles of 3 min I/R of upper arm No 
 
 
 
1.7.1 Inter-organ preconditioning 
The effect of RIPC is not confined to one organ but impact on multiple organs. 
Similarly, different organs can be used as the RIPC site. Table 1.2 summarizes the 
key findings on inter-organ preconditioning studies. Briefly, applying RIPC stimulus 
to different organs has been shown to protect various target organs from I/R injury. 
For more information, please see the references provided.  
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Table 1.2 Key studies on inter-organ preconditioning 
Study (RIPC Site) Species Target organ Result 
 
Renal  
 
McClanahan et al. 
(284) 
Rabbit Heart Infarct size 
Gho et al. (285) Rat Heart Infarct size 
Verdouw et al. (286) Pig Heart Infarct size 
Pell et al. (287) Rabbit Heart Infarct size 
Takaoka et al. (288) Rabbit Heart Infarct size and improved 
myocardial energy metabolism 
Diwan et al. (289) Rat Heart Confers cardioprotection by NFkB 
activation followed by opening of 
K(ATP) channels 
Lang et al. (290) Rat  Heart Infarct size 
Singh et al. (291) Rat  Heart Infarct size and proposed the 
involvement of angiotensin AT(1) 
receptors in renal preconditioning 
Kant et al. (292) Rat Heart Reduces myocardial injury through 
inhibition of hypoxia inducible 
factor-prolyl 4-hydroxylases 
Small Intestine 
 
Gho et al. (285) Rat  Heart Infarct size 
Verdouw et al. (286) Pig Heart Infarct size 
Patel et al. (293) Rat Heart Infarct size 
Heidbreder et al. (294) Rat Heart Infarct size and activated p38 
MAPK, ERK ½ and JNK ½ 
selectively in the intestine but not 
in the heart 
Liver 
 
Ates et al. (295) Rat Kidney Improved creatine clearance and 
improvement in hepatic 
histopathologic parameters 
Brzozowski et al.(296) Rat Gut Reduced gastric mucosa lesion 
Brain 
 
Tapuria et al. (297) Rat Liver Improved hepatic microcirculation 
and reduced hepatic I/R injury. 
 
Hind Limb 
 
Oxman et al. (298) Rat Heart Decreased arrhythmias 
Birnbaum et al. (299) Rabbit Heart Reduced MI size 
Liauw et al. (268) Rat Thigh muscle Reduced muscle necrosis 
Kharbanda et al. (269) Pig Heart Reduced MI size 
Gunaydin et al. (300) Human Heart Enhanced anaerobic glycolysis to 
protect heart 
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Xia et al. (301) Sheep Lung Protected lung from repeated 
coronary artery occlusion (CAO) 
and reperfusion mimicking multi-
vessel off-pump coronary artery 
bypass (OPCAB) revascularization 
and decreased pulmonary vascular 
resistance 
Addison et al. (302) Pig Skeletal muscle Protected global skeletal muscle 
against infarction 
Kuntscher et al. (303) Rat Adipocutaneous flaps Decreased flap necrosis 
 
Kuntscher et al. (304) Rat Cremasteric muscle 
flaps 
Decreased flap necrosis 
Kuntscher et al. (305) Rat Epigastric 
adipocutaneous flaps 
Decreased flap necrosis 
Moses et al. (306) Pig Latissimus dorsi (LD) 
muscle flaps 
Decreased flap infarction 
Wang et al. (307) Rat Cremaster flap Decreased flap necrosis 
Harkin et al. (308) Pig Lung Reduced acute remote lung damage 
against systemic inflammatory 
response from limb I/R injury 
Li et al. (309) Mice Heart Protected (LV) function and 
reduced infarction size 
Konstantinov et 
al.(310) 
 
Pig Heart Reduced I/R injury in the brain-
dead donor heart following 
orthotopic heart transplantation.  
Chen  et al. (311) Rat Heart Reduced infarction size 
Chen  et al. (312) Rat Heart Reduced infarction size through 
free radical pathway 
Luokogeorgakis et al. 
(313) 
Human Forearm Preserves endothelial function in 
the forearm 
Waldow et al. (314) Pig Lung Protects lung function and reduced 
the plasma interleukin-1beta level 
Kristiansen et al. (315) Rat Heart Reduces MI size through a 
mechanism involving mitochondrial 
K(ATP) channels and improves 
(LV) function during reperfusion 
Zhang et al. (316) Rat Heart Reduced infarction size and I/R-
induced plasma lactate 
dehydrogenase level  
Dave et al. (317) Rat Heart Increased neuroprotection from 
asphyxial cardiac arrest 
Kanoria et al. (318) Rabbit Liver Reduced liver I/R injury and 
improved liver function  
Lai et al. (319) Rat Liver RIPC stimulated heme oxygenase-1 
expression in liver tissue and 
associated with liver protection 
from I/R injury 
Cheung et al. (320) 
 
 
Human Heart Postoperative improvement in lung 
function and reduction in plasma 
troponin-I level 
Mudaliar et al. (321)  
 
Rat Heart  Infarct size through JAK-STAT 
pathway upregulation 
` 
 
 
Page | 42  
 
1.7.2 Mechanisms underlying RIPC 
The underlying mechanisms through which brief episodes of I/R in an organ or tissue 
transduces a protective signal to a distant organ and renders it resistant to sustained 
I/R injury is currently not fully understood. Some studies suggest there is similarity in 
the mechanistic process of direct preconditioning and RIPC. Based on the current 
knowledge, proposed mechanisms of RIPC can be divided into three major parts: (i) 
the humoral (ii) the neuronal pathway, and (iii) the systemic pathway. However, 
whether these pathways independently exert protective effect on the target organ or 
that crosstalk is involved is not well understood. Table 1.3 summarizes the major 
studies on the mechanisms of RIPC-induced protection of target organs. The studies 
focused on the neural, humoral and systemic pathways of RIPC. Apart from Jones et 
al. (329) these studies applied intermittent I/R as RIPC stimulus.  For more 
information, please see the references provided. 
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Table 1.3 Key studies on mechanisms of RIPC-induced organ protection 
Study 
 
 
Model RIPC 
Stimulus 
Target 
organ 
Effect on 
the target 
organ 
Mechanistic 
Insight 
Comments 
 
Gho et al. 
(285) 
 
Rats 
 
i) 15 min CAO 
10 min 
reperfusion 
ii) 15 min 
MAO 10 min 
reperfusion 
iii) 15 min 
renal artery 
occlusion 10 
min 
reperfusion 
 
Heart 
 
Infarct 
size 
 
Neural 
pathway 
 
Ganglion blocker 
abolished RIPC effect 
while maintaining 
direct preconditioning 
effect 
Schoem-
aker and 
Heijningen 
(322) 
Rats 15 min 
intestinal 
ischemia 10 
min 
reperfusion 
Heart Infarct 
size 
Neural 
pathway 
Bradykinin, 
Hexamethonium may 
be activating the neural 
pathway 
Liem et al. 
(323) 
Rats 15 min 
intestinal 
ischemia 10 
min 
reperfusion 
Heart Infarct 
size 
Neural 
pathway 
RIPC mediated 
adenosine upregulation 
confers protection 
against I/R and 
adenosine receptor 
blocking abolishes 
RIPC protection 
Dong et al. 
(324) 
Rats 10 min hind 
limb ischemia 
10 min 
reperfusion 
Heart Infarct 
size 
Neural 
pathway 
Dissecting femoral 
nerve of the hind limb 
prior RIPC abolishes 
the RIPC effect on the 
target organ 
Tang et 
al.(325) 
Rabbits 10 min 
intestinal 
ischemia 
15mins 
reperfusion 
Heart Infarct 
size 
Neural 
Pathway 
RIPC mediated 
protective effect is 
associated with 
capsaicin-sensitive 
sensory nerves 
activation 
Brzozowski 
et al. (296) 
Rats i) 2 cycles of 5 
min left 
anterior 
descending 
artery 
occlusion and 
5 min 
reperfusion 
ii) 2 cycles of 
5 min 
occlusion of 
common 
hepatic artery 
and portal vein 
followed by 10 
min 
reperfusion 
Gut Gastric 
mucosal 
lesion 
Neural 
pathway 
Confers 
gastroprotection via 
vagal and sensory 
nerve mediated 
vasodilatory mediators 
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Weinbrenne
r et al. 
(326) 
 
Rabbits 15 min infra-
renal aortic 
ischemia 10 
min 
reperfusion 
Heart 
 
 
Infarct 
size 
Humoral 
Pathway 
Neural ganglion 
blocker could not 
abolish RIPC effect 
Patel et al. 
(293) 
Rats 15 min MAO 
followed by 10 
min 
reperfusion 
Heart Infarct 
size 
Neural 
pathway 
 
Preconditioning-
induced opioid release 
and opioid receptor 
activation protects 
myocardium from 
ischaemic injury. 
Opioid receptor 
antagonist abolished 
the protection 
Konstantino
v et al. 
(327) 
Human 3 cycles of 5 
min forearm 
ischemia and 5 
min 
reperfusion 
Leukocyte Decreased 
CD11B 
expression 
on 
leukocytes 
Systemic 
pathway 
Suppressed pro-
inflammatory and pro-
apoptotic gene 
transcription 
Wolfrum et 
al. (328) 
Rats 15min MAO 
15min 
reperfusion 
Heart Infarct 
size 
Humoral & 
Neural 
pathway 
RIPC increased plasma 
CGRP level and CGRP 
activates PKC via 
neural pathway 
Zhang et al. 
(316) 
Rats 3 cycles of 5 
min femoral 
artery 
occlusion 
followed by 5 
min 
reperfusion 
Heart Infarct 
size 
Neural 
pathway 
Activation of kappa-
opioid receptors 
provides 
cardioprotection 
induced by RIPC and 
mPTP inhibition is 
downstream of kappa-
opioid receptor 
activation 
Konstantino
v et al. 
(310) 
Pigs 4 cycles of 5 
min lower limb 
ischemia 5 min 
reperfusion 
Heart Infarct 
size 
Humoral 
pathway 
Katp channel 
dependent mechanism 
provides RIPC-induced 
cardioprotection and 
excludes afferent 
neurogenic mechanism 
Jones et al. 
(329) 
Mice Abdominal 
incision for 
RIPC of 
trauma 
Heart Infarct 
size 
Neural 
pathway 
Skin nociception 
provides 
cardioprotection 
through neurogenic 
signaling involving 
spinal cords and 
activation of cardiac 
sensory and 
sympathetic nerves 
 
 
 
1.7.2.1 Humoral pathway 
Multiple studies support the theory of blood borne mediators as a signal transduction 
mechanism and the requirement for a period of reperfusion to washout humoral 
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factors generated by RIPC (285), (326). These protective substances circulate via the 
bloodstream and upon reaching the target organ bind to respective receptors and 
activate intracellular signaling pathways. Humoral pathway involvement in RIPC was 
demonstrated by Konstantinov et al. (310). Denervated donor heart recipient pigs that 
underwent remote limb preconditioning showed significant reduction of MI size, 
which provides evidence for the concept of humoral-mediated cardioprotection by 
RIPC. Dickson and colleagues showed for the first time that RIPC could elicit cross 
species protection (330-332). These studies explored transfusing blood from 
preconditioned rabbit hearts and kidneys to a non-preconditioned isolated rabbit heart 
and showed recovery of the heart from myocardial I/R injury by reducing the infarct 
size. These authors also showed that coronary effluent from a preconditioned ex-vivo 
rabbit heart could potentiate the similar infarction limiting effect and improve left 
ventricle function (333). Shimizu et al. reported similar cross species protection after 
using plasma dialysate from remote preconditioned rabbit and human blood to protect 
ex vivo rabbit heart from I/R injury (334). These authors also confirmed that the 
transferrable factors are hydrophobic in nature and <15-kDa in size. Serejo et al. 
provided evidence that the humoral factors released from the ischaemic 
preconditioned heart were thermolabile, hydrophobic, >3.5-kDa and conferred 
cardioprotection via the activation of protein kinase C (PKC) (335). Breivik et al. also 
reported the presence of <30-kDa hydrophobic factors in the coronary IPC effluent, 
which can confer cardioprotection via the PI3K/AKT pathway (336). Interestingly, 
proteomic analysis of renal RIPC conducted by Lang and colleagues could not detect 
any cytoprotective factors larger than 8-kDa (290). The humoral factors responsible 
for the RIPC effect on the target organs still remain unclear and investigation into the 
factors responsible continues.   
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1.7.2.2 Neural pathway 
A neural pathway is one that connects one part of the nervous system with another by 
way of axons. Evidence suggests that intact neural pathway is essential for the remote 
organ or tissue to convey protective signal to the target organ during the process of 
RIPC. Denervation of the neural pathway by resecting the femoral nerve and sciatic 
nerve in mice (325), and resecting the vagus nerve in rabbit abolished RIPC 
protection from MI (337, 338). However, the exact role of the afferent and efferent 
component of the neural pathway is unclear. The involvement of the neural pathway 
in RIPC-mediated cardioprotection was explored by Gho et al. who demonstrated that 
transient occlusion of the anterior mesenteric artery can mediate cardioprotection, 
which can be abrogated by ganglionic blockers (285).  This finding was supported 
with the proposition that RIPC propels the production of autacoids such as adenosine, 
bradykinin, calcitonin gene-related peptide (CGRP) in the remote preconditioned 
organ, which stimulates afferent nerves and relays the neural signal to the 
myocardium via the efferent nerve fibers. Furthermore, Ding et al. explored the role 
of renal nerve-mediated cardioprotection (339). They confirmed that renal nerve 
resection abolished renal preconditioning-induced cardioprotection. Liem et al. 
provided confirmatory evidence implicating adenosine in a neural pathway of 
cardioprotection (323). They reported that adenosine released by the mesenteric artery 
during preconditioning reduced MI size from 68% to 48%, a protective effect that was 
reversed by the ganglionic blocker hexamethonium. In addition, intramesenteric 
artery infusion of adenosine mimicked similar cardioprotection as mesenteric artery-
induced preconditioning, which could be abolished by hexamethonium. From these 
findings, the investigators concluded that locally released adenosine during 
mesenteric artery preconditioning stimulates afferent nerves in the mesenteric bed 
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which helps activate myocardial adenosine receptors. Dong et al. demonstrated that 
dissecting the femoral nerve prior RIPC does not protect the myocardium against I/R 
injury and suggested that an intact neural pathway was required for the sensory 
afferent neural signaling from the preconditioned limb (324). A study carried out by 
Jones and colleagues showed that instead of IPC, abdominal slit in mice activates the 
cardiac sensory and sympathetic nerves. This procedure elicits cardioprotection via 
bradykinin (a known hormone and neurotransmitter) release in the heart by the 
sympathetic nerves and bradykinin dependent activation of PKC- (329).  
 
1.7.2.3 Systemic pathway 
RIPC has been shown to provoke a systemic response by modulating inflammatory 
cells either post-transcriptionally or through transcriptional regulation (340). 
Kharbanda et al. previously showed that RIPC reduced expression of neutrophil CD-
11b and platelet-neutrophil complexes in humans (341). In 2004, Konstantinov et al. 
used microarray analysis of blood samples from healthy human volunteers subjected 
to forearm preconditioning to reveal that preconditioning suppressed genes regulating 
cytokine production, leukocyte chemotaxis, adhesion and migration, exocytosis, 
innate immunity, signaling pathways, and apoptosis, while up-regulating anti-
inflammatory genes such as HSP-70 and calpastatin (327). Later, the same group 
provided evidence to show that RIPC upregulated genes associated with growth and 
metabolism, DNA repair and redox regulation. IPC attenuated P-selectin expression 
in liver and prevented neutrophil infiltration in lung, stomach, pancreas, small 
intestine and colon via inhibition of systemic TNF-α production (342). In another 
study, Albrecht et al.  reported similar findings in human, showing that within the 
early phase of RIPC, serum cytokines were upregulated (343). It may be that, 
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cytokines function as both pro- and anti-inflammatory mediators in ischaemic 
conditioning to prepare the target organ to mitigate the tissue damage. This group’s 
findings showed cardioprotection due to increased neutrophil infiltration after cardiac 
bypass surgery and concurrent increase of IL-8, IL-1, TNF-α in samples taken from 
right atrium (343). 
 
1.7.3 Circulating Mediators of Ischaemic conditioning 
Remote preconditioned organ may require a ‘flush’ after brief ischaemia in order to 
transport humoral factors to the target organ generated by the preconditioning 
stimulus (344). Number of studies focused on identifying the nature of the circulating 
mediators in bloodstream, which likely carries the preconditioning signal from the 
remote organ to the target organ (290, 334, 335). Though the actual identity remains 
elusive, below we discuss a number of blood borne mediators known to be involved 
in mediating the RIPC-induced protection to the heart against I/R injury. 
 
1.7.3.1 Extracellular vesicle 
Giricz et al. (345) recently demonstrated in the Langerdorff rat heart model that 
preconditioning increases the amount of extracellular vesicles (EV) released into the 
coronary perfusate. They found that perfusate collected from preconditioned heart 
reduced MI size significantly, whereas perfusate depleted of EV showed no signs of 
reducing the infarction size. However, in vivo animal models are required to further 
understand the signaling and effector mechanism of the extracellular vesicles. 
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1.7.3.2 Platelet dependent signaling 
Platelet activation by mechanical pressure, ischaemia or tissue damage invokes a 
systemic response as one of the first lines of protective defense. Oberkofler et al. 
(346) addressed the role of activated platelet derived serotonin in RIPC-mediated liver 
and kidney protection against I/R. The group showed that RIPC-induced reduction of 
I/R injury is associated with prompt release of serotonin by activated platelets and 
serotonin-mediated activation of the VEGF/IL-10/MMP8 pathway. Reducing platelet 
numbers by more than 90% by inducing thrombocytopenia with an anti-CD-41 
injection abolished the RIPC-mediated protection against liver I/R injury and 
increased of both ALT/AST levels. RIPC displayed a 40% reduction in platelet 
numbers and when platelet activation was blocked with the PAF receptor antagonist 
SM-12502, the effect of RIPC was eliminated. This supports the importance of 
platelet activation for RIPC. This study demonstrated that serotonin plays a crucial 
role in platelet dependent protection mechanisms. When Tph1-/-mice lacking platelet 
serotonin were subjected to RIPC prior to hepatic I/R injury, they did not show any 
reduction in I/R injury. This result however was reversed by injecting 5HTP, a 
serotonin precursor. Further studies aimed at elucidating the downstream effector of 
serotonin found that RIPC resulted in significant increase in serum VEGF levels, 
which is cardioprotective (347) and can be upregulated by serotonin (348). 
Recombinant VEGF-A treatment prior to I/R resulted in similar effects of RIPC, 
whilst anti-VEGF antibody treatment abolished the RIPC effect, supporting the 
importance of circulating VEGF in RIPC. In addition, RIPC upregulated IL-10 and 
MMP-8 expression in liver, heart, kidney, lung, and intestine. Similar results have 
been achieved by treating mice with serotonin. Despite these results, IL-10-/- mice 
with MMP-8 inhibition showed total amelioration of the RIPC-mediated protection, 
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implicating the involvement of serotonin-VEGF-IL-10/MMP-8 axis in facilitating the 
systemic organ protection induced by platelet activation.  
 
1.7.3.3 Erythropoietin 
Erythropoietin (EPO) is a circulatory 30-kDa glycoprotein, to be a principle regulator 
of red blood production. This 165-amino acid long protein has 4 glycosylated chains, 
which renders its biological activity and protects it from oxygen radicals. Previous 
studies have shown that exogenous administration of EPO as well as increased 
+endogenous serum EPO improves MI pathobiology by reducing the infarction size 
as well as improving cardiac function in a time dependent manner (349-352). EPO 
can prevent apoptotic cell death in isolated cardiomyocytes by activating the JAK2-
PI3K-AKT signaling as well as by suppressing glycogen synthase kinase-3 (GSK-
3), a serine-threonine kinase that induces apoptosis in various cell types including 
vascular smooth muscle cells, cardiomyocytes, and neurons (353-358). Recently Oba 
et al. demonstrated that renal nerve-mediated EPO release is essential for RIPC-
induced cardioprotection (359). In a mouse model with 4 cycles of 5 min hypoxia and 
reoxygenation there was an increase in serum EPO levels in a time dependent manner, 
which peaked 1 h post RIPC and returned to basal levels 24 h post RIPC. Similar 
findings were obtained in a human study of RIPC with 3 cycles of 5 min of upper arm 
ischaemia and 5 min reperfusion. In both cases, cardioprotective cytokines such as 
interleukin-6, G-CSF, and leukemia inhibitory factor (LIF) in serum did not change. 
RIPC reduced renal blood flow (RBF) in mice with production and secretion of EPO, 
which is regulated by tissue oxygen supply. Hypoxic tissue results in increased 
production of EPO and Erythropoietin receptors (EPOR). RIPC activated the Hypoxia 
inducible factor (HIF)-1-EPO pathway and reduced MI size after 2 h of permanent 
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occlusion of the left coronary artery. In addition, injecting the anti-EPO neutralizing 
antibody 24 h prior to RIPC abolished the RIPC-induced attenuation of infarct size. 
However, there is controversy regarding the role of renal nerves in EPO production. 
Oba’s group also found that renal denervation abolished RIPC-mediated serum EPO 
elevation and hence the reduction of MI size. This study elegantly demonstrated that 
RIPC-mediated EPO secretion by the kidney is renal nerve activity-dependent and can 
limit the MI pathology. RIPC failed to confer cardioprotection in rats with renal 
failure, which may be attributed to the lack of EPO release during renal failure (360).  
Further insight into signals transduced from the preconditioned limb to the kidney to 
stimulate the process of EPO production is still needed.   
 
1.7.3.4 Adenosine 
Adenosine plays an important role in many biochemical processes including energy 
transfer, signal transduction or as a neuromodulator. Activation of adenosine 
receptors provides a myocardial preconditioning like affect in rabbits (361), dogs 
(362) and pigs (363). Adenosine activates toxin sensitive G protein, which can 
activate ATP sensitive K+ channel. Surendra and colleagues (364) recently showed 
that δ-opioid and κ-opioid receptors interact with adenosine A1 receptors to mediate 
RIPC-induced cardioprotection. Furthermore, activation of the ATP sensitive K+ 
channel has been demonstrated to be involved in myocardial preconditioning in dogs. 
Conversely, neither adenosine (365) nor the ATP sensitive K+ channel (366) confer a 
protective effect in myocardial preconditioning in a similarly designed rat model. 
However, using the adenosine receptor inhibitor Takaoka and colleagues have shown 
the contribution of adenosine in RIPC through renal artery I/R in a rabbit model and 
reported reduction of MI size (288).   
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1.7.3.5 RNase1 
Extracellular RNA (eRNA) functions as an early signal for tissue stress or damage 
and provides a signal to release cytokines like TNF-α and mediate leukocyte 
trafficking and consequently inflammatory processes (367). Recently, RNase1 has 
been shown to prevent the crosstalk between eRNA and TNF-α in cardiac I/R injury 
(368). RNase1 is ubiquitously expressed and the presence of highly specific RNase 
inhibitors limits its cytotoxicity in the cells. Apart from the gastrointestinal tract, 
which is the primary site for RNase1 production, vascular endothelial cells also 
produce RNase1 (369) primarily during stress (370). Recently Cabrera-Fuentese and 
colleagues demonstrated in a RIPC model of cardiac surgery that, RIPC prior to 
cardiac surgery decreased pathological eRNA and TNF-α expression which was 
otherwise more than 20-fold and 7-fold higher without RIPC, respectively (371). 
Furthermore, RIPC increased the plasma RNase1 activity by more than 5-fold when 
compared with the control. It has been subsequently proposed that RIPC dependent 
endothelial release of RNase1 degrades eRNA and prevents its interaction with TNF-
α and other proteins to limit the pathological features of I/R. However further studies 
that alter RNase1 activity in the RIPC model are required to further understand the 
molecular process of protection mediated by RNase1. 
 
1.7.3.6 Apolipoprotein A-I 
Apolipoprotein A-I (ApoA-I) is the major component of high-density lipoprotein in 
plasma. Hilbert et al. recently demonstrated the potential for ApoA-I as a circulatory 
mediator of RIPC-induced cardioprotection in Wistar rats (372).  They found that, 10 
min of limb reperfusion after 10 min of limb ischaemia increased plasma ApoA-I by 
30% compared to untreated control group, whilst 5 min of limb reperfusion after 10 
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min of limb ischaemia did not change the plasma ApoA-I level compared to the 
untreated rats. When Apo-AI was injected as an intravenous bolus (10mg/kg) 10 min 
prior to ischaemia for 40 min and a reduction of almost 15% in MI size was reported 
after 2 h of reperfusion. A rat plasma proteomic study by Lang et al. (290) did not 
report differential expression of ApoA-I in blood plasma after RIPC. However, there 
were key differences between the two studies; Hibert et al. used renal artery occlusion 
whereas Lang et al. used hind limb occlusion to induce RIPC effect. In addition, the 
reperfusion time after ischaemia was also different between the two studies. The 
beneficial effect of ApoA-I may be attributed to its ability to scavenge the TNF-α 
released by the myocardial tissue. Also, intravenous administration of ApoA-I prior to 
renal pedicle ischaemia and prior to myocardial reperfusion limits the I/R-mediated 
injury. This includes reduced cytokine production by the injured tissue and 
suppressed endothelial ICAM-1 expression along neutrophil adherence and migration. 
Though the molecular mechanisms behind the increased expression of ApoA-I in the 
blood remains unclear, the quick response to RIPC by increasing the plasma 
concentration of ApoA-I led to a theory that suggests that RIPC does not increase the 
level of new ApoA-I synthesis but mobilizes the existing ApoA-I. Further studies are 
required to delineate the proposed theory. 
 
1.7.3.7 MicroRNA-144 
MicroRNAs (miRNA) are a class of endogenous small non-coding RNAs that 
circulate in a stable form in blood and regulate posttranslational gene expression. 
Recently, Li and colleagues (373) reported that circulating microRNA-144 (miR-144) 
plays an important role in MI sparing effect of RIPC. Previously Zhang et al. (374) 
observed that overexpression of miR-144 and miR-151 augmented cytoprotection in 
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response to simulated I/R injury. Also local IPC-mediated myocardial functional 
recovery was lost in antagomiR-51 treated hearts in a murine model but failed to 
mimic similar result in miR-144 treated hearts suggesting that miR-144 may not be an 
important regulator of cytoprotection in IPC. Li and colleagues followed up by 
exploring the role of miR-144 in RIPC. They demonstrated that RIPC increased 
plasma miR-144 in both mice and human. In addition, RIPC also showed an increase 
in myocardial expression of miR-144 in mice, where as I/R injury decreased 
myocardial expression of miR-144. Intravenous administration of miR-144 conferred 
both early (I/R injury immediately after miR-144 administration) and delayed (I/R 
injury after 3 consecutive days of miR-144 administration) cardioprotection whereas 
antisense oligonucleotide targeting miR-144 (antagomiR-144) abolished the RIPC 
effect on the heart. Microvesicles and exosomes are the major carrier of circulating 
miRNA, however analysis of the active constituent of the micro-particles (50-400 nm) 
showed no significant increase in micro-particle numbers and miR-144 which 
contradicts with the finding of Giricz et al. (345). This may be due to differences in 
microparticle isolation, purification, microparticle size and different protocols of 
RIPC. Conversely, the exosome pellet showed almost 4-fold increase in miR-144 
precursor and an increase in miR-144 in exosome-poor serum (345). This group then 
demonstrated that miR-144 binds with Argonaute-2, a known extracellular miRNA 
carrier. Although the source of miR-144 and the exact mechanism of action of miR-
144 in the heart are not clear, the phosphorylation of protective kinases such as Akt, 
GSK-3, p42/44 MAPK increased while inducing autophagy signaling as early as 1 h 
after administration of miR-144. These findings suggest a vital role of miR-144 as a 
circulating mediator of RIPC and plasma miR-144 may be a potential biomarker for 
` 
 
 
Page | 55  
 
the successful application of preconditioning, aiding the study of efficacy of RIPC 
and abrogation of RIPC in clinical trials.  
1.7.3.8 Nitrite 
Ischaemia and shear stress depolarizes cell membrane and inhibits the function of K+ 
channels. Inhibition of K+ channels lead to activation of Ca2+ channels and increased 
Ca2+ influx into endothelial cells and activates Ca2+ dependent endothelial nitric oxide 
synthase (eNOS). Pharmacological and genetic techniques revealed that, eNOS in the 
endothelial cells are the source of nitrite production during reactive hyperemia, which 
is then readily transported to the target organ especially to the myocardium. RIPC 
does not phosphorylate myocardial Akt and Erk proteins, which supports the notion 
that nitrite in the heart is remotely produced (375). Hypoxia and ischaemia inhibits 
oxidative phosphorylation, impairs ATP production and activates xanthine oxidase 
(376). Previously findings in humans, reported that forearm intermittent I/R 
modulates plasma NO• / nitrite levels (377, 378). Nitrite, the oxidation product of NO• 
is a stable reservoir of NO•  and has a half-life of approximately 35 min (379). Rassaf 
and colleagues recently demonstrated that, reactive hyperemia is essential to 
significantly improve the eNOS derived plasma nitrite levels. In addition, eNOS-/- 
mice totally abrogated the MI sparing effect as well as diminishing the RIPC linked 
increase of plasma and myocardial nitrite levels. They also matched RIPC-mediated 
increased level of circulating nitrite with exogenous supplementation of intravenous 
nitrite and reported similar level of cardioprotection as RIPC (375). These findings 
shed further light on why the effect of RIPC is not as pronounced in humans with 
pathological conditions such as atherosclerosis and coronary artery disease, given that 
endothelial function in these patients is partly impaired and impacts circulating nitrite 
levels.  
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1.7.3.9 Calcitonin Gene-Related Peptide (CGRP) 
Recent studies have characterized the involvement of capsaicin sensitive sensory 
neurons in RIPC (322, 380). Sensory neurons are widely spread throughout the 
mammalian cardiovascular system and contain cardio-stimulatory neuropeptides. 
Among the neuropeptides, CGRP, substance P and other neurokines play an intricate 
role in modulating cardiac function through local cardiac reflexes (381-383). CGRP 
release is regulated by multiple factors such as brief ischaemia, hyperthermia or 
autocoids (384-386). Plasma levels of CGRP are increased by brief anterior 
mesenteric artery occlusion (325). Furthermore, CGRP is involved in facilitating 
preconditioning-induced protection (387-389). Similarly, it confers early and delayed 
cardioprotection against reperfusion injury in vivo (88) and in isolated rat heart (387). 
CGRP facilitated early preconditioning is thought to involve only the release of 
CGRP whilst delayed preconditioning involves increased -CGRP but not -CGRP 
expression via NO and/or CO pathways (390). Wolfrum and colleagues explored the 
role of CGRP in MI in vivo and delineated its role in the transduction mechanism of 
RIPC to the heart (328). This group remotely preconditioned rat heart by occluding 
the mesentery artery for 15 min followed by 15 min reperfusion. RIPC by mesentery 
artery occlusion (MAO) in rats reduced MI size by around 40% and increased plasma 
CGRP levels by almost 40%, which was comparable to the plasma level of CGRP 
after pharmacological preconditioning by low dose of CGRP. Even though CGRP has 
a vasodilatory effect, a low dose of CGRP is protective against MI and limits 
infarction size without affecting hemodynamics. In addition, ganglion blocker 
hexamethonium did not prevent CGRP release after mesenteric preconditioning, but it 
abolished CGRP-mediated activation of myocardial PKC and proved that neural 
response to RIPC is due to the systemic release of CGRP (328).  Peng and colleagues 
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used CGRP receptor antagonist, CGRP8-37, to show that IPC-mediated 
cardioprotection involves CGRP whilst pre-treatment with CGRP receptor antagonist 
CGRP8-37 reversed the MI size limiting effect and PKC translocation (391). These 
findings suggest that CGRP is a humoral mediator of RIPC which further targets 
downstream neural pathways to confer cardiac protection. 
 
1.7.3.10 Interleukin-10  
RIPC has been shown to modulate gene expression for proteins involved in 
inflammatory responses such as leukocyte chemotaxis, adhesion to endothelial cells, 
migration, exocytosis, cytokine synthesis, innate immune response and apoptosis in 
circulating human neutrophils (327, 392). Late RIPC inhibits inflammatory responses 
in reperfused tissues. Interleukin-10 (IL-10) is an anti-inflammatory cytokine that 
decreases production of chemokines and cytokines (393) and can activate pro-survival 
pathways (394, 395). IL-10 has two receptor subunits IL-10R1 and IL-10R2. IL-10R1 
is expressed by all IL-10 responsive cells whereas IL-10R2 is ubiquitously expressed. 
IL-10R1 receptors are expressed on cardiomyocytes (396). Late RIPC reduced infarct 
size and increased left ventricular developed pressure (LVDP), which was reversed by 
treating the heart with IL-10 receptor antibodies (396). RIPC did not have 
cardioprotective effects on IL-10 knock out mice and on wild type mice treated with 
IL-10 receptor antibodies blocking the binding of IL-10 to IL-10R1.  However 
pretreatment of IL-10 knock out mice with recombinant IL-10 significantly decreased 
infarct size (396). Furthermore, the size of IL-10 (18-kDa) is consistent with notion 
that humoral mediators are likely to be <30-kDa (393). Increased plasma IL-10 levels 
can quickly accumulate in tissue due to IL-1 receptor expression and high affinity for 
IL-10 on cardiomyocytes. Conversely, IL-10 can increase its own expression in tissue 
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(397, 398). Cai and colleagues showed that late RIPC increased plasma and cardiac 
IL-10 level at 24 h and activated Akt-eNOS signaling pathway through IL-10 
receptors in myocardium while upregulating IL-10 expression in preconditioned 
skeletal muscle (396). Whether increased plasma and cardiac IL-10 is released from 
the preconditioned skeletal muscle remains unclear.   
 
1.7.3.11 Stromal cell derived factor-1α 
Stromal cell derived factor-1α (SDF-1α) is a 10-kDa CXC chemokine involved in 
recruiting bone marrow derived stem cells at the site of myocardial injury (399). SDF-
1α can bind to its receptor CXCR4 and protect the isolated heart from acute injury 
(400). SDF-1α can also protect the heart from acute injury without engaging the stem 
cells, either through direct intracardiac administration prior to ischaemia in vivo or 
after perfusion prior to ischaemia in isolated hearts ex vivo. SDF-1α levels increase in 
response to hypoxia (401). RIPC has been reported to increase plasma SDF-1α levels 
by 50% in rats and SDF-1α treatment confers cardioprotection in isolated papillary 
muscles. This protective effect was abolished by AMD3100, a highly specific 
inhibitor of CXCR4. In addition, AMD3100 prevented the induction of RIPC-induced 
cardioprotection in isolated perfused hearts suggesting the involvement of SDF-1α in 
RIPC (402). However, proteomic analysis of human plasma samples confirmed that 
SDF-1α was not upregulated after RIPC stimulus (403). SDF-1α has a plasma half-
life of about 25 min (404). However, remote postconditioning increased SDF-1α by 1 
h, returning to basal level by 3 h in female Sprague-Dawley rats (405). Conversely, 
similar procedure was reported to increase SDF-1α by 1 h and 3 h in mice (406). It is 
possible that preconditioning-mediated SDF-1α regulation and expression are species 
and time specific. The SDF-1α-/CXCR4 axis is involved in the activation of JAK-
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STAT, PI3K, MAPK pathways which are well known mediators of RIPC-induced 
cardioprotection (400, 407, 408). Nonetheless, it is not clear whether the endogenous 
increase in SDF-1α is sufficient to stimulate RIPC effect in vivo. Further experiments 
are essential to explain whether SDF-1α is an RIPC mimetic or can only be used as a 
biomarker for RIPC optimization.  
 
1.7.4 Current Clinical Trials on RIPC 
Multiple studies are currently on-going to assess the efficacy of RIPC in protecting 
the heart on multiple clinical outcomes. Su and colleagues are  currently recruiting 
around 60 participants to assess the effect of RIPC in patients undergoing CABG, 
with a primary aim of measuring serum troponin T level over 72 hours post CABG 
(NCT03010839). Wang and colleagues are recruiting 66 participants for a randomised 
trial to verify the myocardial protective effect of RIPC in patients undergoing off-
pump coronary artery and exclusion criteria includes LVEF < 35, AMI and multiple 
organ dysfunction. The primary endpoint of this study is the ICU staying time of the 
patients after surgery (NCT03340181). Similarly, Thielmann and colleagues are 
recruiting 500 participants for a phase 2 and phase 3 Germany-based randomised trial 
to study the effect of RIPC in patients undergoing on-pump CABG with crystalloid 
cardioplegic arrest with the primary outcome of assessing perioperative extent of 
myocardial injury by measuring serum troponin I level over 72 hours post CABG 
surgery (NCT01406678). In addition, Voisine and colleagues are recruiting 140 
participants for a randomised trial with a primary objective to verify if RIPC prior to 
aortic valve replacement surgery can confer cardioprotection. This study aims to 
measure the change in troponin T-HS and CK-MB concentration at 6, 12, 24 and 48 
hours post-operatively (NCT03305094). Yellon and colleagues are recruiting 200 
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participants to study the effect of RIPC in type II diabetic patients undergoing CABG 
(NCT00397163). An important facet of this trial is the focus on understanding the 
RIPC-effect on diabetic CABG patients. PREP (Pediatric remote ischemic pre-
conditioning prior to complex cardiac surgery), a randomised pilot study, recruited 53 
participants and aims to assess if RIPC prior to heart surgery can improve the 
recovery of heart and brain after heart surgery in newborn babies with congenital 
heart disease (NCT01739088). This study aims to assess the feasibility for a larger 
randomized controlled study on paediatric RIPC. Deja and colleagues are currently 
recruiting an estimated 120 participants who are presented with stable coronary artery 
disease referred for CABG (NCT01994707). The study aims to assess if RIPC 
changes the extent of apoptosis in human right atrial appendage and myocardial 
biopsy samples from LV harvested during cannulation for CABG. This study will be 
performed under controlled experimental setting which will help to establish if the 
RIPC phenomenon can be effectively used in clinical practice. RICARDO (Remote 
Ischemic Conditioning to Attenuate Myocardial Death and Improve Operative 
Outcome), a phase 2 clinical trial is currently recruiting an estimated 80 participants 
(NCT03363958). The interventional group will recipe RIPC 24 hours prior to off-
pump CABG and immediately prior to CABG. The RIPost group will receive 
intermittent lower limb ischaemic conditioning within 60 min after the surgery, 
whereas control group will receive sham procedure perioperatively. The primary 
outcome measures of this study are postoperative myocardial necrosis at 72 hours 
postoperatively and postoperative kidney injury at 7 days postoperatively.  
 
Two large randomized controlled trials- CONDI-2 (Effect of RIPC on Clinical 
Outcomes in STEMI Patients Undergoing pPCI; NCT01857414) and ERIC-PPCI 
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(Effect of Remote Ischaemic Conditioning on clinical outcomes in STEMI patients 
undergoing PPCI; NCT02342522) are recruiting an estimated 2600 and 2000 
participants respectively, randomized to RIPC or sham are nearing completion with 
harmonized primary endpoint of cardiac death and hospitalization for heart failure at 
1 year in STEMI patients treated with PCI. ERIC-PPCI clinical trial includes two sub-
studies: the biomarker sub-study will investigate enzymatic infarct size at 6 months 
and the cardiac magnetic resonance (CMR) sub-study will investigate infarct size at 6 
months. RECOND (Reduction in Infarct Size by Remote Per-postconditioning in 
Patients With ST-Elevation Myocardial Infarction), a randomized trial assessing the 
effect of RIPC prior to PCI has completed study with 120 participants and will report 
on the changes in myocardial infarct size at 1 week determined by CMR 
(NCT02021760). RIC-STEMI (Remote ischemic conditioning in ST-elevated 
Myocardial Infarction as Adjuvant to Primary Angioplasty) has recruited 516 patients 
and aims to assess the effect of remote ischaemic conditioning on cardiac-related 
death or hospitalization for heart failure rates up to 1 year during PCI in patients for 
STEMI (NCT02313961). CORIC-MI (Comprehensive Remote Ischemic 
Conditioning in Myocardial Infarction) is recruiting an estimated 200 participants to 
evaluate whether comprehensive remote ischaemic perconditioning (5 cycles of 5 min 
inflation and 5 min deflation of cut on a lower limb prior to PCI), postconditioning (5 
cycles of 5 min inflation and 5 min deflation of cuff on a lower limb immediately 
after PCI) and delayed ischaemic conditioning (5 cycles of 5 min inflation and 5 min 
deflation of cuff on a lower limb daily on 2-28 days post MI)  as an adjunctive 
therapy in STEMI patients undergoing PCI can improve left ventricular ejection 
fraction (LVEF) and remodeling at 30 days assessed by CMR with a minimum follow 
up time period of 1 year (NCT03233919). DREAM (Daily Remote conditioning in 
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Acute Myocardial Infarction), a UK based multicenter randomized controlled phase 2 
trial has completed the study on estimated 90 participants (NCT01664611). This 
study focused on evaluating the effect of daily RIPC for 4 weeks post MI. The 
inclusion criteria included previous STEMI, successful PCI and LVEF<45% on 
baseline echocardiography. The primary outcome data are obtained from baseline and 
4 month CMR to assess the changes in LVEF. CRIC-RCT (Chronic Remote Ischemic 
Conditioning to Modify Post-MI Remodeling) is a multicenter clinical trial is 
currently recruiting an estimated 20 participants who are presented with STEMI 
involving LAD within 12 hours of onset of the symptoms (NCT01817114). In this 
study, the effect of 4 cycles of 5 min-each ischaemia and reperfusion of the right arm 
prior to PCI will be evaluated by assessing the changes in left ventricular end diastolic 
volume (LVEDV) at 28 days post PCI by MRI. This clinical trial excludes diabetic 
patients. 
 
CONDI-PET (Effects of Remote Ischemic Conditioning on Myocardial Perfusion in 
Humans), a non-randomized phase 3 clinical trial in Denmark has completed the 
study on 50 participants with the primary objective of assessing the feasibility of 
using RIPC to treat ischaemic heart disease and soon to report on changes in 
myocardial blood flow following intervention in these participants (NCT02230098). 
ERIC-LYSIS (Effect of Remote Ischemic Conditioning in Heart Attack Patients) has 
completed a randomized controlled trial on 519 participants to study whether remote 
ischaemic conditioning in patients with STEMI can reduce myocardial tissue damage 
thereby preventing the onset of heart failure. The primary aim of this study was to 
measure serum CK-MB and troponin T levels at different time points post 
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thrombolysis to estimate the extent of myocardial damage during a heart attack 
(NCT02197117).  
 
A phase 2 clinical trial is underway, studying the protective effect of RIPC on heart, 
kidney and brain in patients undergoing transcatheter aortic valve implantation 
(TAVI) on 100 recruited participants(NCT02080299). The primary endpoint of this 
study is peri-interventional myocardial injury by assessing the changes in troponin I 
serum concentrations at 72 hours post intervention. We speculate that once these 
randomized trials are completed and the findings are reported, we will be in a better 
position to address the role of RIPC in protecting the heart from reperfusion injuries, 
and remodeling and whether this non-invasive technique merits phase 3 randomized 
trials before widely using in patient care.  
 
 
1.8 Nucleic acid therapeutics 
Recent genomic advancement has shifted our focus to complex molecular and cellular 
pathways that are regulated by range of key genes. Almost 30 years ago Patterson and 
colleagues demonstrated the use of nucleic acids in modulating gene expression 
(409). Over the years the field of nucleic acid in therapeutics has evolved with 
numerous genetic target. Currently a number of these natural and synthetic molecules 
are being used in vitro and in vivo in variety of pathological settings with mixed 
success.  
 
` 
 
 
Page | 64  
 
1.8.1. DNAzymes 
DNAzymes or deoxyribozymes are akin to gene specific molecular scissors. 
DNAzymes are not found in nature and unlike cellular double-stranded DNAs, 
DNAzymes contain a single-stranded catalytic core. All existing DNAzyme were 
isolated using a combinatorial technique known as ‘in vitro selection’. The most well-
characterized DNAzyme contain a cation dependent catalytic core that is that binds to 
and cuts its target mRNA. The activity of DNAzyme depends on the secondary 
structure of the target RNA at the cleavage site (410). Hence it is crucial to test a 
range of molecules to identify the ones that show a high-level activity against relevant 
biological targets. “Scrambled DNAzyme” can serve as a biological specificity 
control as the binding arms of the scrambled DNAzyme contains jumbled nucleotide 
sequence while preserving the catalytic core and it produces a molecular of identical 
size, net charge and same percentage make up of nucleic acids while the bindings 
sequence to the target gene are not matched. Enzymatically inactive DNAzyme with 
nonsense or mismatched sequences in the binding arms or point mutations in the 
catalytic core can serve as addition controls.  In order to improve the stability and 
potency of DNAzymes, few structural modifications have been incorporated. 
Modifications such as 3’-3’ inverted nucleotide addition at the 3’ end of the 
DNAzymes prevents the exonuclease degradation and it significantly extended the 
half of the molecule from ~70 min to >21 h in human serum (411). The introduction 
of phosphorothioate (PS) linkages enhanced resistance to endogenous nucleases 
(412). However, PS linkage may affect cleavage efficiency (411, 413), toxicity (414), 
immunological response (415), and may cause sequence-independent effects due to 
increased affinity for cellular proteins (416, 417).  
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1.8.2 siRNA 
Andrew Fire and Craig Mello first demonstrated the double-stranded RNA-mediated 
degradation of target mRNA in Caenorhabditis elegans (418). Short interfering RNA 
(siRNA) is 21-23 nucleotide long and are processed by RNase III family member 
Dicer. siRNA in then incorporated into an RNA-induced silencing complex (RISC) 
(419). During the formation of the RISC complex, the sense strand of the double-
stranded siRNA is cleaved. The double-stranded siRNA is unwinded by RNA 
helicases and RISC is guided to the complementary target mRNA by antisense strand 
and the target mRNA is cleaved by RISC (420-422).  One of the key advantages of 
siRNA-mediated gene silencing is that, it avoids the long double-stranded RNA-
mediated activation of the interferon pathway, which can prevent protein synthesis 
and cause nonspecific mRNA degradation (423). However, the major concerns 
associated with in vivo application of siRNA are tissue specificity and resistance 
against nucleases (424).  
 
1.8.3 Antisense Oligonucleotides 
Antisense oligonucleotides are single stranded 15-25 base pair long DNA or RNA. 
Although the exact mechanism of action is not well known, however, their function is 
controlled via hydrogen bonding with the target mRNA, which blocks ribosomal 
movement along the mRNA transcript and prevents the protein translation (424). In 
addition, endogenous RNAase-H targets the DNA or RNA heteroduplex and degrade 
the mRNA(425). As unmodified antisense oligonucleotides are likely to be degraded 
and their negative charge makes the cell membrane permeability difficult, modern day 
oligo’s contain variety of modifications such as PS backbone modification. PS 
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modification increases oligonucleotides half-life but also increases the chances  of 
nonspecific protein interaction, resulting in cytotoxicity and sequence independent 
phenotypic changes. 
 
1.8.4 Decoys 
Oligonucleotide decoys are short, double-stranded DNA molecules and contains 
binding elements for various proteins and inhibit promoter binding and gene (424).  
Issues limiting the clinical use of oligos includes vulnerability to nuclease 
degradation, host immunological responsiveness, and transfection difficulties. 
 
1.8.5 Ribozymes 
Ribozymes are RNA molecules and can mediate site-specific cleavage of target 
mRNA(424). In order to function, ribozymes need to access their binding sites in the 
target mRNA (424). Ribozymes are found in nature and most well studied ribozymes 
are hammerhead and hairpin ribozymes (426). These two types of ribozymes varies in 
their catalytic response to changes in the solvent pH(427). Substitution of 
deoxyribonucleotides for ribonucleotides at noncatalytic bases can improve the 
overall activity and stability of ribozymes(428).  
 
1.8.6 Aptamers 
Aptamers are synthetic nucleotide ligands and binds to their target protein with high 
affinity and specificity(424). Chemical modifications such as substituting the 2’-OH 
group of the ribose backbone provides resistance to enzymatic degradation and makes 
it clinically appealing (429).  
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1.9 Scope of the thesis 
In light of the importance of RIPC in reducing the I/R injury in AMI, it is important to 
identify the underlying mechanism of RIPC. This thesis explores the underlying 
mechanism of RIPC-induced cardioprotection from myocardial I/R injury, in 
experimental in vitro and in vivo models.  
 
The major aims of this thesis are to: 
1. To examine the apoptotic pathways involved in I/R injury both in vitro 
and in vivo and to assess if the apoptotic pathways cross-talk in I/R injury 
setting in vitro (Chapter 3). 
2. To identify the effect of RIPC on myocardial I/R injury-mediated 
apoptotic signaling in vitro and in vivo (Chapter 4). 
3. To examine the effect of RIPC on myocardial autophagy activity and to 
ascertain if autophagy is cardioprotective or detrimental in RIPC (Chapter 
5).  
4. To identify the regulator gene of RIPC-induced cardioprotection. 
Specifically, we will examine the role of Egr-1 gene as a master regulator 
of RIPC-induced cardioprotection (Chapter 6).  
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CHAPTER 2.                
Methods and Materials 
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2.1 Cell culture 
2.1.1 Cell culture 
Cardiac derived H9C2 cells (ATCC CRL 1446) were purchased as frozen stocks. 
Cells were grown in DMEM (Sigma-Aldrich, Missouri, USA) supplemented with 
10% fetal bovine serum (FBS) (Hyclone Logan, Utah), 4mM L-glutamine (Life 
Technologies, Carlsbad, California, USA)  and 100U/ml penicillin/streptomycin (Life 
Technologies) at 37C in a humidified chamber equilibrated with 5% CO2. Cells were 
used between passages 3-9 at 70% -80% confluency unless otherwise stated.  
 
2.1.2 Sub culture  
Cells were sub-cultured in every 2-3 days in 1: 3 ratio. For sub-culturing and 
harvesting, cells were washed with D-PBS (Thermofisher Scientific, Massachusetts, 
USA) twice and 3ml of 0.5% Trypsin/EDTA (Thermofisher Scientific) was added to 
the 75cm3 cell culture flask (Sigma Aldrich, Missouri, USA) and total culture surface 
area was covered. Cells were incubated at 37C in a humidified chamber equilibrated 
with 5% CO2 for 5 min and checked for detachment under the inverted light 
microscope. Detached cells appear completely rounded and slightly tapping the side 
of the flasks detaches the rounded-up cells. Cells were aspirated and re-suspended in 
5ml FBS containing complete cell culture media as used in section 2.1.1. Residual 
cells were washed with D-PBS and pooled together with the aspirated cells in 
complete media and centrifuged at 1,000 rpm (110g) for 5 min. Supernatants were 
removed and cell pellets were re-suspended in 10ml complete cell culture media, 
aspirated in a new 75cm3 cell culture flask and cultured as described in section 2.1.1. 
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2.1.3 Cryopreservation of cells 
Confluent cells were harvested according to section 2.1.2, re-suspended in 
cryopreservation solution (90% complete cell culture media + 10% v/v DMSO) at  a 
desired concentration of  0.5- 1 x 106 cells/ml   and aliquoted in a cryopreservation 
vial (Sigma-Aldrich, Missouri, USA). Vials were stored in a freezing container 
(Nalgene Labware, USA) and stored at -80C over-night and transferred to vapor 
phase nitrogen tank for long term storage.  
 
2.1.4 Thawing cryopreserved cells 
Vials containing cells were removed from nitrogen tank and transferred immediately 
to a 37C water bath and thawed with constant gentle agitation. Once thawed, cells 
were added drop by drop to a 15ml centrifuge tube containing 10 ml of complete cell 
culture media with gentle agitation to mix well. Cells were centrifuged at 1,000 rpm 
(110 g) for 5 min. Supernatant was discarded and cell pellet was re-suspended in 10 
ml of complete cell culture media and sub cultured as described in section 2.1.2.  
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2.2 Remote hypoxic preconditioning in vitro 
2.2.1 Recipe of hypoxic and normoxic media 
Remote hypoxic preconditioning and H/R injury was achieved by using hypoxic and 
normoxic media. Recipe for these two medias are as below: 
 
2.2.1.1 Normoxic media 
Table 2.1 Normoxic media formulation 
Reagent 
Molar 
Concentration (g/L) 
Required Molar 
Concentration 
Mass 
(g/500ml) 
DMEM (Catalogue No. 
5030, Sigma Aldrich, 
Missouri, USA) 
8.3  4.15 
Glucose (Sigma-Aldrich) 180.16 10mM 0.9 
HEPES (Sigma-Aldrich) 238.30 10mM 1.19 
2.2.1.2 Hypoxic media  
Table 2.2 Hypoxic media formulation 
Reagent 
Molar 
Concentration (g/L) 
Required Molar 
Concentration 
Mass (g/500ml) 
DMEM (Catalogue 
No. 5030, Sigma-
Aldrich) 
8.3  4.15 
Glucose Nil Nil Nil 
HEPES 238.30 10mM 1.19 
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2.2.2 Remote hypoxic preconditioning in vitro 
In order to make the hypoxia media hypoxic, nitrogen was bubbled directly into the 
media for 15 min to achieve less than 2% O2 followed by tightly closing the lid. 
Normoxic media was not bubbled with nitrogen. H9C2 cells (donor cells) grown to 
70%-80% confluency in a flask were washed twice with D-PBS and subjected to 5 
min hypoxia with hypoxia media in a hypoxic chamber followed by 5 min of 
reoxygenation. Reoxygenation was quickly achieved by pipetting the hypoxia media 
of the designated flasks up and down  followed by placing them in the incubator for 5 
min. These procedures were repeated three times. Followed by 3 cycles of hypoxia 
and reoxygenation, this media is labeled as the preconditioned (RIPC) media.  
 
2.3 Hypoxia-reoxygenation in vitro 
 
Serum starved H9C2 cells (recipient cells) grown to 70%-80% confluency were 
washed with warm D-PBS twice and thereafter exposed to 3 different experimental 
conditions: (1) Normoxic control where cells received normoxic media and left in the 
incubator for 1.5 h (2) Hypoxia-reoxygenation (H/R) cells received hypoxic media 
and exposed to 30 min hypoxia in the hypoxic chamber (3) RIPC-H/R cells received 
RIPC media and exposed to 30 min hypoxia in the hypoxic chamber. After 30 min, 
hypoxic and RIPC media was changed and followed by a warm D-PBS wash, H/R 
and RIPC-H/R cells were exposed to normoxic media for 1h in normoxic condition 
(20% O2). 
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Figure 2.1 Schematic diagram of RIPC in vitro 
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2.4 Western blot 
Cells were washed with cold D-PBS and trypsinized. Trypsinized cells were 
centrifuged at 1,000 rpm (110 g) for 5 min at 4ºC and supernatant discarded. Cell 
pellet was resuspended in RIPA cell lysis buffer containing 50mM Tris-HCL, 150mM 
NaCl, 5mM EDTA (pH 7.4), 0.5% Triton X-100 and protease and phosphatase 
inhibitor (Roche Diagnostics, Manheim, Germany). Cell lysate was centrifuged at 
14,000 rpm (20,800g) for 15 min at 4ºC and supernatant stored at -80ºC. Protein 
quantification was carried out using BCA protein estimation kit (Thermofisher 
Scientific, Massachusetts, USA) in accordance with the manufacturer’s instruction. 
Protein was prepared for electrophoresis by mixing protein sample with 10x DDT 
(Life Technologies, Carlsbad, California, USA) and 4x gel loading buffer (Life 
technologies) and boiling samples at 70ºC for 5 min. Equal amount of protein was 
resolved using Bolt Bis-Tris gel (Life Technologies) for 1h at 150V. Depending on 
the separation required, either MES (Life Technologies) or MOPS buffer (Life 
Technologies) was used as running buffer. Proteins were transferred to Hybond 
Nitrocellulose membranes (Amersham Pharmacis Biotech, Bucks, UK) using Bolt 
transfer buffer (Life technologies) by wet transfer method. Membranes were blocked 
in Tris-buffered saline containing 0.5% Tween-20 (TBST) (Thermofisher Scientific) 
in either 5% skim milk or 5% BSA (for phospho-proteins) for 1 h and then incubated 
overnight at 4ºC with the primary antibodies. Primary antibody concentrations and the 
host species is as below: 
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Table 2.3 Primary antibodies used  
Antibody Source Dilution Blocking 
buffer 
Company 
Egr-1 Rabbit 1:500 5% skim milk Santa Cruz        
(Dallas, Texas, 
USA) 
Cleaved PARP Rabbit 1:1000 5% BSA Cell signaling 
(Danver, 
Massachusetts, 
USA) 
Bcl-2 Rabbit 1:1000 5% BSA Cell signaling 
Bax Rabbit 1:1000 5% BSA Cell signaling  
Bcl-xl Rabbit 1:500 5% skim milk Santa Cruz 
Atg5 Rabbit 1:1000 5% BSA Cell signaling 
LC3B Rabbit 1:1000 5% BSA Cell signaling 
-actin Mouse 1:1000 5% skim milk Santa Cruz 
GAPDH Mouse 1:1000 5% skim milk Santa Cruz 
VCAM-1 Mouse 1:1000 5% BSA Abcam 
(Cambridge, 
UK) 
TRAIL Rabbit 1:500 5% skim milk Santa Cruz 
Cleaved 
Caspase-8 
Rabbit 1:1000 5% skim milk Novus 
Biologicals, 
(Colorado, 
USA) 
Phospho 
STAT3 
Rabbit 1:1000 5% BSA Cell signaling 
Total STAT3 Mouse 1:1000 5% skim milk BD Biosciences 
(New Jersey, 
USA) 
Phospho p38 
MAPK 
Rabbit 1:1000 5% BSA Abcam 
Total p38 
MAPK 
Rabbit 1:1000 5% skim milk Cell signaling 
Phospho-
GSK3β  
Rabbit  1:1000 5% BSA Cell signaling 
Total GSK3β  Rabbit  1:1000 5% skim milk Cell signaling 
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Table 2.4 Secondary antibodies used 
Antibody Source Dilution Blocking 
buffer 
Company 
Anti Rabbit Goat 1:5000 5% skim milk/ 
5% BSA 
Santa Cruz 
Anti Mouse Goat 1:5000 5% skim milk/ 
5% BSA 
Santa Cruz 
 
Membranes were washed 3x10 min with TBST and incubated with 1:5000 
horseradish peroxidase conjugated secondary antibody in either 5% skim milk or 5% 
BSA (for phosphor proteins) for 2 h at room temperature. Membranes were washed 
3x10 min with TBST. Proteins were visualized using Supersignal West Pico 
Chemiluminescent substrate (ECL) kit (Thermofisher) in LAS 4000 machine. Either 
Actin or GAPDH was used as a loading control and semi-quantitative analysis was 
performed using Multigauge software (Fujifilm). 
 
2.5 Real-Time Polymerase Chain Reaction assay 
2.5.1 Preparation of sample for RNA extraction  
2.5.1.1: RNA extraction from cell 
After exposure to experimental condition, cells were washed with ice-cold D-PBS and 
trypsinized cells (5x106 to 1x107 cells) were centrifuged at 14,000 rpm (20,800g). 
Cell pellet was resuspended in 500l Lysis solution/ 2-ME mixture and total RNA 
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extracted using the Gen elute Mammalian Total RNA Mini Prep Kit (Sigma-Aldrich, 
Missouri, USA). 
2.5.1.2: RNA extraction from tissue sample 
Tissue sample was excised and washed with ice-cold D-PBS and “snap-frozen” in dry 
ice. 500l to Lysis solution/2-ME mixture was added to the frozen tissue and 
homogenized in a flat bottom DNAase, RNAse free cell culture tube on ice with 
TissueRuptor (Qiagen, USA). Total RNA was isolated using the Gen elute 
Mammalian Total RNA Mini Prep kit (Sigma-Aldrich, Missouri, USA). 
 
2.5.2 Total RNA concentration measurement 
Concentration of total RNA was measured from 2l of the extracted RNA sample 
using NanoDrop 1000 Spectrophotometer (Thermofisher Scientific, Massachusetts, 
USA). 
 
2.5.3 cDNA synthesis  
RNA was reverse transcribed to 1g cDNA using Tetro cDNA Synthesis Kit (Bioline, 
London, UK) in accordance with the manufacturer’s instruction. cDNA was stored in 
-20°C. 
 
2.5.4 Real-Time PCR 
RT-PCR was performed with the cDNA samples prepared from Section 2.4.3 and RT-
PCR mixture prepared using SensiFast SYBR HI ROX Kit (Bioline, London, UK) in 
accordance with the manufacturer’s instruction. Initially, serial dilution of cDNA 
sample was done and RT-PCR was run to generate standard curve to estimate the 
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efficiency of the primers. RT-PCR was performed in an ABI Prism 7900 HT 
Sequence Detection System (Applied Biosystems, Foster City, CA). Reactions were 
performed in at least triplicate and were analyzed by relative quantitation using RQ 
Manager software, version 1.2 (Applied Biosystems). 
 
Primer sequences used for RT-PCR are as below: 
 
Egr-1:          Forward 5′-CTTACTCCTCTCCGGGCTCCTCTAC-3′  
                   Reverse 5′-CCCTCCCTTTGCTCTCTTTCATTC-3’  
 
Cardiotrophin-1:                  Forward 5′-AGCCTTCCTGATTTCTGCAGGCT-3’  
                                                Reverse 5′-AATT TCTGTGTTGGCGCAGTGTGG-3’  
 
LIF:               Forward 5′-TGTGGTAGCAGCCGAGTCATAAT-3’  
                                                Reverse 5′-CGTGGCTTGTGTGTTCGGTTTCAT-3’ 
 
 IL-6:    Forward 5′-GCTCGTCGTCGACAACGGCCTC-3’  
                                              Reverse 5′-CAAACATGATCTGGGTCATCTTCTC-3’ 
 
 IL-11:              Forward 5′-CGTGAAGCTGTGTTGTCCTG-3’  
                          Reverse 5′-GCTCCTAGGACTGTCTTCTTC-3’ 
 
GAPDH:               Forward 5′-ATGGGAAGCTGGTCATCAAC-3′ 
                          Reverse 5′ GTGGTTCACACCCATCACAA-3′ 
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2.6 Flow cytometry   
2.6.1 In vitro apoptosis study 
After the experiments, H9C2 cells were washed with cold D-PBS twice. Followed by 
trypsinization, cells were centrifuged at 1,000 rpm (110 g) for 5 min. Cell pellet was 
suspended in 1x Binding buffer at a concentration of 1 x 10^6 cells/ml. 100l of the 
solution was transferred to FACS tubes. 5l of Annexin V FITC (BD Biosciences, 
New Jersey, USA) and 5l of propidium iodide (PI) (BD Biosciences) was added to 
the tube and incubated for 15 min at room temperature in dark. Prior running the 
sample in the flow cytometry machine, 400l of 1x binding buffer (BD Bioscience) 
was added to each tube and the apoptotic cells were determined by analyzing 10,000 
gated cells using BD FACS flow cytometer.  
 
2.6.2 Mitochondrial membrane potential loss study 
After the experiments, H9C2 cells were washed with cold D-PBS twice. Followed by 
trypsinization, cells were centrifuged at 1,000 rpm (110 g) for 5 min. Cell pellet was 
suspended in D-PBS at a concentration of 1 x 10^6 cells/ml. 100l of the solution was 
transferred to FACS tubes. 5l of 2M stock of DiLC5 dye (Thermofisher Scientific, 
Massachusetts, USA) was added to the cells and incubated at room temperature for 15 
min in the dark. Fluorescence intensity of the cells were analyzed by gating 10,000 
cells using BD FACS flow cytometer. 
 
 
` 
 
 
Page | 80  
 
2.7 Cell viability assay 
2.7.1 Cell viability imaging 
Cell viability was measured using Live/Dead Cell Imaging Kit (Thermofisher, 
ScientificMassachusetts, USA). Cells were seeded in 6 well plate and after 
experiments, wells were washed 2 times with D-PBS. Live Green vial from the kit 
was thawed and transferred to the Dead Red vial to prepare 2x stock. Equal volume of 
2x stock and live cell imaging solution (140 mM NaCl, 2.5mM KCl, 1.8 mM CaCl2, 
1.0 mM MgCl2, 20mM HEPES, pH 7.4) and incubated at room temperature for 15 
min. Fluorescence images were taken using GFP and Texas Red filter in EVOS FL 
Auto Cell Imaging System (Thermofisher Scientific). 
 
 
2.7.2 Trypan blue exclusion assay 
After the experiments, H9C2 cells were washed with cold D-PBS twice. Followed by 
trypsinization, cells were centrifuged at 1,000 rpm (110 g) for 5 min. Cell pellet was 
suspended in cold D-PBS. Equal volume of 0.4% solution of trypan blue dye (Sigma-
Aldrich, Missouri, USA) and suspended cells in D-PBS was mixed and loaded onto a 
hemocytometer. The percentage of viable cells was determined by recording the 
number of cells that excluded 0.4% solution trypan blue dye. The cells were 
photographed using an Olympus SC35 camera attached to an Olympus CK40 
microscope.  
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2.8 Transfection 
2.8.1 DNAzyme preparation 
ED5 is Egr-1 specific DNAzyme and ED5 Scr is a scrambled DNAzyme that acts as a 
control. DNAzymes were synthesized with a 3’ linked inverted T at the 3’ termini for 
increased stability (Tri Link, San Diego, CA, USA). Sequences for DNAzymes are:  
ED5: 5¢-CCGCTGCCAGGCTAGCTACAACGACCCGGACGTTi3’; 
ED5Scr: 5¢GCCAGCCGCGGCTAGCTACAACGATGGCTCCACTi-3’; 
(Ti. 3’ 3’-linked inverted T). 
 
2.8.2 Transient transfection in vitro 
H9C2 cells were seeded in a 6 well plate. After 70% confluency, cells were 
transfected with 3:1 Fugene-6: DNAzyme ratio in 1ml serum free, antibiotic free 
DMEM overnight. Next day, cells were washed with warm D-PBS and changed to 
completed growth media (Section 2.1). Transfection efficiency was confirmed with 
RT-PCR as described in Section 2.4.  
 
 
 
 
 
 
2.9 In vivo experiment 
2.9.1 Animals 
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Sprague-Dawley rats (male, 350-400g), after a week of acclimatization period were 
used for the surgery. 
 
2.9.2 Anesthesia 
Anesthesia was induced in an induction chamber using 5% (v/v) vaporized isoflurane. 
The animal was positioned supine and endotracheal intubation performed using an 18 
gauge plastic cannula. Anesthesia was maintained with 2% (v/v) isoflurane and the 
animal ventilated at a rate of 80 breaths per min with a tidal volume of 1.5 mL per 
100 g body weight using a small animal ventilator.  
 
2.9.3 ED5 and ED5 Scr Injection preparation 
DNAzyme solution was delivered into the hind-limb muscle tissue at multiple sites 
within the designated RIPC area 3 h prior to RIPC. DNAzyme (ED5 and ED5 Scr) 
injection was prepared in 200l volumes containing sterile water, 60l FuGene6, 1 
mM MgCl2 and 500g DNAzyme (Both ED5 and ED5 Scr). 
 
 
 
 
 
 
2.9.4 Remote hind limb 
preconditioning 
RIPC consisted of fastening a 
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tourniquet around the hind limb of the rat for 3 x 5 min alternating cycles of 
tightening and loosening.  Limb ischemia was confirmed by cyanosis and drop in feet 
temperature. 
 
 
 
 
 
 
 
Figure 2.2 Hind limb preconditioning in rats 
 
 
 
2.9.5 Ischemia reperfusion injury model 
Immediately prior to surgery an intramuscular injection of lignocaine (10 mg per kg 
body weight) and subcutaneous injection of Temgesic (0.1 mg per kg body weight) 
was administered. The rat was placed on a heating pad and the thorax was shaved, 
cleaned using Betadine antiseptic, and a thoracotomy performed at the 5th intercostal 
space with an incision parallel to the ribs. After that, the heart was exposed by 
spreading the ribs using a self-retaining retractor. The pericardium was opened using 
sharp forceps. Then, the left coronary artery (LCA) was ligated using a 6/0 silk suture 
(Ethicon, New Jersey, USA), which was passed through the myocardium deep to the 
vessel and through a snare in preparation for a 30 min transient ligation and cyanosis 
of a significant area below the snare was confirmed.  
 
 
` 
 
 
Page | 84  
 
 
 
 
 
 
Figure 2.3 Cyanosis of the heart after LAD ligation 
Following 30 min, the snare was released and the suture tied loosely in place. Then, 
the chest cavity was closed with layered sutures. After that, the animal was revived 
and placed in an isolated chamber for recovery. For the sham control group, the 
operative technique was identical except that no ligation of the LCA was performed. 
Rats in the ED5 and ED5 scramble group, received ED5 and ED5 Scr injection in the 
hind limb 3 h prior RIPC as described in Section 2.8.3. 
 
2.9.6 Blood collection 
At 24 h post reperfusion (unless otherwise stated), abdominal incision was made on 
the anesthetized rats and renal artery visualized and 3-4 ml of blood was withdrawn 
with 22-gauge hypodermic needle and quickly transferred into a Lithium-Heparin 
Blood collection tube (BD Biosciences, New Jersey, USA) and kept on ice till 
centrifugation.  
 
2.9.7 Infarct size measurement 
Rats were anesthetized and intubated as described previously in section 2.8.3. After 
performing echocardiography as described in section 2.8.2, sutures were removed and 
self-retaining retractor was used to re-open the chest. LAD was re-occluded and 5ml 
of 3% Evans blue (Sigma-Aldrich, Missouri, USA) in D-PBS solution was injected 
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into the tail vein, and allowed to perfuse for 3 to 5 min. The heart was excised, 
washed in PBS. The heart was wrapped in cling wrap, placed in a container and kept 
on dry ice. Semi frozen heart was sliced transversely into 1 to 2mm thick slices. Slices 
were incubated in 1% TTC (Sigma-Aldrich) in D-PBS solution for 10 min each side 
at 37C followed by immersion in 10% neutral formal buffer to increase the contrast, 
examined and digitally photographed. Images were analyzed by using ImageJ 
(version 1.51q, Java based software program, NIH). Non-area at risk (AAR) appeared 
as blue. Area not appeared as blue was considered as area at risk (AAR). TTC stained 
viable myocardium as red/pink and infarcted tissue appeared as white. Total infarct 
size was calculated as the percentage of infarct size/AAR.  
 
2.10 ELISA 
Enzyme-linked immunosorbent assay (ELISA) kits were used to determine the 
concentration of IL-6 (Rat IL-6 Quantikine ELISA Kit, R&D Systems, Minneapolis, 
USA) protein. For circulating protein levels, blood from rats collected in Lithium-
Heparin tube spun at 2,500 rpm (950g) for 5 min and plasma was collected. For IL-6 
protein secreted into the preconditioned media by H9C2 cells, media was collected 
and spun at 1,000 rpm (110 g) for 5 min. For detection of both plasma IL-6 and H9C2 
cells secreted IL-6, 50 l of rat plasma and  media were used respectively and protein 
estimated as per the manufacturer’s instruction. 
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2.11 Animal ethics 
In vivo experiments were approved by the Animal Care and Ethics Committee of 
Royal North Shore Hospital and were performed according to the recommendations 
of the Australian Council for Animal Care. 
2.12 Statistical analysis 
Normalised results are expressed as mean ± standard error of the mean (SEM).  
Statistical analysis between groups was performed by one-way ANOVA, followed by 
post hoc comparison using Tukey’s multiple comparison tests using GraphPAd Prism 
software (GraphPad software version 7.02; GraphPad Inc, San Diego, CA, USA). 
Comparison between two groups was performed using two-tailed Student’s T-test.  p 
≤ 0.05 was considered to be significant.  
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CHAPTER 3.              
Ischaemia reperfusion injury 
involves cross-talk between 
extrinsic and intrinsic pathway of 
apoptosis 
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3.1 Aims  
3.1.1 To study the effect of H/R injury on cardiomyocyte viability and apoptosis 
in vitro 
3.2.2 To elucidate the apoptotic pathways involved in I/R injury both in vitro 
and in vivo 
3.2.3 To assess if the apoptotic pathways cross-talk in I/R injury setting in vitro 
3.2.4 To evaluate the effect of extrinsic pathway of apoptosis inhibition prior to 
H/R on intrinsic pathway of apoptosis in vitro 
3.2.5 To evaluate the effect of extrinsic pathway of apoptosis inhibition prior to 
H/R on the overall apoptosis level in vitro 
 
3.2 Introduction 
Major organs in the human body, including heart, kidney, brain, gut, and liver are 
particularly sensitive to I/R injury (430). Over the last few decades, increasing 
evidence suggests that cardiomyocyte apoptosis is a key part of the pathogenesis of 
several myocardial diseases (431). In particular, cardiomyocyte apoptosis is a 
prominent feature of myocardial infarction after coronary artery occlusion and 
resultant prolonged ischaemia in isolated perfused heart, and myocardial hibernation 
(432-434). 
 
Whilst reperfusion is the most effective strategy in preventing cell death in MI, 
reperfusion itself can result in contradictory injury. Reperfusion of the ischaemic 
myocardium results in increased apoptotic and necrotic cell death. Myocardial 
protection strategies during AMI have been of clinical interest (11). Over the years,  
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very few anti-apoptotic therapeutic strategies have been used to minimize I/R-induced 
apoptotic cell death (11).  Most of these studies, however, have provided minimal 
insight into the apoptotic signaling mechanisms and their specific roles in mediating 
apoptosis. Apoptosis mechanisms can be classified into two major pathways; extrinsic 
death pathway and intrinsic apoptosis pathway (435). The extrinsic death receptor 
pathway is activated by binding the death ligands to the death domain receptors on the 
cell surface. The Fas-Fas ligand or TNF-TNF-receptor interaction triggers the 
extrinsic apoptosis signaling that proceeds via caspase 8 to activate executioner 
caspases via caspase 3 (435). The intrinsic apoptosis pathway is stimulated by stress 
related signalling. Activated intrinsic apoptosis pathway causes DNA and/or 
cytoskeleton, mitochondria, golgi, and sarcoplasmic reticulum damage (436-441).  
 
 
3.3 Rationale 
Both the intrinsic and extrinsic pathways of apoptosis synergistically contribute to cell 
death in clinical settings such as stroke (442, 443), MI (444, 445) and heart failure 
(446, 447). However, little research has been done to elucidate the role of these 
apoptotic pathways in the myocardial I/R injury setting. This underlines the necessity 
to delineate the significance of the pathways involved in myocardial I/R injury-
mediated apoptosis. 
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3.4 Methods  
3.4.1 Hypoxia-reoxygenation (H/R) in vitro 
H/R in H9C2 cells was accomplished as described in chapter 2.3. Briefly, for H/R, 
overnight serum starved H9C2 cells were exposed to 30 min hypoxia (<2% O2) 
followed by 1 h reoxygenation in normoxic media at 37°C for 1.5 h. 
 
3.4.2 In vivo experiments 
Male Sprague-Dawley rats (250-300g) were subjected to 30 min ischaemia by 
transient suture ligation of the left coronary artery followed by 24 h reperfusion as 
previously described in chapter 2.9.5 and outlined in figure 3.4.1. 
 
 
Figure 3.4.1 Schematic illustration of the protocol used for rats in vivo. 
 
3.4.3 Western blot 
Protein expression from myocardial tissue extracted from the cardiac apex and H9C2 
cell lysate was measured using western immunoblot as previously described (see 
chapter 2.4). Briefly, protein was extracted from whole cell lysate or tissue lysate and 
run on a western blot to determine the protein expression. Membranes were blocked 
in Tris-buffered saline containing 0.2% Tween-20 (TBST) in 5% skim milk for 1 h 
and then incubated overnight at 4 ºC with the following antibodies –cleaved PARP 
I	 R	
	
A B C
A. 30 min LAD occlusion 
B. Reperfusion 
C. 24 h reperfusion, tissue extraction and infarct size measurement
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1:1000 (Cell signaling, Massachusetts, USA), Bax 1:1000 (Cell signaling, 
Massachusetts, USA), Bcl-2 1:1000 (Cell signaling, Massachusetts, USA), Bcl-xl 
1:1000 (Cell signaling, Massachusetts, USA), TRAIL 1:500 (Santa Cruz, Texas, 
USA), cleaved caspase 8 1:1000 (Novus Biologicals, Colorado, USA).   Even protein 
loading was confirmed by probing for either -actin 1: 1000 (Santa Cruz, Texas, 
USA) for cell lysate or GAPDH 1:1000 (Santa Cruz, Texas, USA) for tissue lysate. 
 
3.4.4 Flow cytometry 
H9C2 cells were collected and resuspended in binding buffer followed by incubation 
with Annexin V-FITC and Propidium Iodide (PI) (BD Biosciences, New Jersey, 
USA). The percentage of apoptotic cells was quantified by flow cytometry. 
Mitochondrial membrane potential of H9C2 cells was measured by adding DiLC5 dye 
(Thermofisher Scientific, Massachusetts, USA) to the cells followed by analysing the 
fluorescence intensity of the cells by flow cytometry.  
 
3.4.5 Cell viability  
Cell viability was measured using Live/Dead Cell Imaging Kit (Thermofisher 
Scientific, Massachusetts, USA) as described in chapter 2.7.1. Cell viability was also 
assayed by trypan blue exclusion method as described in chapter 2.7.2. An equal 
volume of 0.4% solution of trypan blue dye (Sigma-Aldrich, Missouri, USA) and 
suspended H9C2 cells in D-PBS were mixed and loaded onto a haemocytometer. The 
percentage of viable cells was determined by recording the number of cells that 
excluded 0.4% solution trypan blue dye. The cells were photographed using an 
Olympus SC35 camera attached to an Olympus CK40 microscope. 
3.4.6 Reagents 
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Extrinsic pathway of apoptosis was blocked by targeting caspase 8 with Z-IETD-
FMK (BD Biosciences, New Jersey, USA). H9C2 Cells were treated with 50µM Z-
IETD-FMK for 2 h prior to H/R as previously described (448). 
  
3.4.7 Statistical analysis 
Normalised results are expressed as mean ± standard error of the mean (SEM).  
Statistical analysis between groups was performed by one-way ANOVA, followed by 
post hoc comparison using Tukey’s multiple comparison tests using GRAPHPAD 
software (GraphPad software version 7.02; GraphPad Inc, San Diego, CA, USA). 
Comparison between two groups was performed using two-tailed Student’s T-test.  p 
≤ 0.05 was considered to be significant.  
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3.5 Results 
 
3.5.1 H/R reduces cell viability and increases apoptosis in H9C2 cells 
 
H/R injury to H9C2 cells significantly reduced cell viability from 74.27 ± 3.79% to 
34.93 ± 3.68% (p<0.0001) (Figure 3.5.1 B). A similar pattern was observed in cell 
viability assay with trypan blue exclusion method (Figure 3.5.1 C), where H/R injury 
caused significant cell death compared to normoxic control (91.05 ± 3.45% vs. 40.72 
± 11.80%, p<0.05). 
 
H/R injury increased apoptotic cell death in H9C2 cells compared to normoxic control 
(4.24 ± 1.14% vs. 1.43 ± 0.36%, p<0.05) (Figure 3.5.1 D) and increased apoptotic 
protein marker PARP cleavage by 2.45  0.23-fold relative to normoxic control 
(p<0.01) (Figure 3.5.1 E).  
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Figure 3.5.1 Extent of cell viability and apoptosis in H9C2 cells following H/R. 
(A) H9C2 cells were stained with calcein AM (green) to indicate live cells and 
Ethidium homodimer-1 (red,) to indicate dead cells. The scale bar represents 1000 
μm. (B) Quantitative analysis of live/dead cells expressed as the percentage of cell 
viability. (C) Cell death measured by trypan blue exclusion method expressed as the 
percentage of viable cells. (D) Cell apoptosis was assessed by Annexin V-FITC and 
propidium Iodide (PI) double staining and FACS. Quantitative analysis of the 
percentage of apoptotic cells (Annexin-V+/PI+) is expressed as mean ± SEM (E) 
Western blot analysis of cleaved PARP. Results are expressed as mean ± SEM; n= at 
least 3 biological replicates, *p<0.05 vs. normoxic control, **p<0.01 vs. normoxic 
control, ****p<0.0001 vs. normoxic control.  
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3.5.2 H/R injury activates the intrinsic pathway of apoptosis in H9C2 
cells  
 
H/R injury significantly increased the pro-apoptotic Bax protein level by 1.4 ± 0.11-
fold relative to normoxic control (p<0.01) (Figure 3.5.2 A). In contrast, anti-apoptotic 
protein Bcl-2 (Figure 3.5.2 B) and Bcl-xl protein level (Figure 3.5.2.C) decreased to 
0.49 ± 0.14-fold relative to normoxic control (p<0.01) and 0.71 ± 0.10-fold relative to 
normoxic control (p<0.05) respectively. Furthermore, H9C2 cells subjected to 
simulated H/R injury lost their mitochondrial membrane potential by 40% compared 
to normoxic control (p<0.01) (Figure 3.5.2 D). 
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Figure 3.5.2 Expression of the intrinsic pathway of apoptosis proteins in H9C2 
cells following H/R injury. Western blot analysis of (A) Bax protein, (B) Bcl-2 
protein, (C) Bcl-xl protein. (D) Geo mean fluorescence of mitochondrial membrane 
potential loss assessed by DiLC5 staining. Results are expressed as mean ± SEM of 
the fold change relative to normoxic control; n= at least 3 biological replicates, 
*p<0.05 vs. normoxic control, **p<0.01 vs. normoxic control. 
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3.5.3 I/R injury activates the intrinsic pathway of apoptosis in rat 
myocardial tissue 
 
Activation of the intrinsic pathway expresses pro-apoptotic Bax protein. In rat 
myocardial tissue, 24 h following I/R injury, pro-apoptotic Bax protein expression in 
the rat myocardium was significantly upregulated by 1.43 ± 0.13-fold relative to sham 
control (p<0.05, Figure 3.5.3).  
 
 
Figure 3.5.3 Expression of the intrinsic pathway of apoptosis protein marker in 
rat heart after I/R injury. Representative immunoblot of the intrinsic apoptosis 
marker Bax in lysates from rat heart with and without I/R. Results are expressed as 
mean ± SEM, fold relative to sham control (n=5, *p<0.05 vs. sham). 
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3.5.4 H/R injury activates the extrinsic pathway of apoptosis in H9C2 
cells  
 
TRAIL activates the extrinsic apoptosis pathway and cleaves procaspase 8 to form 
cleaved caspase 8. In H9C2 cells, H/R injury significantly upregulated TRAIL protein 
level by 2.25 ± 0.27-fold relative to normoxic control (p<0.0005, Figure 3.5.4 A). 
Consistent with this, H/R injury significantly increased cleaved caspase 8 subunit 
(p43/p41) by 1.4 ± 0.07-fold relative to normoxic control (p<0.01, Figure 3.5.4 B).  
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Figure 3.5.4 Expression of the extrinsic pathway of apoptosis proteins in H9C2 
following H/R injury. Western blot analysis of (A) TRAIL protein, (B) Cleaved 
Caspase-8 protein expression in H9C2 cells subjected to H/R. Results are expressed 
as mean ± SEM, fold relative to normoxic control, n= at least 3 biological replicates,    
**p<0.01  vs. normoxic control, ***p<0.0005 vs. normoxic control. 
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3.5.5 I/R injury activates the extrinsic pathway of apoptosis in vivo in 
rat myocardial tissue 
 
At 24 h following I/R injury, pro-caspase 8 in rat heart was significantly cleaved into 
caspase 8 subunits (p18) (1.39 ± 0.14-fold relative to sham control, p<0.05)      
(Figure 3.5.5).  
 
 
 
 
Figure 3.5.5 Expression of the extrinsic pathway of apoptosis proteins in rat 
heart following I/R injury. Representative immunoblot of the extrinsic apoptosis 
marker cleaved caspase 8 in lysates from rat heart with and without I/R. Results are 
expressed as mean ± SEM, fold relative to sham control (n=11, *p<0.05 vs. sham). 
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3.5.6 Extrinsic pathway of apoptosis cross-talk with the intrinsic 
pathway of apoptosis 
 
H9C2 cells treated with caspase 8 inhibitor Z-IETD-FMK prior to H/R injury showed 
significantly decreased caspase 8 cleavage compared to H/R group (1.12 ± 0.10 vs. 
1.40 ± 0.07-fold relative to normoxic control, p<0.05) (Figure 3.5.6 A). Z-IETD-FMK 
treatment prior to H/R injury reduced the expression of proapoptotic Bax protein 
compared to H/R group (0.78 ± 0.45 vs. 1.42 ± 0.23, fold relative to normoxic 
control, p<0.01) (Figure 3.5.6 B) and upregulated anti-apoptotic Bcl-2 protein level 
compared to H/R group (1.12 ± 0.16 vs. 0.64 ± 0.06, fold relative to normoxic 
control, p<0.05) (Figure 3.5.6 C).  
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Figure 3.5.6 Cross-talk between the extrinsic and intrinsic pathway of apoptosis 
following H/R injury. Western blot analysis of (A) Cleaved caspase 8, (B) Bax, (C) 
Bcl-2 protein expression in H9C2 cells subjected to Z-IETD-FMK treatment prior to 
H/R injury. Results are expressed as mean ± SEM; n= at least 3 biological replicates, 
*p<0.05, **p<0.01. 
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3.5.7 Inhibition of the extrinsic pathway of apoptosis does not reduce 
H/R-induced apoptosis in H9C2 cells 
 
H/R injury significantly increased apoptotic cell death in H9C2 cells compared to 
normoxic control group (0.22 ± 0.01% vs. 0.09 ± 0.03%, p<0.01), however pre-
treatment with Z-IETD-FMK had no effect on the apoptotic cell death (0.21 ± 0.03% 
vs. 0.22 ± 0.01%, p=0.90). (Figure 3.5.7). 
 
 
 
Figure 3.5.7 Effect of caspase 8 inhibition prior to H/R on cellular apoptosis. 
Quantitative analysis of the percentage of apoptotic (Annexin-V+/PI+) cells are 
represented as the mean ± SEM; n= at least 3 biological replicates, **P<0.01 vs. 
normoxic control, NS (not significant). 
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3.6 Discussion 
Myocardial I/R injury is a continuous process rather than ‘an all or none’ 
phenomenon, which progresses to irreversible I/R injury (449-451). Myocardial 
ischaemia primarily results in necrosis due to depleted ATP, calcium overload, 
acidosis and oxidative stress (434, 452, 453). One of the main pathological 
consequences of MI is cardiomyocyte apoptosis. Previous research suggests that both 
the intrinsic (mitochondrial) pathway and extrinsic (death receptor) pathway are 
involved in apoptosis of cardiomyocytes (454, 455). However, the impact of the 
individual pathways in I/R injury have not been elucidated. This study demonstrates 
for the first time the cross-talk between the intrinsic and extrinsic apoptosis pathways, 
as well as the importance of apoptosis in I/R injury. 
 
Previous research suggests that 15 min of normothermic regional ischaemia does not 
cause detectable necrosis or apoptosis, however, increasing the ischaemic period 
causes irreversible I/R injury with larger infarct size, decreased myocardial function 
and significantly increased apoptosis (450, 456). Several studies in human, rabbit and 
rat hearts suggest that apoptosis contributes to overall cell loss during myocardial 
ischaemia (432-434), however, an increase of the infarct size was observed after 
reperfusion (457). Additionally, cardiomyocyte apoptosis was reported to be 
associated with LV dysfunction after cardiac surgery, whilst cardioplegia efficiently 
protects the heart from impaired LV dysfunction and apoptosis (458). Consistent with 
previous findings, this study demonstrates the expression of apoptosis in an in vitro 
model of I/R injury known as H/R injury. Cleaved PARP protein expression was 
significantly increased after H/R, resulting in increased apoptotic cells in vitro and an 
overall reduction in cell viability following H/R injury. This suggests that the 
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inhibition of apoptosis may provide a new therapeutic strategy to minimize I/R injury 
associated myocardial damage.  
 
Mitochondria are major organelles in apoptosis, and the mitochondrial membrane 
potential may play a significant role in intracellular ion homeostasis (459). 
Mitochondria also act as a Ca2+ buffer by regulating the intracellular Ca2+ 
concentration (460). Changes in this buffer system may initiate a pathological 
increase in Ca2+, with subsequent mitochondrial membrane depolarization (461). 
Mitochondrial membrane depolarization, in turn, triggers Ca2+ shift from the matrix to 
the cytoplasm and initiates the apoptotic cascade (462). The reduction in 
mitochondrial membrane potential is associated with the activation of pro-apoptotic 
Bax proteins, that are involved in permeabilizing the mitochondrial outer membrane 
(463). Upon apoptotic stimulation, Bax oligomerizes and translocates from the 
cytosol to mitochondrial membranes (464). Through interactions with mitochondrial 
membrane pore proteins, Bax increases the membrane’s permeability, which releases 
cytochrome C from mitochondria, activates caspase 9 and initiates caspase cascade 
(463, 465). In this study, a significant increase in pro-apoptotic Bax protein 
expression was observed, while anti-apoptotic Bcl-2 protein expression significantly 
reduced, suggesting an activated intrinsic pathway of apoptosis induced by I/R injury.  
 
The cell extrinsic pathway of apoptosis is initiated by binding of the TNF superfamily 
proteins to its receptors (466). The most commonly characterised member of the TNF 
superfamily, TRAIL, is significantly increased in vitro after I/R injury in this current 
study. TRAIL binds to its receptors and initiates the trimerization and clustering of 
the death domain (DD) of its receptors, leading to the formation of the death inducing 
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signaling complex (DISC) (82, 92, 93). Trimerization of the DDs leads to the 
recruitment of an adapter molecular, FADD and formation of a DD associated 
proteins complex with pro-caspase 8, resulting in the proteolytic cleavage of pro-
caspase 8 into large and small subunit, which in turn activates procaspase 3 through 
proteolytic cleavage and activates the apoptosis cascade (466). Similar to this we 
demonstrate an increase of cleaved caspase 8 after I/R injury in both in vitro and in 
vivo studies suggesting an activated extrinsic pathway of apoptosis induced by I/R 
injury.  
 
Growing evidence suggests that extrinsic and intrinsic apoptotic pathways are highly 
interconnected and Bid protein plays a major role in linking the two pathways 
together (467). Following death stimulus cleaved caspase 8 can efficiently truncate 
Bid (468) and truncated Bid (tBid) translocates from the cytosol to mitochondrial 
membrane and activates Bax or inactivates Bcl-2 (469). It is likely that in I/R injury 
involves cross-talk between the extrinsic and intrinsic pathway of apoptosis, which 
was blocked by inhibiting the extrinsic pathway. It is possible that the cross-talk 
between the two apoptotic pathways amplifies the apoptosis signal. However, 
inhibition of the extrinsic pathway through caspase 8 blocking failed to reduce the 
overall apoptosis level. These findings raise the question, whether or not extrinsic 
pathway is involved in I/R-induced apoptosis. Considering the effect of caspase 8 
inhibition on the intrinsic pathway, it is likely that both pathways are involved in I/R-
induced apoptosis.  
 
Recently, it has been suggested that Fas ligand and TRAIL receptor engagement can 
induce the expression of inflammatory cytokines and chemokines (470-472). This 
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inflammatory response is somewhat regulated by receptor interacting protein kinase 1 
(RIPK1), but mostly dependent on caspase 8 (471). RIPK1 is a major upstream 
regulator of necroptosis (473-475). Interestingly, caspase 8 also has a pro-survival 
role and is essential for embryonic development (476). Caspase 8 also suppresses 
TLR and death receptor-mediated necroptotic death (477) and inhibition of caspase 8 
by mammalian inhibitors, chemical inhibitors, and genetic silencing promotes 
necroptosis (478). Activated RIPK1 can activate pro-inflammatory receptor 
interacting protein kinase 3 (RIPK3) leading to necroptosis (479). Caspase 8 can 
cleave both RIPK1 and RIPK3 to prevent necroptosis (480-482) and FLIPL inhibits 
caspase 8 from initiating apoptosis in this setting (483). Caspase 8 deficient mice 
were not viable whereas caspase 8 and RIPK3 double knockout mice were viable 
suggesting that, in absence of caspase 8-necroptotic death dominates (483).   
 
In summary, the extrinsic and intrinsic pathway of apoptosis cross-talk in I/R injury to 
induce apoptosis. Blocking the extrinsic pathway only does not induce protection 
against apoptosis in I/R injury. Rather the intrinsic pathway is still active and may 
take over the extrinsic pathway role. Additionally, inhibition of the extrinsic apoptotic 
pathway may cause necroptotic cell death instead. Therefore, myocardial protective 
therapies blocking apoptosis should aim to block both proapoptotic and necroptotic 
cell death pathway concurrently to gain maximal cellular protection.   
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3.7 Limitations 
In vitro model used in this study only stimulates H/R injury, which is one part of 
myocardial I/R. Therefore, this model does not fully replicate in vivo setting. In 
addition, only cardiomyocytes were used in this study to assess the effect of H/R 
injury in vitro, which only partially address the complex cellular environment of the 
heart. Cardiomyocyte-endothelial cell co-culture model would better replicate the 
cardiac cellular composition.  
 
3.8 Importance 
First, this study elucidates the apoptotic pathways involved in I/R injury. Second, this 
establishes the relative importance of the apoptotic pathways in I/R injury-induced 
apoptosis and suggests that necroptotic pathways may also need to be targeted if the 
therapeutic benefit is to be achieved through blocking the extrinsic pathway of 
apoptosis. 
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Chapter 4.                
Remote ischaemic preconditioning 
protects against myocardial 
ischaemia reperfusion injury  
 
 
 
 
 
  
` 
 
 
Page | 110  
 
4.1 Aims 
4.1.1 To identify the effect of RIPC on myocardial I/R injury-mediated 
apoptotic signaling in vitro and in vivo 
4.1.2 To examine the effects of RIPC on myocardial infarct size and 
inflammation 
4.1.3 To elucidate the effects of RIPC prior to myocardial I/R on Egr-1 mRNA 
and protein expression 
4.1.4 To ascertain the pathways involved in RIPC-mediated myocardial 
protection 
 
4.2 Introduction 
Acute myocardial infarction (AMI) is one of the leading causes of mortality and 
morbidity worldwide (2). To prevent ischaemic damage to the heart it is critical to 
restoring blood flow to ischaemic tissue by opening the blocked coronary artery. 
Rapid restoration of oxygenated blood supply to ischaemic tissue induces oxidative 
stress, inflammation, and cardiomyocyte death, eventually contributing to a larger 
infarct size. Early growth response-1 (Egr-1) is a transcription factor playing a key 
role in regulating endothelial and vascular smooth muscle cell responses to 
mechanical and I/R injuries (223, 240, 484). Activated endothelial cells express 
VCAM-1 (485) that interacts with leukocytes and mediate inflammatory response. 
 
Treating AMI patients with antioxidant therapy including Na+-H+ inhibitors to reduce 
Ca2+ overload, anti-inflammatory agents, metabolic modulators, and hypothermia 
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amongst other strategies have not achieved expected clinical outcomes (10), hence the 
need to develop alternative therapies. Ischaemic conditioning, in which brief periods 
of non-lethal ischaemia and reperfusion is applied directly to the heart, is an 
endogenous approach that has been shown to induce a cardioprotective effect in I/R 
setting (259). Upregulation of pro-inflammatory cytokines are involved in mediating 
late phase of ischemic preconditioning (486). However, its clinical application is 
restricted to elective cardiac surgeries due to its invasive approach. This phenomenon 
of eliciting cardioprotection through endogenous response is not limited to directly 
conditioning the target organ. A similar level of protection can be achieved even 
when the stimulus is applied to distant or ‘remote’ organs such as kidney, liver, 
intestine, skeletal tissue. This alternative approach is termed as remote ischaemic 
preconditioning (RIPC). Continuous progress is being made in translating the concept 
of RIPC from bench to bedside. RIPC has shown its cardioprotective effect in patients 
undergoing elective abdominal aortic aneurysm repair, elective percutaneous coronary   
(PCI), coronary angioplasty and coronary artery bypass surgery (274, 282, 487-489), 
while many studies failed to demonstrate the cardioprotective nature of RIPC in 
clinical settings (273), (277), (278), (283). Although the exact trigger of RIPC-
mediated cardioprotection is unknown, increasing number of studies have suggested 
multiple signaling mechanisms in the target organ. Previous studies have implicated 
the involvement of signal transducer and activator of transcription (STAT) proteins 
which are part of Janus Kinase (JAK)-STAT pathway, mitogen activated protein 
kinases (MAPK) pathways in the complex signaling transduction process of  
ischaemic preconditioning (490-492). However, the signal transduction mechanism of 
RIPC remains elusive.  
` 
 
 
Page | 112  
 
4.3 Rationale  
Despite recent advances in translating the RIPC concept in a clinical setting, 
characterization, and mechanism of RIPC remains to be fully defined H9C2 neonatal 
cardiomyocyte cell line was used as donor cells (RIPC site) in this study, as this cell 
line is widely used as a mimetic for skeletal and cardiac muscle due to its 
biochemical, morphological and electro/hormonal signaling properties (493, 494). 
4.4 Methods  
 
4.4.1 RIPC and H/R in vitro 
RIPC and H/R were performed as described in chapter 2.2 and chapter 2.3 
respectively. Briefly, for RIPC, H9C2 cells grown to 70-80% confluency was exposed 
to 3 cycles of intermittent hypoxia (<2% O2) and reoxygenation. For H/R, overnight 
serum starved H9C2 cells were exposed to 30 min hypoxia followed by 1 h 
reoxygenation in normoxic media. RIPC-H/R group received preconditioned media 
during the 30 min hypoxia followed by 1 h reoxygenation in normoxic media. 
Normoxia group received the normoxic media and left in the incubator at 37°C for  
1.5 h. 
 
4.4.2 In vivo experiments 
Male Sprague-Dawley rats (250-300g) were subjected to RIPC by fastening a 
tourniquet around the hind limb for 3 x 5 min alternating cycles of I/R as previously 
described in chapter 2.9.4. Myocardial I/R injury was induced by blocking the left 
coronary artery for 30 min followed by 24 h reperfusion. Surgical intervention was 
carried out as previously described in chapter 2.9.5 and outlined in figure 4.4.1.  
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Figure 4.4.1 Schematic illustration of the protocol used for rat in vivo. 
 
4.4.3 Western blot 
Protein expression from myocardial tissue extracted from the cardiac apex and H9C2 
cell lysate was measured using western immunoblot as previously described (see 
chapter 2.4). Briefly, protein was extracted from whole cell lysate or tissue lysate and 
run on a western blot to determine the protein expression. Membranes were blocked 
in Tris-buffered saline containing 0.2% Tween-20 (TBST) in 5% skim milk for 1 h 
and then incubated overnight at 4 ºC with the following antibodies – Egr-1 1:500 
(Santa Cruz, Texas, USA), cleaved PARP 1:1000 (Cell signaling, Massachusetts, 
USA), Bax 1:1000 (Cell signaling, Massachusetts, USA), Bcl-2 1:1000 (Cell 
signaling, Massachusetts, USA), Bcl-xl 1:1000 (Cell signaling, Massachusetts, USA), 
TRAIL 1:500 (Santa Cruz, Texas, USA), VCAM-1 1:1000 Abcam (Cambridge, UK), 
phosphorylated STAT3 1:1000 (Cell signaling, Massachusetts, USA), STAT3 1:1000 
(Cell signaling, Massachusetts, USA), phosphorylated p38 MAPK 1:1000  (Cell 
signaling, Massachusetts, USA), p38 MAPK 1:1000  (Cell signaling, Massachusetts, 
USA), phosphorylated GSK3β 1:1000 (Cell signaling, Massachusetts, USA), 
GSK3β 1:1000 (Cell signaling, Massachusetts, USA). Even protein loading was 
I	 R	 I	 R	 I	 R	 I	 R	
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confirmed by probing for either -actin 1: 1000 (Santa Cruz, Texas, USA) for cell 
lysate or GAPDH 1:1000 (Santa Cruz, Texas, USA) for tissue lysate. 
4.4.4 Real time PCR 
RNA extraction and real time PCR were performed as previously described in chapter 
2.5. Briefly, RNA from tissue or H9C2 cells was extracted using Gen elute 
Mammalian Total RNA Mini Prep Kit (Sigma, St Louis, MO, USA). Tetro cDNA 
Synthesis Kit was used to synthesize cDNA and RT-PCR was performed to assess 
Egr-1 mRNA expression using SensiFast SYBR HI ROX Kit (Bioline, London, UK) 
in accordance with the manufacturer’s instruction. 
 
4.4.5 Flow cytometry 
H9C2 cells were collected and resuspended in binding buffer followed by incubation 
with Annexin V-FITC and Propidium Iodide (PI) (BD Biosciences, New Jersey, 
USA).  The percentage of apoptotic cells was quantified by flow cytometry. 
Mitochondrial membrane potential of H9C2 cells was measured by adding DiLC5 dye 
(Thermofisher Scientific, Massachusetts, USA) to the cells followed by analysing the 
fluorescence intensity of the cells by flow cytometry.  
 
4.4.6 Cell viability  
Cell viability was measured using Live/Dead Cell Imaging Kit (Thermofisher 
Scientific, Massachusetts, USA) as described in chapter 2.7.1. Cell viability was also 
assayed by trypan blue exclusion method as described in chapter 2.7.2. An equal 
volume of 0.4% solution of trypan blue dye (Sigma-Aldrich, Missouri, USA) and 
suspended H9C2 cells in D-PBS were mixed and loaded onto a hemocytometer. The 
percentage of viable cells was determined by recording the number of cells that 
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excluded 0.4% solution trypan blue dye. The cells were photographed using an 
Olympus SC35 camera attached to an Olympus CK40 microscope.  
 
4.4.7 Statistical analysis 
Normalised results are expressed as mean ± standard error of the mean (SEM).  
Statistical analysis between groups was performed by one-way ANOVA, followed by 
post hoc comparison using Tukey’s multiple comparison tests using GRAPHPAD 
software (GraphPad software version 7.02; GraphPad Inc, San Diego, CA, USA). 
Comparison between two groups was performed using two-tailed Student’s T-test.  p 
≤ 0.05 was considered to be significant.  
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4.5 Results 
4.5.1 RIPC protects against H/R-induced cell death. 
 
H/R injury to H9C2 cells significantly reduced the cell viability from 74.27 ± 3.79% 
to 34.93 ± 3.68% (p<0.0001) (Figure 4.5.1 A). RIPC prior to H/R effectively 
abolished the effect of H/R on cell viability (78.43 ± 2.18% vs. 34.93 ± 3.68%, 
p<0.0001). No significant difference was observed between the normoxic control 
group and RIPC-H/R group.  
 
A similar pattern was observed in cell viability assay using trypan blue exclusion 
method (Figure 4.5.1 B). H/R injury caused significant cell death compared to 
normoxic control (40.72 ± 11.80% vs. 91.05 ± 3.45%, p<0.05) whereas RIPC prior to 
H/R significantly improved the cell viability compared to H/R (84.81 ± 2.11% vs. 
40.72 ±11.80%, p<0.05). 
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Figure 4.5.1 Cell viability in H9C2 cells following H/R with prior RIPC. (A) The 
cells were stained with calcein AM (green) to indicate live cells and Ethidium 
homodimer-1 (red) to indicate dead cells. The scale bar represents 1000 μm. 
Quantitative analysis of live/dead cells are expressed as mean ± SEM. (B) Cell death 
measured by trypan blue exclusion method are expressed as mean ± SEM; n= at least 
3 biological replicates, *p<0.05, ****p<0.0001. 
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4.5.2 RIPC prior to H/R protects against apoptotic cell death. 
 
H/R injury significantly elevated the apoptotic cell death to 4.98  1.13% compared to 
normoxic control at 1.66  0.36% (p<0.05) (Figure 4.5.2 A). In contrast, exposing the 
cells to RIPC media prior to H/R ameliorated apoptotic cell death to 1.84  0.16% 
(p<0.05 vs. H/R).  Similar findings were observed at protein level measured by 
Western Blot analysis, with H/R injury significantly increasing cleaved apoptotic 
protein marker PARP compared to normoxic control (2.45  0.23-fold relative to 
normoxic control, p<0.0001). RIPC prior to H/R significantly reduced PARP 
cleavage compared to H/R group (1.60  0.17-fold relative to normoxic control, 
p<0.01 vs. H/R) (Figure 4.5.2 B).  In line with these findings, mitochondrial 
membrane potential was lost in H/R group, whereas RIPC-H/R group successfully 
maintained mitochondrial membrane potential (0.66  0.05% vs. 1.01  0.08%, fold 
relative to normoxic control, p<0.01) (Figure 4.5.2 C).  
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Figure 4.5.2 Extent of apoptosis in H9C2 cells following H/R with prior RIPC.     
(A) Cell apoptosis assessed by Annexin V-FITC and propidium Iodide (PI) double 
staining and FACS. Quantitative analysis of percentage of apoptotic cells (Annexin-
V+/PI+) cells expressed as the mean ± SEM (B) Western blot analysis of PARP 
cleavage expressed as mean ± SEM (C) Mitochondrial membrane potential at 1 h post 
reoxygenation assessed by DiLC5 staining and FACS. Results represented as the 
percentage geo mean fluorescence ± SEM; n= at least 3 biological replicates,  
*p<0.05, **p<0.01, ****p<0.0001.  
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4.5.3 RIPC abolishes H/R-induced pro-apoptotic protein expression 
and increases anti-apoptotic protein expression 
 
H/R injury in H9C2 cells significantly upregulated pro-apoptotic Bax (1.22  0.08-
fold relative to normoxic control, p<0.05 vs. normoxic control) (Figure 4.5.3 A) and 
TRAIL protein (1.61  0.17-fold relative to normoxic control, p<0.01 vs. normoxic 
control) (Figure 4.5.3 B). Concurrently, a significant decrease in anti-apoptotic Bcl-xl 
protein level was observed in H/R group compared to normoxic control (0.78  0.09-
fold relative to normoxic control, p<0.05 (Figure 4.5.3 C)).  
 
In contrast, RIPC prior to H/R ameliorated this increase in pro-apoptotic Bax (1.01  
0.05 vs. 1.22  0.08, fold relative to normoxic control, p<0.05) (Figure 4.5.3 A) and 
TRAIL protein levels (0.94  0.10 vs. 1.61  0.17, fold relative to normoxic control, 
p<0.01) (Figure 4.5.3 B) and increased the anti-apoptotic Bcl-xl protein level 
compared to H/R group (1.33  0.17 vs. 0.77  0.09, fold relative to normoxic 
control, p<0.05) (Figure 4.5.3 C). There was no significant difference in pro-apoptotic 
(Bax and TRAIL) and anti-apoptotic (Bcl-xl) protein levels between RIPC-H/R group 
and normoxic control group.  
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Figure 4.5.3 Effect of RIPC on apoptotic protein expression in H9C2 cells. 
Western blot analysis of (A) Bax, (B) TRAIL, (C) Bcl-xl protein expression. Results 
expressed as mean  SEM, fold relative to normoxic control; n= at least 3 biological 
replicates, *p< 0.05, **p<0.01. 
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4.5.4 RIPC confers cardioprotection in vivo against I/R injury in rats 
 
At 24 h following I/R injury, rats showed MI size of 51.5  2.55%, which was 
reduced to 30.2  5.16% with RIPC prior to I/R injury (p<0.01) (Figure 4.5.4 A).  
There was no significant difference in the area at risk (AAR) between groups (Figure 
4.5.4 B). 
 
Consistent with this, I/R injury significantly increased PARP cleavage by 4.30  0.45-
fold relative to the sham group (p<0.05). However, RIPC prior to I/R significantly 
reduced PARP cleavage compared to I/R injury (1.42  0.29 vs. 4.30  0.45-fold 
relative to the sham group, p<0.05) (Figure 4.5.4 C). 
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Figure 4.5.4 RIPC prior to I/R limits MI size and reduces apoptotic protein 
expression. Rats subjected to I/R with and without prior RIPC. (A) MI size expressed 
as the percentage of infarct size/ AAR (n=7-10 rats per group, mean  SEM), (B) 
Cumulative data of AAR/ left ventricle (LV) expressed as percentage of mean ± 
SEM, (C) Western blot analysis of PARP cleavage. Results expressed as mean  
SEM, fold relative to the sham group; *p<0.05, **p<0.01.  
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4.5.5 RIPC alleviates I/R-induced inflammatory response in the heart 
 
At 24 h following I/R injury, the VCAM-1 protein was significantly upregulated 
compared to the sham group in the heart (2.56 ± 0.58-fold relative to the sham group, 
p<0.05) (Figure 4.5.5). However, VCAM-1 protein levels with RIPC prior to I/R were 
similar to those seen in the sham group and significantly less than those seen in the 
I/R group (0.68 ± 0.10 vs. 2.56 ± 0.58-fold relative to the sham group, p<0.05 vs. 
I/R). (Figure 4.5.5). 
 
 
 
Figure 4.5.5 Inflammatory response after I/R with and without RIPC. 
Representative western blot demonstrating VCAM-1 protein expression in rat hearts 
(n=8) subjected to myocardial I/R and RIPC prior to I/R. Results expressed as mean  
SEM, fold relative to the sham group *p <0.05.   
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4.5.6 RIPC reduces myocardial I/R-induced Egr-1 expression 
 
H/R injury in H9C2 cells significantly increased Egr-1 protein level by 1.85 ± 0.14-
fold relative to normoxic control (p<0.05 vs. normoxic control), which was 
ameliorated by exposing the cells to preconditioned media prior to H/R injury (1.01 ± 
0.08 vs. 1.85 ± 0.14, fold relative to normoxic control, p<0.05) (Figure 4.5.6 A). 
Similar finding was noted in vivo, at 24 h following I/R injury, Egr-1 protein 
expression was increased compared to sham group (1.2 ± 0.03-fold relative to sham 
group, p<0.01) and RIPC prior to I/R injury significantly reduced Egr-1 expression 
compared to I/R group (0.72 ± 0.11 vs. 1.2 ± 0.03, fold relative to sham group, 
p<0.05) (Figure 4.5.6 B). Consistent with this, Egr-1 mRNA expression in the rat 
heart followed similar trend, increasing with I/R injury compared to sham group (2.09 
± 0.25-fold relative to sham group, p<0.01), while RIPC prior to I/R reduced Egr-1 
mRNA expression level compared to I/R group (0.52 ± 0.10 vs. 2.09 ± 0.25, fold 
relative to sham group, p<0.05) (Figure 4.5.6 C). There was no significant difference 
between the sham group and RIPC-I/R group at both protein and mRNA level.  
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Figure 4.5.6 Effect of RIPC on myocardial I/R-induced Egr-1 expression.  
Western blot analysis of Egr-1 protein expression in (A) H9C2 cells (n= at least 3 
biological replicates) after H/R with and without prior RIPC. (B) Rat heart tissue after 
I/R with and without prior RIPC (n=7). (C) Egr-1 mRNA expression after I/R with 
and without prior RIPC (n=7). Data represented as mean ± SEM, fold relative to 
control, *p<0.05, **p<0.01.  
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4.5.7 RIPC activates cardioprotective pathways in the heart 
 
At 24 h following I/R injury, I/R significantly increased phosphorylation of STAT3 
compared to sham group (2.26 ± 0.10-fold relative to the sham group, p<0.05) (Figure 
4.5.7 A). In contrast, RIPC prior to I/R significantly increased phosphorylation level 
of STAT3 at Tyrosine-705 compared to I/R (3.81 ± 0.07 vs. 2.26 ± 0.10-fold relative 
to the sham group, p<0.01). I/R significantly elevated the phosphorylation level of 
GSK-3β by 1.78 ± 0.14-fold relative to the sham group (p<0.05), which was reversed 
to almost sham group level by RIPC manoeuvre prior to I/R (0.80 ± 0.07-fold relative 
to the sham group, p<0.05) (Figure 4.5.7 B). Phosphorylation of p38 MAPK did not 
increase after I/R compared to sham group (1.08 ± 0.13-fold relative to the sham 
group) (Figure 4.5.7 C). p38 MAPK phosphorylation level in RIPC I/R group was 
similar to I/R group (1.67 ± 0.30 vs. 1.08 ± 0.12-fold relative to the sham group, 
p=0.19).  
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Figure 4.5.7 Cardioprotective pathways after RIPC. Western blot analysis of the 
rat heart tissue (n=8 for STAT3 and GSK-3β, n=5 for p38) at 24 h post I/R with and 
without prior hind limb RIPC assessing the phosphorylated level of (A) STAT3, (B) 
GSK-3β (C) p38 MAPK. Protein expression was relative to total STAT3, GSK-3β, 
and p38 MAPK respectively. Results are expressed as mean ± SEM; *p<0.05, 
**p<0.01, ****<0.0001. 
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4.6 Discussion 
 
Apoptosis in MI is a predominantly reperfusion-related phenomenon, with evident 
increases in pro-apoptotic protein, likely contributing to the caspase activation. I/R-
induced activation of caspases subsequently cleaves PARP and leads to apoptotic cell 
death (495, 496). In this chapter, RIPC prior to H/R demonstrates effective reduction 
of pro-apoptotic protein expression and the activity of cleaved PARP, resulting in 
significantly decreased apoptotic cells in vitro, overall improving cell viability 
following H/R injury.  
  
 The current study demonstrated that I/R injury significantly increased Egr-1 
expression with concurrent upregulation of VCAM-1 whereas RIPC prior to I/R 
reduced the MI size with simultaneous downregulation of Egr-1 and VCAM-1 
expression in rats. We observed a similar trend of Egr-1 expression in vitro. 
Importantly, suppression of these key proteins is associated with reduced infarct size. 
In addition, Egr-1 down regulation is essential to achieve the cardioprotective effect 
of RIPC as we previously demonstrated that RIPC failed to confer cardioprotection 
against H/R-induced apoptosis in Egr-1 overexpressing H9C2 cells (321). Egr-1 is 
well known as a key regulator of reperfusion injury and inflammation associated 
tissue damage (163, 484). Neutrophil infiltration is one of the key features of AMI, 
with neutropenia contributing to the reduction of MI size. As an acute response to 
AMI, neutrophils adhere to vascular endothelial cells and undergo extravasation into 
myocardial tissue in ICAM-1, VCAM-1 dependent cell adherence process (497-499). 
I/R associated Egr-1 expression mediates the expression of VCAM-1 (223) and 
increase in VCAM-1 expression chemoattracts leukocytes. Egr-1 suppression reduces 
myocardial MI size and reperfusion injury (500-502).  
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In this study, while a significant increase in GSK-3β phosphorylation was seen in the 
I/R group compared to the sham group, no increase was seen in the group with I/R 
following RIPC. GSK-3β, ubiquitously expresses serine/threonine kinase, was 
initially found to be a glycogen synthesis regulator. GSK-3β is activated during the 
ischaemic phase by dephosphorylating at serine 9 (Ser9) where as it is activated by 
phosphorylating at Ser9 during reperfusion.  Ser9 phosphorylation negatively 
regulates the activity of GSK-3β (503). Inactivated GSK-3β delays the opening of the 
mitochondrial permeability transition pore (mPTP) in the inner membrane of the 
mitochondria and protects cells from the mitochondrial cell death (504). Similar 
findings have been reported in liver, kidneys, and brains where GSK-3β inhibition 
conferred protection against I/R injury (505-508). Pharmacologic inhibition of GSK-
3β also limits the myocardial I/R injury by regulating the mPTP opening. However, 
prolonged ischaemia may aggravate the myocardial injury even before reperfusion. 
 
Myocardial I/R has been shown to activate p38 MAPK (509, 510). In contrast to these 
previous findings, we did not see any significant change in I/R associated p38 MAPK. 
Paradoxically, in our study, p38 MAPK was upregulated with RIPC prior to I/R. Our 
group has recently reported that p38 MAPK inhibition prior to RIPC blocks the 
cardioprotective effect of RIPC through Egr-1 upregulation (321). However, the role 
of p38 MAPK in preconditioning-induced cytoprotection has been controversial. 
Ischaemia phosphorylates p38 MAPK and inhibition of p38 MAPK contributes to the 
protective effect of ischaemic preconditioning in murine and porcine models (511, 
512). However, the influence of this ischaemia-induced p38 MAPK activation on 
myocardial injury remains elusive. Transient activation of p38 MAPK can be 
observed within 10-20 min of ischaemia. However, reperfusion further increases p38 
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MAPK phosphorylation, which can be observed within 10 min post reperfusion. This 
transient increase in p38 MAPK declines thereafter (513). In the current study, the rat 
heart was reperfused for 24 h which is way beyond the activation time point as 
reported by Ma and colleagues (513). It is possible that p38 MAPK differentially 
regulated by RIPC stimulus. Nitric oxide activates p38 MAPK (514) and RIPC 
mediates cardioprotection by circulating nitrite/nitric oxide (375). In this study, we 
did not examine whether RIPC-associated p38 MAPK upregulation is regulated by 
nitrite/nitric oxide.  
 
It has been previously reported that JAK-STAT signalling pathway is also involved in 
RIPC (396, 492, 515). JAK-STAT signalling pathway regulates the stress responsive 
genes. STAT3 acutely translocates into the mitochondrial matrix to inhibit the mPTP 
opening and reduces the overwhelming ROS production (516-519). In addition, 
STAT3 translocates into the nucleus and increases the expression of known 
cardioprotective proteins such as cyclooxygenase-2 (COX-2) and haem oxygenase-1 
(HO-1) at 24 h post-RIPC (520, 521). RIPC manoeuvre upregulates STAT3 activation 
and RIPC prior to H/R maintains the mitochondrial membrane potential of H9C2 cells 
which is an indication of closed mPTP (522). In the current study, the expression of 
COX-2 and HO-1 was not explored and hence unable to address if JAK-STAT 
pathway activation through preconditioning involves COX-2 and HO-1 expression. 
Taken together, these data support the activation of p38 MAPK and JAK-STAT 
pathway by RIPC whereas GSK-3β pathway was inhibited by RIPC. Hence, 
pharmacological stimulation of these pathways may provoke cardioprotective effect 
against AMI.  
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We previously reported that intermittent hypoxia and reoxygenation of the donor 
H9C2 cells to mimic preconditioning released IL-6 protein (321). I/R and MI have 
been reported to induce and release IL-6 (523-525). Cardiomyocytes also produce IL-
6 in response to hypoxia (526) and deletion of IL-6 gene does not affect the infarction 
size and left ventricular remodelling after permanent coronary occlusion in mice 
(527). IL-6 can mediate exercise preconditioning against myocardial I/R injury (528). 
Dawn and colleagues have demonstrated that IL-6 is obligatory for late 
preconditioning-mediated cardioprotection via the JAK-STAT pathway and does not 
provide infarct size reducing effect without preconditioning stimulus (515). Previous 
studies suggested that humoral factors smaller than 30-kDa may confer RIPC-induced 
protection (336), which is consistent with the 21-kDa molecular weight of IL-6 (529).  
Though the current study has demonstrated the upregulation of STAT3 after RIPC 
manoeuvre, the direct relationship between IL-6 and STAT3 upregulation was not 
studied.  
 
In summary, the present data demonstrated that RIPC prior to I/R reduced MI size in 
association with decreased inflammation and oxidative damage at the cellular level. 
Moreover, pro-apoptotic proteins were substantially down regulated along a 
significant decrease in cellular apoptosis. The present data provide significant insights 
into the mechanisms of RIPC-induced protection. Given the rising burden of AMI and 
its sequelae, these are observations of a potentially non-invasive therapeutic strategy 
(530).   
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4.7 Limitations 
The rat model of myocardial I/R lacks human MI characterizing atherothrombosis. In 
addition, thoracotomy to expose the heart causes additional surgical stress that 
changes the haemodynamic and neurohormonal factors and possibly modifies the 
gene expression.  
 
4.8 Importance 
This study demonstrated the effect of RIPC on I/R injury and highlighted the 
underlying mechanisms involved in RIPC-mediated cardioprotection. 
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Chapter 5.             
Autophagy is essential for remote 
preconditioning-induced 
cardioprotection and may involve 
JAK-STAT pathway for 
activation 
 
 
 
\ 
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5.1 Aims 
5.1.1 To assess the effects of RIPC prior to myocardial I/R on autophagy 
activity in vitro and in vivo 
5.1.2 To assess if RIPC alone can activate autophagy and cardioprotective 
pathways  
5.1.3 To optimize the rapamycin concentration to induce autophagy in H9C2 
cells and to examine the effects of rapamycin treatment prior to H/R on cell 
viability and apoptosis 
5.1.4 To evaluate the effect of autophagy inhibition on cell viability and 
apoptosis in H9C2 cells 
5.1.5 To examine the effect of RIPC on cytokine expression in the 
preconditioned hind limb tissue and to estimate the level of plasma IL-6 
5.1.6 To examine the effect of recombinant IL-6 treatment prior to H/R on 
autophagic activity in H9C2 cells and the effect on cardioprotective pathways 
 
5.2 Introduction 
Autophagy is a cellular process by which mammalian cells degrade and recycle 
damaged organelles and proteins (531). It plays a major role in maintaining 
intracellular homeostasis. Upregulation of autophagy in response to glucose 
deprivation and hypoxia with subsequent reoxygenation and glucose supply in foetal 
mouse hearts organ culture was first described by Sybers and colleagues in 1976 
(532). They suggested that, focal injury stimulates endoplasmic reticulum to enclose 
damaged component to be digested by lysosomes without damaging the whole cell. 
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Decker and Wildenthal observed upregulation of autophagy in Langendorff model of 
rabbit heart subjected to ischaemia and reperfusion (533, 534). They reported that 20 
min of ischaemia did not increase autophagy, but the number of autophagosomes 
increased after reperfusion. In contrast, 40 min of ischaemia alone increased 
autophagy, which was further increased by reperfusion. Extending the ischaemia to 60 
min resulted in large and dysfunctional lysosomes and ultrastructural analysis showed 
autophagosomes in close proximity to swollen and fragmented mitochondria 
suggesting that prolonged ischaemia may impair the autophagy-mediated lysosomal 
activity (534). Similar finding was reported in rodents where 30 min ischaemia 
resulted in significant increase in autophagosome formation (110). Autophagic 
activity was reported to be particularly evident in the salvaged cardiomyocytes 
bordering the infarcted area within 30 min following coronary ligation in mice (535).  
 
Autophagy during reperfusion is likely to be damaging under some experimental 
settings. Inhibition of H/R-induced autophagy by 3-methyladenine (3-MA) or Beclin-
1 knockdown decreased cardiomyocyte death in vitro (112). In addition, blocking the 
autophagic activity during reperfusion phase resulted in significantly smaller infarct 
size and cardiomyocyte apoptosis in Beclin-1+/- mice suggesting that autophagy 
during reperfusion is detrimental. It is suggested that, hyperactivated autophagy 
results in cell death, however, this can be species and experimental condition 
dependent.   
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5.3 Rationale 
Up-regulation of autophagy has been reported to be associated with myocardial 
infarct size reducing effect of ischaemic preconditioning (536-538) and post-
conditioning (539). These studies reported an increase in autophagosome formation, 
LC3 and Beclin-1 protein level in response to brief preconditioning stimulus (536, 
537). Autophagy inhibition by wortmannin treatment reversed the protective effect of 
preconditioning and postconditioning (536, 539). Recently,  RIPC has been shown to 
protect the liver (540) and brain (541) from I/R injury by inducing autophagy. In 
addition, RIPC induces autophagy signalling in the heart while conferring 
cardioprotection against I/R injury (542). However, the pattern of autophagy response 
varied depending on the extent of preconditioning stimulus prior to stressing the heart 
to sustain I/R.  
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5.4 Methods 
5.4.1 Western blot 
Protein expression from myocardial tissue extracted from the cardiac apex and H9C2 
cell lysate was measured using western immunoblot as previously described (see 
chapter 2.4). Briefly, protein was extracted from whole cell lysate or tissue lysate and 
run on a western blot to determine the protein expression. Membranes were blocked 
in Tris-buffered saline containing 0.2% Tween-20 (TBST) in 5% skim milk for 1 h 
and then incubated overnight at 4 ºC with the following antibodies – LC3 1:1000 
(Cell signaling, Massachusetts, USA), Atg5-Atg12 conjugate 1:1000 (Cell signaling, 
Massachusetts, USA), Bax 1:1000 (Cell signaling, Massachusetts, USA), 
phosphorylated STAT3 1:1000 (Cell signaling, Massachusetts, USA), STAT3 1:1000 
(Cell signaling, Massachusetts, USA), phosphorylated p38 MAPK 1:1000  (Cell 
signaling, Massachusetts, USA), p38 MAPK 1:1000  (Cell signaling, Massachusetts, 
USA), phosphorylated GSK3β 1:1000 (Cell signaling, Massachusetts, USA), 
GSK3β 1:1000 (Cell signaling, Massachusetts, USA). Even protein loading was 
confirmed by probing for either -actin 1: 1000 (Santa Cruz, Texas, USA) for cell 
lysate or GAPDH 1:1000 (Santa Cruz, Texas, USA) for tissue lysate. 
 
5.4.2 In vivo experiments 
Male Sprague-Dawley rats were subjected to RIPC by fastening a tourniquet around 
the hind limb for 3 x 5 min alternating cycles of ischaemia and reperfusion as 
previously described in chapter 2.8.4. Surgical intervention was carried out as 
previously described in chapter 2.8.5. 
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5.4.3 Flow cytometry 
Flow cytometry was performed as described in chapter 2.5.1. Briefly, H9C2 cells 
were collected and resuspended in binding buffer followed by incubation with 
Annexin V-FITC and propidium iodide (PI). The percentage of apoptotic cells was 
quantified by flow cytometry. 
 
5.4.4 Cell viability 
Cell viability was measured using Live/Dead Cell Imaging Kit (Thermofisher 
Scientific, Massachusetts, USA) as described in chapter 2.7.1. Cell viability was also 
assayed by trypan blue exclusion method as described in chapter 2.7.2. An equal 
volume of 0.4% solution of trypan blue dye (Sigma-Aldrich, Missouri, USA) and 
suspended H9C2 cells in D-PBS were mixed and loaded onto a haemocytometer. The 
percentage of viable cells was determined by recording the number of cells that 
excluded 0.4% solution trypan blue dye. The cells were photographed using an 
Olympus SC35 camera attached to an Olympus CK40 microscope. 
 
5.4.5 ELISA 
ELISA kit was used to determine the concentration of IL-6 (Rat IL-6 Quantikine 
ELISA Kit, R&D Systems, Minneapolis, USA) protein. For circulating protein levels, 
blood from rats collected in Lithium-Heparin tube spun at 2,500 rpm (950g) for 5 min 
and plasma was collected. For detection of plasma IL-6 50 l of rat plasma was used 
and protein estimated as per the manufacturer’s instruction. 
 
 
` 
 
 
Page | 140  
 
5.4.6 Real time PCR 
RNA extraction and real time PCR were performed as previously described in chapter 
2.5. Briefly, RNA from tissue or H9C2 cells was extracted using Gen elute 
Mammalian Total RNA Mini Prep Kit (Sigma, St Louis, MO, USA). Tetro cDNA 
Synthesis Kit was used to synthesize cDNA. RT-PCR was performed to assess IL-6, 
cardiotrophin-1, IL-11, LIF and IL-1 β mRNA expression using SensiFast SYBR HI 
ROX Kit (Bioline, London, UK) in accordance with the manufacturer’s instruction. 
 
 
5.4.7 Reagents  
Rapamycin and 3-MA were purchased from Sigma Aldrich (St Louis, MO, USA). 
Recombinant IL-6 was purchased from BD Biosciences. Recombinant IL-6 was 
added to hypoxic media and H9C2 cells were exposed to recombinant IL-6 containing 
hypoxic media during 30 min hypoxia. In order to optimize rapamycin (a powerful 
inducer of autophagy (543)) concentration to induce autophagy, we treated overnight 
serum starved H9C2 cells with different concentration of rapamycin for 4 h in serum-
free DMEM and finally used 1000 nm rapamycin to induce autophagy in vitro. 3-MA 
blocks autophagic sequestration and autophagosome formation by inhibiting the class 
III phosphatidylinositol 3-kinase (PI3K) (544, 545). Thus 3-MA downregulates 
autophagic activity at the early stage and widely used to understand the role of 
autophagy (546-548). In previous studies, pre-treatment with 10 mM 3-MA for 2 h 
has been shown to effectively block autophagic activity (549). Hence, H9C2 cells 
were treated with 10nM 3-MA for 2 h in serum-free DMEM. Tyrphostin AG 490 was 
purchased from Sigma Aldrich (St Louis, MO, USA). H9C2 cells were pre-treated 
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with 200 μM  Tyrphostin AG 490 for 1 h prior to exposing the cells to H/R to inhibit 
JAK-STAT pathway as previously described (321).   
  
5.4.8 Statistical analysis 
Normalised results are expressed as mean ± standard error of the mean (SEM).  
Statistical analysis between groups was performed by one-way ANOVA, followed by 
post hoc comparison using Tukey’s multiple comparison tests using GRAPHPAD 
software (GraphPad software version 7.02; GraphPad Inc, San Diego, CA, USA). 
Comparison between two groups was performed using two-tailed Student’s T-test.  p 
≤ 0.05 was considered to be significant.  
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5.5 Results 
 
5.5.1 RIPC promotes autophagy in H9C2 cells 
 
H/R increased autophagy marker Atg5-Atg12 conjugate (Figure 5.5.1 A) and LC3 
expression (Figure 5.5.1 B) relative to normoxic control. RIPC stimulation prior to 
H/R in H9C2 cells led to a higher level of Atg5-Atg12 conjugate expression (1.89 ± 
0.19-fold relative to normoxic control) (p<0.05). Similarly, RIPC prior to H/R 
significantly increased LC3 marker compared to H/R group (1.70 ± 0.10 vs. 1.24 ± 
0.11-fold relative to normoxic control, p<0.01). Although, no significant difference 
was observed in Atg5-Atg12 conjugate and LC3 marker between H/R alone group 
and normoxic control. 
 
 
Figure 5.5.1 Effect of RIPC prior to H/R on autophagy protein expression in 
H9C2 cells. Western blot analysis of (A) Atg5-Atg12 conjugate, (B) LC3 protein 
levels expressed as mean ± SEM, fold relative to normoxic control; n= at least 3 
biological replicates, *p<0.05, **p<0.01, ****p<0.0001.  
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5.5.2 RIPC prior to I/R upregulates autophagic activity in rat heart 
 
At 24 h following I/R injury, RIPC in the hind limb prior to I/R significantly elevated 
autophagy factor, Atg5-Atg12 conjugate (Figure 5.5.2 A) and autophagy marker, LC3 
level (Figure 5.5.2 B) compared to I/R cohort (2.24 ± 0.36 vs. 1.29 ± 0.0.19-fold 
relative to the sham group, p<0.05 and 3.69 ± 0.99 vs. 1.46 ± 0.38-fold relative to the 
sham group, p<0.05 respectively). However, no significant change was observed in 
Atg5-Atg12 conjugate and LC3 protein level in the I/R group compared to the sham 
group (1.29 ± 0.19-fold relative to the sham group and 1.46 ± 0.38-fold relative to the 
sham group respectively).  
 
 
Figure 5.5.2 Expression of autophagy markers in rat heart after I/R with and 
without prior RIPC. Representative immunoblots and statistical data of autophagy 
proteins Atg5 and LC3 level from rat heart lysates are expressed as mean ± SEM, fold 
relative to the sham group; n=7, *p < 0.05, **p<0.01. 
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5.5.3 Autophagy functions as a signalling mechanism for RIPC 
 
H9C2 cells exposed to preconditioned media without further H/R significantly 
increased LC3 protein level by 1.75 ± 0.34-fold relative to normoxic control (p<0.05) 
(Figure 5.5.3 A). In rats subjected to RIPC only, LC3 protein levels in the heart 
increased by 1.37 ± 0.13-fold relative to the sham group at 24 h (p<0.05 vs. sham, 
p<0.05 vs. RIPC 15 min) (Figure 5.5.3 B). However, RIPC alone did not elevate LC3 
protein level at 15 min post-RIPC compared to the sham group (1.03 ± 0.08-fold 
relative to the sham group) (Figure 5.5.3 B). Nonetheless, at 15 min post RIPC, 
STAT3 protein phosphorylation increased by 3.97 ± 1.33-fold relative to the sham 
group (p<0.05). However, 24 h post-RIPC this value decreased to 2.21 ± 0.45-fold 
relative to the sham group (p=0.32 vs. RIPC 15 min) (Figure 5.5.3 C).  
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Figure 5.5.3 Effect of RIPC alone on autophagy and cardioprotective signalling 
mechanism. (A) H9C2 cells were subjected to RIPC, and preconditioned media was 
added to the normoxic control group for 1.5 h under normoxic condition and western 
blot analysis of LC3 protein level are expressed as mean ± SEM, fold relative to 
normoxic control; n= at least 3 biological replicates, *p<0.05. Rats (n=7) were 
subjected to RIPC, and (B) LC3 protein level, (C) STAT3 phosphorylation level in 
the heart assessed at 15 min and 24 h post RIPC.  Results are expressed as mean ± 
SEM, fold relative to the sham group; *p < 0.05. 
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5.5.4 Rapamycin upregulates autophagy in H9C2 cells 
 
In H9C2 cells, 1000 nM rapamycin increased LC3 protein level to a maximal level of 
1.83 ± 0.09-fold relative to untreated control (p<0.01 vs. untreated) (Figure 5.5.4).  
 
 
 
Figure 5.5.4 Optimization of rapamycin concentration. Western blot analysis of 
LC3 protein level in H9C2 cells treated with different concentrations of rapamycin 
are expressed as mean ± SEM, fold relative to the untreated control group; n= at least 
3 biological replicates, **p<0.01.   
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5.5.5 Rapamycin treatment prior to H/R increases autophagic 
activity in H9C2 cells 
RIPC prior to H/R increased LC3 protein level compared to H/R group (1.92 ± 0.19 
vs. 1.14 ± 0.12-fold relative to normoxic control, p<0.05). Rapamycin treatment prior 
to H/R significantly increased LC3 level compared to untreated H/R group (1.86 ± 
0.24 vs. 1.14 ± 0.12-fold relative to normoxic control, p<0.05). No difference was 
observed in LC3 level in rapamycin treated RIPC H/R group compared to untreated 
RIPC-H/R group (2.51 ± 0.16 vs. 1.92 ± 0.19-fold relative to normoxic control, 
p=0.12). However, LC3 level in rapamycin treated RIPC H/R group was significantly 
different compared to untreated H/R group (2.51 ± 0.16 vs. 1.14 ± 012-fold relative to 
normoxic control, p<0.001).  
 
Figure 5.5.5 Rapamycin treatment prior to H/R increases autophagic activity. 
Representative western blot of LC3 protein level in H9C2 cells treated with 1000 nM 
rapamycin for 4 h prior to exposing them to H/R and RIPC-H/R are expressed as 
mean ± SEM, fold relative to normoxic control; *p<0.05, ***p<0.001. 
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5.5.6 Rapamycin treatment prior to H/R confers RIPC-like effect in 
H9C2 cells 
 
H/R injury to H9C2 cells significantly reduced the cell viability from 74.27 ± 3.79% 
to 34.93 ± 3.68% (p<0.0001) (Figure 5.5.6). In contrast, exposing the cells to RIPC 
prior to H/R maintained the cell viability to 78.43 ± 2.18% (vs H/R, p<0.0001). No 
significant difference was observed between normoxic control and RIPC-H/R group 
(74.27 ± 3.79% vs. 78.43 ± 2.18%, p=0.89). However, pre-treating the cells with 
rapamycin prior to exposing them to H/R significantly improved the cell viability 
compared to untreated H/R group (60.32 ± 2.37% vs. 34.93 ± 3.68%, p<0.001). Pre-
treating RIPC H/R group with rapamycin maintained high cell viability compared to 
untreated H/R group (64.93 ± 3.47% vs. 34.93 ± 3.68%, p<0.0001). No significant 
difference in cell viability was observed between rapamycin treated H/R and 
rapamycin treated RIPC-H/R group (60.32 ± 2.37% vs. 64.93 ± 3.47%).  
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Figure 5.5.6 Cell viability in H9C2 cells after autophagy stimulation. H9C2 cells 
were treated with 1000 nM rapamycin for 4 h prior to exposing them to H/R and 
RIPC-H/R. The cells were stained with calcein AM (green) to indicate live cells and 
ethidium homodimer-1 (red) to indicate dead cells. The scale bar represents 1000 μm. 
Quantitative analysis of live/dead cells expressed as percentage of mean ± SEM; n= at 
least 3 biological replicates, *p<0.05, ***p<0.001, ****p<0.0001. 
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5.5.7 Autophagy stimulation with rapamycin confers 
preconditioning-like protection against apoptotic death 
 
H/R injury elevated the apoptotic cell death compared to normoxic control group 
(5.01 ± 0.30% vs. 1.45 ± 0.44%, p<0.01) (Figure 5.5.7). In contrast, RIPC prior to 
H/R ameliorated apoptotic cell death to 2.09 ± 0.44% (p<0.01 vs. H/R). Treatment 
with rapamycin prior to H/R resulted in significant decrease in apoptosis level in H/R 
group compared to untreated H/R group (2.75 ± 0.79% vs. 5.01 ± 0.30%, p<0.05). 
Rapamycin treatment in the RIPC H/R group did not have any significant effect on 
apoptosis level compared to untreated RIPC H/R group (2.18 ± 0.49% vs. 2.09 ± 
0.44%).  
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Figure 5.5.7 Extent of apoptosis in H9C2 cells after rapamycin treatment. Cell 
apoptosis assessed by Annexin V-FITC and propidium iodide (PI) double staining and 
FACS. Quantitative analysis of percentage of apoptotic cells (Annexin-V+/PI+) cells 
are represented as mean ± SEM; n= at least 3 biological replicates, *p<0.05, 
**p<0.01. 
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5.5.8 3-MA treatment abolishes autophagy in H9C2 cells 
 
H/R upregulated LC3 protein level by 1.41 ± 0.43-fold relative to normoxic control 
which was further increased by RIPC prior to H/R (2.19 ±0.63-fold relative to 
normoxic control) (Figure 5.5.8). 3-MA pre-treatment reduced LC3 protein level in 
H/R group but was not statistically significant compared to untreated H/R group (1.02 
± 0.36 vs. 1.40 ± 0.43-fold relative to normoxic control). However, 3-MA treatment 
prior to H/R significantly downregulated LC3 protein level in RIPC H/R group 
compared to untreated RIPC H/R group (0.72 ± 0.18 vs. 2.19 ± 0.63-fold relative to 
normoxic control, p<0.05). 
 
 
Figure 5.5.8 Autophagy level after 3-MA treatment. H9C2 cells subjected to 3-MA 
treatment prior to exposing to H/R and RIPC-H/R. Western blot analysis of LC3 
protein level expressed as mean ± SEM, fold relative to normoxic control; n= at least 
3 biological replicates, *p< 0.05.   
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5.5.9 Autophagy inhibition abolishes RIPC-induced protection 
against cell death 
 
H/R injury to H9C2 cells significantly reduced the cell viability from 74.27 ± 3.79% 
in normoxic conditions to 34.93 ± 3.68% with H/R injury (p<0.0001), which was 
ameliorated by exposing the cells to RIPC media prior to H/R (Figure 5.5.9). RIPC 
prior to H/R significantly improved cell viability to 78.43 ± 2.18% (p<0.0001 vs. 
H/R). No significant difference was observed between the normoxic control group 
and RIPC-H/R group. Pre-treating the cells with 3-MA prior to exposing them to H/R 
had no effect on cell viability compared to untreated H/R group (44.64 ± 1.66% vs. 
34.93 ± 3.68%, p=0.07). Pre-treating RIPC H/R group with 3-MA prior to H/R 
completely abrogated preconditioning induced protection against cell death compared 
to untreated RIPC-H/R group (38.89 ± 4.44% vs. 78.43 ± 3.68%, p<0.0001). No 
significant difference in cell viability was observed between 3-MA treated H/R and 3-
MA treated RIPC-H/R group (44.64 ± 1.66% vs. 38.89 ± 4.44%, p=0.83).  
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Figure 5.5.9 Cell viability in H9C2 cells after autophagy inhibition. H9C2 cells 
were stained with calcein AM (green) and ethidium homodimer-1 (red). Green: live 
cells, Red: dead cells; The scale bar is 1000 μm. Quantitative analysis of percentage 
of live/dead cells expressed as mean ± SEM; n= at least 3 biological replicates, 
****p<0.0001. 
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5.5.10 Autophagy inhibition ameliorates RIPC-induced protection 
against apoptotic death 
 
H/R injury resulted in an increase in pro-apoptotic Bax protein expression (5.55 ± 
0.40-fold relative to normoxic control) but exposing the cells to RIPC media prior to 
H/R reversed this effect (1.44 ± 0.11-fold relative to normoxic control, p<0.05 vs 
H/R) (Figure 5.5.10 A). Conversely, 3-MA pre-treated H/R group  and untreated H/R 
group had similar Bax protein expression (3.50 ± 0.35 vs. 5.55 ± 0.40-fold relative to 
normoxic control, p=0.37). However, 3-MA pre-treatment prior to H/R in RIPC H/R 
group exhibited a significant upregulation of Bax protein expression compared to 
untreated RIPC-H/R group (7.02 ± 1.60 vs. 1.44 ± 0.11-fold relative to normoxic 
control, p<0.01).  
 
Consistent with the increase in Bax protein upregulation, pre-treatment with 3-MA 
resulted in significant increase in H9C2 cell apoptosis in RIPC-H/R group compared 
to untreated RIPC-H/R group (6.13 ± 0.77% vs. 2.97 ± 0.69%, p<0.05), whereas 
apoptotic cells in 3-MA pre-treated H/R group were similar to untreated H/R group 
(6.09 ± 1.21% vs. 5.72 ± 1.28%, p=0.80) (Figure 5.5.10 B).  
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Figure 5.5.10 Extent of apoptosis in autophagy inhibited H9C2 cells. (A) Western 
blot analysis of pro-apoptotic Bax protein expression are expressed as mean ± SEM, 
fold relative to normoxic control (B) Cell apoptosis assessed by Annexin V-FITC and 
propidium iodide (PI) double staining and FACS. Quantitative analysis of percentage 
of apoptotic cells (Annexin-V+/PI+) cells are represented as mean ± SEM; n= at least 
3 biological replicates, *p<0.05, **p<0.01  
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5.5.11 RIPC modifies cytokine expression in rat hind limb tissue and 
increases plasma IL-6 
 
In rats subjected to RIPC, circulating IL-6 protein in the plasma was significantly 
increased to 103.4 ± 1.08 pg/ml compared to 98.4 ± 0.68 pg/ml in the sham group 
(p<0.01, Figure 5.5.11 A). Similarly, in rat hind limb tissue where RIPC was 
performed, localised mRNA IL-6 expression was upregulated by 1.87 ± 0.22-fold 
relative to the sham group (p<0.05, Figure 5.5.11 B). In contrast, RIPC did not 
modulate the expression in the hind limb tissue of other critical cytokines in 
cardiovascular pathology including cardiotrophin-1 (1.30 ± 0.16-fold relative to the 
sham group) (Figure 5.5.11 C) , IL-11 (0.84 ± 0.33-fold relative to the sham group) 
(Figure 5.5.11 D), LIF (0.89 ± 0.21-fold relative to the sham group) (Figure 5.5.11 E), 
IL-1β (1.53 ± 0.32-fold relative to the sham group) (Figure 5.5.11 F).  
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Figure 5.5.11 Cytokine expression in hind limb tissue and plasma IL-6 level after 
RIPC. (A) Plasma IL-6 expression at 15 min post RIPC expressed as mean ± SEM, 
n=5, p<0.01. mRNA expression of (B) IL-6 (C) Cardiotrophin-1, (D) IL-11, (E) LIF, 
(F) IL-1β 15 min post RIPC assessed by qPCR expressed as mean ± SEM; n=9, 
*p<0.05.  
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5.5.12 Recombinant IL-6 treatment prior to H/R increases 
autophagic activity 
 
In H9C2 cells subjected to H/R, all dose of recombinant IL-6 significantly 
upregulated LC3 protein level compared to untreated H/R group (p<0.05) and with no 
dose response relationship (Figure 5.5.12). However, LC3 protein level in IL-6 treated 
H/R groups were similar to RIPC-H/R group.  
 
 
Figure 5.5.12 Autophagy level after recombinant IL-6 treatment. Western blot 
analysis of LC3 protein level pre-treated with different concentrations of IL-6 during 
hypoxia followed by reoxygenation expressed as mean ± SEM, fold relative to H/R 
group; n= at least 3 biological replicates, *p<0.05, ***p<0.0005.  
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5.5.13 Recombinant IL-6 treatment activates JAK-STAT pathway  
 
H/R upregulated STAT3 phosphorylation by 1.66 ± 0.02-fold relative to normoxic 
control (Figure 5.5.13 A). Increasing concentrations of IL-6 treatment during hypoxia 
followed by reoxygenation increased STAT3 phosphorylation in a dose dependent 
manner. In contrast, p38 MAPK phosphorylation increased by 1.54 ± 0.53-fold 
relative to normoxic control after H/R (p=0.90) (Figure 5.5.13 B). However, 
recombinant IL-6 treatment during hypoxia followed by reoxygenation did not 
modulate the phosphorylation level of p38 MAPK. H/R increased GSK-3β 
phosphorylation by 7.24 ± 1.76-fold relative to normoxic control (Figure 5.5.13 C). 
Increasing concentrations of IL-6 treatment during hypoxia followed by 
reoxygenation reduced the phosphorylation level of GSK-3β however, it did not reach 
statistical significance compared to untreated H/R group.  
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Figure 5.5.13 Effect of recombinant IL-6 treatment on cardioprotective 
pathways. Representative immunoblots and statistical data of phosphorylated (A) 
STAT3, (B) GSK-3β and (C) p38 MAPK in lysates from H9C2 cells treated with or 
without increasing concentrations of IL-6 during hypoxia followed by reoxygenation. 
Results are expressed as mean ± SEM, fold relative normoxic control, n= at least 3 
biological replicates.   
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5.5.14 IL-6-induced autophagy activation involves JAK-STAT 
pathway 
 
Pre-treatment of H9C2 cells with Tyrphostin-AG490 (50µM) prior to RIPC-H/R 
significantly reduced STAT3 phosphorylation compared to untreated RIPC-H/R 
group (0.49 ± 0.11-fold relative to untreated RIPC-H/R group, p<0.01) (Figure 5.5.14 
A). Tryphostin-AG490 pre-treatment significantly reduced RIPC-H/R-induced 
increase in LC3 protein level compared to untreated RIPC-H/R group (0.86 ± 0.02-
fold relative to untreated RIPC-H/R group, p<0.01) (Figure 5.5.14 B). As donor cells 
released roughly around 400pg/ml of IL-6 into the preconditioned media (Chapter 4, 
Figure 4.5.9 B) and 500pg/ml recombinant IL-6 treatment upregulated STAT3 
phosphorylation (Figure 5.5.13 A), we treated H9C2 cells with 500pg/ml of 
recombinant IL-6 during the hypoxic period prior to exposing to reoxygenation. 
Tyrphostin AG-490 pre-treatment prior to H/R failed to upregulate LC3 protein level 
despite IL-6 treatment (1.08 ± 0.03 vs. 1.27 ± 0.08-fold relative to normoxic control, 
p<0.05) (Figure 5.5.14 C). 
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Figure 5.5.14 Effect of JAK-STAT pathway inhibition on IL-6-mediated 
autophagy. H9C2 cells exposed to RIPC-H/R with and without JAK-STAT pathway 
inhibitor Tyrphostin AG-490. Representative immunoblots and statistical data of (A) 
phosphorylated STAT3 and (B) LC3 protein are expressed as mean ± SEM, fold 
relative to RIPC-H/R group (C) Representative immunoblot of LC3 protein level in 
H9C2 cells with IL-6 treatment during hypoxia with and without Tyrphostin AG-490 
pre-treatment followed by reoxygenation are expressed as mean ± SEM, fold relative 
to normoxic control; n= at least 3 biological replicates, *p<0.05, **p<0.01 
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5.6 Discussion 
Initially, autophagy was thought to be involved in non-apoptotic programmed cell 
death and was considered a doubled-edged sword in cell survival (550, 551). Matsui 
and colleagues suggested that, autophagy is cardioprotective in the case of myocardial 
ischaemic injury, however autophagy during reperfusion causes cell death (552). 
Previously, direct preconditioning of the myocardium demonstrated to induce 
cardioprotective autophagy (537). This study has explored the role of autophagy in 
RIPC. To extend the potential significance of autophagy in cardioprotection beyond 
RIPC, IL-6 was found to be a possible mediator of autophagy in RIPC.  
 
The current study has demonstrated the increase of autophagy in the myocardial tissue 
after I/R. Interestingly, RIPC prior to I/R further upregulated autophagy correlating 
with smaller infarct size of the rat heart after I/R (Figure 4.5.4 A). Autophagy has 
long been known to occur in the myocardium (553). Consistent with our findings, 
Sala-Mercado demonstrated that,- chloramphenicol succinate conferred 
cardioprotection against I/R injury through upregulating autophagy in swine model 
(554). Yan and colleagues showed that, autophagy was well defined in the viable 
tissue of the chronically ischaemic heart tissue (555). However, Gedik and colleagues 
recently reported that,-RIPC prior to coronary artery bypass grafting failed to activate 
autophagy in left ventricular myocardium despite activated cardioprotective signalling 
cascades (556).  
 
To date little is known whether the cardioprotective effect of RIPC is related with 
autophagy induction. This study demonstrated that, rapamycin treatment significantly 
reduced apoptosis and improved cell viability in both H/R and RIPC-HR group 
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suggesting, autophagy upregulation can mimic cardioprotective effect against H/R 
injury. Cardiomyocytes require large amount of energy, which is generated by 
mitochondria through oxidative phosphorylation. Due to the high demand for ATP, 
cardiomyocytes have the highest volume of mitochondria density among all cell types 
in the body and its ubiquitous presence ensures efficient ATP supply (557). 
Autophagy in the heart ensures that excess and dysfunctional mitochondria are 
removed. Dysfunctional mitochondria often results in activation of both autophagy 
and mitochondrial apoptosis in the same cell (558). In order to prevent cell death, 
cells selectively engulf dysfunctional mitochondria by autophagosomes and remove 
them through autophagy (558). Mitochondrial integrity and the maintenance of ATP 
are crucial for RIPC-induced protection against I/R injury. Purportedly, IPC 
mechanism involves flickering of the mPTP pore causing mild depolarization of the 
mitochondrial membrane to open mitochondrial KATP channel (559).  Transient mPTP 
opening can stimulate mitochondrial ROS release (560). Increased ROS and mPTP 
opening triggers autophagy (561). Rodriquez-Hernandez and colleagues reported that 
autophagy upregulation in Coenzyme Q10 deficient fibroblasts was abolished by 
antioxidant or Cyclosporine A treatment (562). In chapter 4 (Figure 4.5.5), we have 
demonstrated the involvement of ROS in RIPC-induced protection. It is possible that 
moderate ROS production may be linked with cardioprotective autophagy 
upregulation whereas, overwhelming ROS produced by I/R may damage the 
autophagy machinery leading to decreased autophagy compared to RIPC-induced 
autophagy. Depolarization of the mitochondria signals for damaged mitochondria 
removal by autophagy. Selective removal of mitochondria through autophagy leaves 
behind a pool of robust mitochondria that are better fitted to resist ischaemic stress. 
During I/R, depolarized mitochondria would hydrolyse ATP in a futile manner to 
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restore the membrane potential, hence removal of these mitochondria would actually 
result in increased ATP after I/R (538).  
 
In response to ischaemia, endogenous STAT3 level increases, however, ischaemia-
induced increase in STAT3 is not sufficient to protect the mitochondria. Nonetheless, 
overexpressing STAT3 has been shown to protect the mitochondria during ischaemia 
(519). Our results demonstrating the increase in STAT3 phosphorylation after RIPC 
alone is this study and maintenance of mitochondrial membrane potential after H/R 
(Chapter 4) with prior RIPC are consistent with these previous reports. Though I/R 
increased STAT3 phosphorylation, RIPC increased STAT3 phosphorylation beyond 
that by reperfusion per se in our study. Hence, it is possible that, increase in STAT3 
phosphorylation by RIPC primed the heart to enhance the mitochondrial respiration 
during the stress and generated ROS which triggered autophagy. 
  
To further clarify the contribution of the autophagy mechanism in RIPC-induced 
cardioprotection, in this study autophagy was inhibited prior to H/R using 3-MA. The 
present study demonstrated that, 3-MA pre-treatment almost completely suppressed 
the protective effect of RIPC as suggested by significant increase in apoptosis and 
decline in cell viability in RIPC-H/R group. However, 3-MA pre-treatment did not 
have any significant effect on H/R group suggesting that autophagy might not have 
any contributing role in the deleterious effect of H/R injury in this study.   
 
We have demonstrated in Chapter 4 that, RIPC increases p38 MAPK 
phosphorylation. Our results also revealed a positive correlation between p38 MAPK 
phosphorylation and increase in LC3 protein level. Some researchers have implicated 
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p38 MAPK phosphorylation to induce autophagy (563). We previously confirmed 
RIPC-induced reduction of GSK-3β phosphorylation (Chapter 4) and subsequent 
autophagy activation. Activation of GSK-3β stimulates autophagy during ischaemia 
whereas inactivation of GSK-3β inhibits autophagy during reperfusion (564). 
Endogenous GSK-3β is phase dependently regulated and GSK-3β inhibition results in 
mTOR dependent attenuation of detrimental autophagy during prolonged ischaemia 
and protective against reperfusion injury. However, inhibition of mTOR by 
rapamycin reversed this inhibitory effect of GSK-3β inhibition on myocardial 
autophagy and abolished the reperfusion injury suggesting that dephosphorylated state 
of GSK-3β has cardioprotective role during the ischaemic phase through upregulation 
of autophagy.  
 
Previously it was thought that, due to key differences between RIPC and direct pre-
and postconditioning stimuli, RIPC cannot trigger cardiac changes linked with 
anaerobic metabolism such as changes in the ATP content. We found that, RIPC 
alone increased autophagy in the rat heart at 24 h.  However, JAK-STAT pathway 
activation as early as 15 min in our study suggests that, cardioprotective kinase 
pathways activation precedes autophagy machinery activation and RIPC-induced 
autophagy may have signalling role in cardioprotection. Recent study in mice by 
Ghani and colleagues suggested that, RIPC induces cardiac stress and accumulates 
cardiac adenosine prior to subjecting cardiac ischaemia (565). Autophagy can 
function as a damaged organelles removal mechanism as well as regulating diverse 
stress response mechanism (566).  
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We demonstrate that RIPC induces the expression of IL-6 and increases plasma IL-6 
protein level without elevating the expression of the other cytokines including 
leukaemia inhibitory factor (LIF), cardiotrophin, interleukin-11 (IL-11). Dawn and 
colleagues previously highlighted the involvement of IL-6 in late preconditioning-
induced cardioprotection via JAK-STAT pathway (515). Recent studies have 
documented the role of STAT3 in autophagy regulation (567). The current study 
found that, up to 1ng/ml dosage of IL-6 pre-treatment increased LC3 protein level. 
Increasing the IL-6 dosage by 10 times to 10ng/ml did not increase the LC3 protein 
level any further. It is possible that, 1ng/ml of IL-6 pre-treatment increased cellular 
autophagy to its maximum level. Hence increasing the dosage couldn’t increase 
autophagy any further. We also demonstrated that, increasing dosage of IL-6 
increases phosphorylation of STAT3, whereas inhibition of JAK-STAT pathway with 
AG-490 failed to upregulate autophagy despite pre-treatment with IL-6 during the 
hypoxic period. It is likely that, RIPC mediates autophagy through IL-6 / JAK-STAT 
dependent axis.  
 
5.7 Limitations 
This study did not modulate autophagy in vivo to analyse its effect on RIPC-induced 
cardioprotection. As we have showed that, autophagy activates in a time dependent 
manner, further experiments are needed to establish the therapeutic window of 
cardioprotection by autophagy activation in order to clinically translate autophagy in 
therapeutic settings.  
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5.8 Importance 
The key findings of our study are that, autophagy appears to be essential in RIPC- 
mediated cardioprotection and autophagy may prompt the heart resistant to cellular 
stress by activating the cardioprotective signalling mechanisms. In addition, IL-6 may 
function as a circulating mediator of RIPC-induced autophagy. It establishes IL-6 as a 
mediator of autophagy in RIPC and suggests possible mechanistic pathway through 
which IL-6 could be inducing autophagy. 
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Chapter 6.           
Early growth response-1 functions 
as a master regulator of remote 
preconditioning-induced 
cardioprotection 
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6.1 Aims 
6.1.1 To examine the effect of RIPC on Egr-1 mRNA expression in vitro in 
donor cells and in vivo 
6.1.2 To assess the effects of Egr-1 inhibition prior to RIPC on IL-6 mRNA 
expression  
6.1.3 To assess the effects of Egr-1 inhibition prior to RIPC on H/R-induced 
cell viability and apoptosis in vitro  
6.1.4 To assess the effects of Egr-1 inhibition in the hind limb prior to RIPC on 
myocardial infarct size, pro-apoptotic protein expression in the heart and 
preconditioned hind limb tissue  
6.1.5 To evaluate the effects of Egr-1 inhibition in the hind limb prior to RIPC 
on the cardioprotective pathways 
 
6.2 Introduction 
The deleterious process triggered by ischaemia and reperfusion are central to the 
pathological response seen in MI. Increasing evidence has implicated Egr-1 in various 
pathological settings (163). Egr-1 is an immediate and early gene which plays a key 
role in regulating I/R injury in the heart (500-502, 568, 569), gut (570), kidney (571, 
572) and lungs (240). RIPC has been widely studied over the years however, the 
findings are varied and clinical effectiveness of RIPC in protecting the heart from 
reperfusion injury is controversial (Table 1). We have previously demonstrated the 
negative regulation of Egr-1 by RIPC in chapter 4. Progress has been made over the 
years in translating the concept of RIPC in patient care. RIPC has been effectively 
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trialled in patients undergoing cardiac surgery (274, 276, 320, 573, 574). However, 
the underlying processes of gene regulation of RIPC-induced cardioprotection 
remains unclear. Egr-1 is quiescent under basal conditions and is rapidly upregulated 
in response to pathologic stimuli including ischaemia and I/R (502).  
 
6.3 Rationale 
Egr-1 gene is positioned upstream of multiple cytokines. We demonstrated in chapter 
4 that, H9C2 cells secrete IL-6 cytokine in response to RIPC. Previous studies have 
shown that Egr-1 transcriptionally regulates IL-6 (575), TNF–α (576) and IL-1β (240) 
expression. IL-6, TNF–α, IL-1β can act as signalling molecules by activating 
downstream myocardial intracellular signalling cascades leading to cardioprotection 
from myocardial I/R injury (577, 578). In chapter 4 and 5 we demonstrated that, IL-6 
is upregulated by RIPC and that IL-6 can bind to IL-6 receptors and activate the JAK-
STAT pathway. RIPC is known to confer cardioprotection through the JAK-STAT 
pathway (321). As Egr-1 transcriptionally regulates IL-6, we hypothesized that Egr-1 
may play a key role in RIPC-induced cardioprotection. 
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6.4 Methods 
6.4.1 RIPC and H/R in vitro 
RIPC and H/R were performed as described in chapter 2.2 and chapter 2.3 
respectively. Briefly, for RIPC, H9C2 cells grown to 70-80% confluency were 
exposed to 3 cycles of intermittent hypoxia (<2% O2) and reoxygenation. For H/R, 
overnight serum starved H9C2 cells were exposed to 30 min hypoxia followed by 1 h 
reoxygenation in normoxic media. RIPC-H/R group received the preconditioned 
media during the 30 min hypoxia while H/R group was exposed to hypoxic media 
during the hypoxia. Normoxia group received the normoxic media and left in the 
incubator at 37°C for 1.5 h.  
 
6.4.2 In vivo experiments 
6.4.2.1 DNAzyme preparation and delivery 
DNAzyme solution was delivered into the hind-limb muscle tissue at multiple sites 
within the designated RIPC area 3 h prior to RIPC. DNAzyme (ED5 and ED5 Scr) 
injection was prepared in 200l volumes containing sterile water, 60l FuGene6, 1 
mM MgCl2 and 500g DNAzyme (Both ED5 and ED5 Scr). 
 
6.4.2.2 RIPC and surgical intervention 
Male Sprague-Dawley rats (250-300g) were subjected to RIPC by fastening a 
tourniquet around the hind limb for 3 x 5 min alternating cycles of ischaemia and 
reperfusion as previously described in chapter 2.9.4. Surgical intervention was carried 
out as previously described in chapter 2.9.5.  
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Figure 6.4.1 Schematic illustration of the protocol used for rat in vivo. 
 
6.4.3 Western blot 
Protein expression from myocardial tissue extracted from the cardiac apex and H9C2 
cell lysate was measured using western immunoblot as previously described (see 
chapter 2.4). Briefly, protein was extracted from whole cell lysate or tissue lysate and 
run on a western blot to determine the protein expression. Membranes were blocked 
in Tris-buffered saline containing 0.2% Tween-20 (TBST) in 5% skim milk for 1 h 
and then incubated overnight at 4 ºC with the following antibodies – Bax 1:1000 (Cell 
signaling, Massachusetts, USA), phosphorylated STAT3 1:1000 (Cell signaling, 
Massachusetts, USA), STAT3 1:1000 (Cell signaling, Massachusetts, USA), 
phosphorylated p38 MAPK 1:1000  (Cell signaling, Massachusetts, USA), p38 
MAPK 1:1000  (Cell signaling, Massachusetts, USA), phosphorylated GSK3β 1:1000 
(Cell signaling, Massachusetts, USA), GSK3β 1:1000 (Cell signaling, Massachusetts, 
USA). Even protein loading was confirmed by probing for either -actin 1: 1000 
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(Santa Cruz, Texas, USA) for cell lysate or GAPDH 1:1000 (Santa Cruz, Texas, 
USA) for tissue lysate. 
 
 
6.4.4 Real time PCR 
RNA extraction and quantitative real time PCR (qPCR) were performed as previously 
described in chapter 2.5. Briefly, RNA from tissue and H9C2 cells was extracted 
using GenElute Mammalian Total RNA Mini Prep Kit (Sigma, St Louis, MO, USA). 
Tetro cDNA Synthesis Kit was used to synthesize cDNA. RT-PCR was performed to 
assess Egr-1, IL-6, cardiotrophin-1, IL-11, LIF and IL-1 β mRNA expression using 
SensiFast SYBR HI ROX Kit (Bioline, London, UK) in accordance with the 
manufacturer’s instruction. 
 
6.4.5 Flow cytometry 
H9C2 cells were collected and resuspended in binding buffer followed by incubation 
with Annexin V-FITC and Propidium Iodide (PI) (BD Biosciences, New Jersey, 
USA).  The percentage of apoptotic cells was quantified by flow cytometry. 
Mitochondrial membrane potential of H9C2 cells was measured by adding DiLC5 dye 
(Thermofisher Scientific, Massachusetts, USA) to the cells followed by analysing the 
fluorescence intensity of the cells by flow cytometry.  
 
6.4.6 Cell viability imaging 
Cell viability was measured using Live/Dead Cell Imaging Kit (Thermofisher 
Scientific, Massachusetts, USA) as described in chapter 2.7.1. Cell viability was also 
assayed by trypan blue exclusion method as described in chapter 2.7.2. An equal 
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volume of 0.4% solution of trypan blue dye (Sigma-Aldrich, Missouri, USA) and 
suspended H9C2 cells in D-PBS were mixed and loaded onto a haemocytometer. The 
percentage of viable cells was determined by recording the number of cells that 
excluded 0.4% solution trypan blue dye. The cells were photographed using an 
Olympus SC35 camera attached to an Olympus CK40 microscope. 
 
6.4.7 ELISA 
ELISA kit was used to determine the concentration of IL-6 (Rat IL-6 Quantikine 
ELISA Kit, R&D Systems, Minneapolis, USA) protein. For circulating protein levels, 
blood from rats collected in Lithium-Heparin tube spun at 2,500 rpm (950g) for 5 min 
and plasma was collected. For detection of plasma IL-6 50 l of rat plasma was used, 
and protein estimated as per the manufacturer’s instruction. 
 
6.4.8 Statistical analysis 
Normalised results are expressed as mean ± standard error of the mean (SEM).  
Statistical analysis between groups was performed by one-way ANOVA, followed by 
post hoc comparison using Tukey’s multiple comparison tests using GRAPHPAD 
software (GraphPad software version 7.02; GraphPad Inc, San Diego, CA, USA). 
Comparison between two groups was performed using two-tailed Student’s T-test.  p 
≤ 0.05 was considered to be significant.  
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6.5 Results   
6.5.1 RIPC increases Egr-1 mRNA expression in vitro and in vivo 
 
RIPC upregulated Egr-1 mRNA expression in donor H9C2 cells by 1.52 ± 0.11-fold 
relative to normoxic control (p<0.05, Figure 6.5.1 A). A similar finding was observed 
in vivo. At 15 min post RIPC, Egr-1 mRNA expression in rat hind limb tissue 
increased by 1.42 ± 0.10-fold relative to sham control (p<0.05, Figure 6.5.1 B). 
 
 
 
 
Figure 6.5.1  Effect of RIPC on Egr-1 expression in vitro and in vivo. Egr-1 
mRNA expression in (A) H9C2 cells (n= at least 3 biological replicates) and (B) Rat 
(n=4) hind limb tissue at 15 min post RIPC expressed as mean ± SEM; *p< 0.05. 
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6.5.2 Egr-1 inhibition prior to RIPC abolishes preconditioning-
induced upregulation of cardioprotective IL-6 in H9C2 cells 
 
Egr-1 mRNA expression after RIPC in the donor H9C2 cells did not increase when 
pre-treated with ED5 (1.10 ± 0.07-fold relative to normoxic control) (Figure 6.5.2 A).      
Egr-1 mRNA expression in the ED5 Scr group after RIPC was significantly higher 
compared to both normoxic control group (1.52 ± 0.10-fold relative to normoxic 
control, p<0.0005) and ED5 RIPC group (1.52 ± 0.10 vs. 1.10 ± 0.07-fold relative to 
normoxic control, p<0.01).  
ED5 treatment in H9C2 cells prior to RIPC significantly reduced IL-6 mRNA 
expression levels compared to ED5 Scr treated group (Figure 6.5.2 B). In the control 
group, there were no significant differences in IL-6 mRNA expression between ED5 
RIPC and ED5 Scr RIPC group. However, IL-6 mRNA expression was significantly 
higher in ED5 Scr RIPC group 0.5 h post RIPC compared to ED5 RIPC group at the 
same time point (3.72 ± 0.06 vs. 2.60 ± 0.10-fold relative to ED5 control value, 
p<0.05). IL-6 mRNA expression in the ED5 Scr RIPC group reached its maximum 
expression level 1 h post RIPC (5.82 ± 0.10-fold relative to ED5 RIPC control value, 
p<0.01) while decreased at 2 h post RIPC (3.03 ± 0.07-fold relative to ED5 control 
value). In contrast, IL6 mRNA expression in the ED5 RIPC group was suppressed 
even further at 2 h post RIPC (0.63 ± 0.02-fold relative to ED5 RIPC control value, 
p<0.0005).  
 
Furthermore, increasing concentrations of recombinant IL-6 treatment on H9C2 cells 
during hypoxia significantly reduced pro-apoptotic Bax protein expression in a dose 
dependent manner (p<0.05) (Figure 6.4.2 C).  
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Figure 6.5.2 IL-6 expression in H9C2 cells after RIPC with ED5 treated donor 
cells. ED5 treated H9C2 mRNA expression of (A) Egr-1 post RIPC and (B) IL-6 post 
RIPC assessed at different time points. (C) Representative western blot demonstrating 
Bax protein expression in H9C2 cells subjected to H/R with and without increasing 
concentrations of recombinant IL-6 treatment. Results expressed as mean ± SEM; n= 
at least 3 biological replicates, *p<0.05, **p<0.01, ***p<0.0005. 
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6.5.3 Egr-1 inhibition prior to RIPC abolishes RIPC-induced 
protection against cell death 
 
H/R injury to H9C2 cells significantly reduced the cell viability from 74.27 ± 3.79% 
to 34.93 ± 3.68% (p<0.0001. This effect was abolished by exposing the cells to RIPC 
media prior to H/R 78.43 ± 2.18% (p<0.0001) (Figure 6.5.3). No significant 
difference was observed between normoxic control and RIPC-H/R group. ED5 
treatment of donor cells prior to RIPC (63.36 ± 3.07%) significantly reduced cell 
viability compared to no pre-treatment (RIPC H/R) group (78.43 ± 2.18%, p<0.05) or 
pre-treatment with ED5 Scr (91.18 ± 0.92%, p<0.005). However, no significant 
difference was observed between RIPC H/R group and ED5 Scr RIPC H/R group 
(78.43 ± 2.18% vs. 91.18 ± 0.92%).  
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Figure 6.5.3 Cell viability in H9C2 recipient cells after RIPC with ED5 treated 
donor cells. H9C2 cells were stained with calcein AM (green, live cells) and 
Ethidium homodimer-1 (red, dead cells). Scale bar represents 1000 μm. Quantitative 
analysis percentage of live/dead cells expressed as mean ± SEM; n= at least 3 
biological replicates, *p<0.05, ***p<0.0005, ****p<0.0001. 
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6.5.4 Egr-1 downregulation prior to RIPC abolishes preconditioning-
induced protection against H/R injury related apoptosis in H9C2 
cells 
 
H/R injury elevated the apoptotic cell death to 5.17  0.90% compared to normoxic 
control at 1.43  0.36% (p<0.005) (Figure 6.5.4 A). In contrast, RIPC prior to H/R 
ameliorated apoptotic cell death to 1.98  0.18% (p<0.01 vs. H/R). H9C2 cells 
exposed to preconditioned media from ED5 treated donor cells prior to H/R lost 
RIPC-conferred protection against H/R-related apoptosis. However, H9C2 cells 
exposed to preconditioned media from ED5 Scr treated donor cells prior to H/R 
conferred protection by decreasing the apoptosis level to 2.23  0.34% (p<0.05 vs. 
ED5 RIPC H/R group). There was no significant difference between RIPC-H/R group 
and ED5 Scr RIPC H/R group. 
 
In line with these findings, mitochondrial membrane potential was lost in H/R group, 
whereas RIPC-H/R group successfully maintained mitochondrial membrane potential 
(0.56  0.06% vs. 1.03  0.09%, fold relative to normoxic control, p<0.01) (Figure 
6.5.4 B). Mitochondrial membrane potential was lost in ED5 RIPC H/R group despite 
RIPC prior to H/R, however, ED5 Scr RIPC H/R group successfully maintained 
mitochondrial membrane potential (0.58  0.11% vs. 1.0  0.14%-fold relative to 
normoxic control, p<0.05).  
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Figure 6.5.4 Extent of apoptosis and mitochondrial membrane potential in H9C2 
cells after RIPC with ED5 treated donor cells. (A) Cell apoptosis assessed by 
Annexin V-FITC and propidium Iodide (PI) double staining and FACS. Quantitative 
analysis of percentage of apoptotic cells (Annexin-V+/PI+) (B) Mitochondrial 
membrane potential at 1 h post reoxygenation assessed by DiLC5 staining and FACS 
represented as the percentage geo mean fluorescence ± SEM, fold relative to 
normoxic control; n= at least 3 biological replicates, *p<0.05, **p<0.01, ***p<0.005.  
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6.5.5 Egr-1 downregulation prior to RIPC abolishes RIPC-induced 
activation of JAK-STAT pathway in H9C2 cells  
 
ED5 Scr treatment prior to RIPC followed by H/R increased STAT3 phosphorylation 
by 1.66 ± 0.15-fold compared to ED5 treatment prior to H/R (p<0.05) (Figure 6.5.5).  
 
 
 
Figure 6.5.5 STAT3 phosphorylation after RIPC with ED5 treated donor cells. 
Representative immunoblots and statistical data of phosphorylated STAT3 normalised 
to total STAT3. Data presented as mean ± SEM, fold relative to ED5 RIPC H/R 
group; n= at least 3 biological replicates, *p<0.05.  
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6.5.6 Egr-1 down regulation prior to RIPC in the hind limb abolishes 
RIPC-induced cardioprotection 
 
At 24 h, I/R injury in rats caused an infarct size of 52.96 ± 1.48% relative to the area 
at risk (AAR) (Figure 6.5.6 A). This was significantly reduced to an infarct size of 
36.66 ± 3.87% (p<0.01 vs. I/R) in rats exposed to hind limb RIPC prior to I/R. Pre-
treatment with ED5 in the hind limb 3h prior to RIPC significantly abolished this 
cardioprotective effect of RIPC, producing an infarct size of 65.90 ± 2.38% at 24 h 
post I/R injury (p<0.0001 vs. RIPC I/R). ED5 Scr treated group did not show any 
significant difference in MI size compared to RIPC I/R group (41.00 ± 2.83% vs. 
36.66 ± 3.87%, p=0.68). A significant difference in MI size was observed between 
ED5 RIPC and ED5 Scr RIPC groups (65.90 ± 2.38% vs. 41.00 ± 2.83%, p<0.0001). 
There was no significant difference in the area at risk (AAR) between groups (Figure 
6.5.6 B). 
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Figure 6.5.6 MI size in rats with Egr-1 inhibition in hind limb prior to RIPC. (A) 
Evan’s blue and TTC staining as a ratio of infarct size and AAR at 24 h post I/R. (B) 
Cumulative data of AAR/ left ventricle (LV) expressed as percentage of mean ± 
SEM. Results are presented as percentage of mean ± SEM; *p<0.05, **p<0.01, 
***p<0.005, ****p<0.0001.  
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6.5.7 Egr-1 expression is essential for RIPC-induced protection 
against myocardial apoptosis in rats 
 
At 24 h following I/R injury in the rat myocardium, Bax protein expression increased 
by 1.49 ± 0.22-fold of sham control (Figure 6.5.7). RIPC at the rat hind limb prior to 
I/R markedly attenuated I/R-induced Bax upregulation in rat myocardium (0.71 ± 
0.19-fold relative to sham control, p<0.05). However, ED5 treatment in the rat hind 
limb prior to RIPC significantly increased Bax expression in the heart compared to 
both RIPC I/R (1.96 ± 0.51 vs. 0.71 ± 0.19, p<0.01) and ED5 Scr RIPC group (1.96 ± 
0.51 vs. 0.91 ± 0.08-fold relative to sham control, p<0.05). 
  
Figure 6.5.7 Apoptotic protein markers within myocardial tissue following I/R 
injury. Representative immunoblot and statistical data of Bax protein levels in rats 
(n=5) subjected to I/R with and without prior RIPC including two groups treated with 
ED5 and ED5 Scr in the hind limb prior to RIPC. Data expressed as mean ± SEM; 
*p<0.05, **p<0.01.  
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6.5.8 Egr-1 inhibition in hind limb prior to RIPC alters 
preconditioning-induced cytokine expression in hind limb muscle  
 
ED5 treatment in the hind limb prior to RIPC restricted the localized IL-6 mRNA 
expression to almost sham group IL-6 mRNA expression level (0.95 ± 0.20-fold 
relative to sham group) (Figure 6.5.8 A). However, ED5 Scr RIPC group showed six-
fold increase in IL-6 mRNA expression compared to sham group (6.08 ± 1.40-fold 
relative to sham group) (p<0.05) (Figure 6.5.8 A). ED5 and ED5 Scr treatment in the 
hind limb 3 h prior to RIPC did not modulate the expression of other critical cytokines 
in cardiovascular pathology including cardiotrophin-1 (1.02 ± 0.19 and 0.82 ± 0.10-
fold relative to sham group respectively)  (Figure 6.5.8.B), IL-11 (0.75 ± 0.19 and 
1.03 ± 0.22-fold relative to sham group respectively) (Figure 6.5.8.C), LIF (0.88  ±  
0.30 and 0.76 ± 0.29-fold relative to sham group respectively) (Figure 6.5.8.D), IL-1β              
(1.47 ± 0.65 and 1.27 ± 0.61-fold relative to sham group respectively) (Figure 
6.5.8.E) in the preconditioned hind limb muscle.  
 
` 
 
 
Page | 189  
 
 
 
Figure 6.5.8 Cytokine expression after RIPC in ED5 treated hind limb tissue. 
Preconditioned hind limb muscle tissue assessed for (A) IL-6, (B) Cardiotrophin-1, 
(C) IL-11, (D) LIF, (E) IL-1β mRNA expression at 15 min post RIPC by qPCR. 
Results expressed as mean ± SEM; n=9 rats per group, *p<0.05.  
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6.5.9 Egr-1 downregulation in the hind limb prior to RIPC decreases 
plasma IL-6 level 
 
In rats, ED5 RIPC and ED5 Scr RIPC group showed significantly higher level of IL-6 
in blood plasma 15 min post RIPC compared to sham group [(118.30 ± 4.30 pg/ml vs. 
100.80 ± 2.06 pg/ml, p<0.01) and (130.50 ± 1.29 pg/ml vs. 100.80 ± 2.06 pg/ml, 
p<0.0001) respectively] (Figure 6.5.9). However, ED5 treatment in the hind limb 
prior to RIPC significantly lowered plasma IL-6 level compared to ED5 Scr RIPC 
group (118.30 ± 4.30 pg/ml vs. 130.50 ± 1.29 pg/ml, p<0.05). 
 
 
 
Figure 6.5.9 Plasma IL-6 level after RIPC. Rats (n=6) were treated with 
DNAzymes prior to RIPC. Plasma IL-6 level at 15 min post RIPC expressed as mean 
± SEM, *p<0.05, **p<0.01, ****p<0.0001. 
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6.5.10 Egr-1 expression in the hind limb is essential for RIPC-
induced activation of the cardioprotective pathways in rats 
I/R increased the phosphorylation of STAT3 protein in the heart tissue compared to 
the sham group (1.85 ± 0.10-fold relative to sham group), however RIPC prior to I/R 
significantly upregulated phosphorylated levels of STAT3 compared to I/R alone 
(1.85 ± 0.10 vs. 3.18 ± 0.05-fold relative to sham group, p<0.01) (Figure 6.5.10 A). 
ED5 treatment in the hind limb prior to RIPC significantly reduced phosphorylation 
level of STAT3 compared to both RIPC I/R (1.66 ± 0.05 vs. 3.18 ± 0.05-fold relative 
to sham group, p<0.01) and ED5 Scr group (1.66 ± 0.05 vs. 2.86 ± 0.07-fold relative 
to sham group, p<0.05). 
In contrast, I/R significantly phosphorylated GSK-3β compared to sham group (2.19 ± 
0.13-fold relative to sham group, p<0.05), which was reversed to almost basal level 
by RIPC prior to I/R (0.93 ± 0.06-fold relative to sham group, p<0.05) (Figure 6.5.10 
B). ED5 treatment prior to RIPC did not have any significant effect on GSK-3β 
phosphorylation level compared to RIPC I/R group and the phosphorylation level of 
GSK-3β in both ED5 and ED5 Scr group remained to almost basal level (1.07 ± 0.07 
and 1.33 ± 0.11-fold relative to sham group respectively). 
I/R did not increase p38 MAPK phosphorylation compared to sham group (1.08 ± 
0.05-fold relative to sham group, p=0.99) (Figure 6.5.10 C). Phosphorylated p38 
MAPK level with RIPC prior to I/R was similar to those seen in I/R group (1.45 ± 
0.13 vs. 1.08 ± 0.05-fold relative to sham group, p=0.45). Both ED5 and ED5 Scr pre-
treatment prior to RIPC did not have any effect on p38 MAPK phosphorylation 
compared to RIPC I/R group [(0.94 ± 0.08 vs. 1.45 ± 0.13-fold relative to sham 
group, p=0.25) and (1.69 ± 0.14 vs. 1.45 ± 0.13 -fold relative to sham group, p=0.99) 
respectively].  
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Figure 6.5.10 Changes in cardioprotective pathways after RIPC in ED5 treated 
hind limb. Representative immunoblots and statistical data of phosphorylated and 
total (A) STAT3, (B) GSK-3β, (C) p38 MAPK in heart tissue lysates from rats (n=7 
for STAT3 and GSK-3β, n=5 for p38 MAPK) subjected to I/R with and without prior 
RIPC. Two groups of rats were pre-treated with ED5 and ED5 Scr in the hind limb 
tissue 3 h prior to RIPC. Data represented as mean ± SEM; *p<0.05, **p<0.01, 
***p<0.0005, ****p<0.0001. 
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6.6 Discussion 
Cellular response to ischaemia has largely been defined by studies focusing on 
hypoxia-inducible factor (HIF)-1 (579-581). However, Yan and colleagues reported 
the role of Egr-1 in the regulation of ischaemic stress related gene pool (240). They 
reported fibrin deposition in lung vasculature due to production of procoagulant tissue 
factor (TF) (240), which is induced by Egr-1 in response to ischaemia (218, 582). 
Egr-1 contains three zinc fingers of Cys2-His2 subtype that preferentially binds to GC-
rich elements (218). Our group has previously studied the efficacy of DNAzyme in 
silencing Egr-1 in I/R injury studies in rat (500, 501) and pig (502) model.  
 
The transcription factor Egr-1 is widely recognised for its crucial role in the injury 
response of various pathological settings such as myocardial I/R injury (500-502), 
vascular restenosis (222), and lung I/R injury (240). A previously unidentified role of 
Egr-1 in RIPC-induced cardioprotection has been demonstrated in the current studies. 
Egr-1 knockdown in the hind limb of rats prior to RIPC led to a loss of 
cardioprotection from subsequent I/R injury as indicated by increased apoptosis, loss 
of mitochondrial membrane potential in vitro as well as increased Bax protein 
expression in the heart tissue at 24 h post reperfusion. This study suggest that Egr-1 
regulates the RIPC-induced signal from the donor organ site to the heart (target 
organ).  
 
In this study, ED5 treatment prior to RIPC reduced the phosphorylation level of 
STAT3. RIPC prior to I/R as well as ED5 and ED5 Scr pre-treatment prior to RIPC 
did not have any effect on p38 MAPK phosphorylation. JAK-STAT (321), p38 MAPK 
(321), GSK-3β (583) have been previously reported to confer RIPC-mediated 
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cardioprotection. The role of p38 MAPK in cardioprotection has been controversial. 
p38 MAPK inhibition with specific inhibitors has been demonstrated to abolish the 
preconditioning-induced cardioprotection in murine and porcine models (511, 512). 
GSK-3β is activated during the ischaemic phase by dephosphorylating at serine 9 
(Ser9) where as it is deactivated by phosphorylating at Ser9 during reperfusion. Ser9 
phosphorylation negatively regulates the activity of GSK-3β (503). In contrast to the 
findings of Hu and colleagues (583), we did not observe any significant change in 
GSK-3β phosphorylation level after ED5 treatment prior to RIPC suggesting that, 
GSK-3β is not involved in Egr-1 regulated RIPC signalling mechanism.  
 
The current study found that, IL 6-STAT3-axis is involved in Egr-1 regulated RIPC-
induced myocardium protection. IL-6 binds to IL-6 receptor (IL-6R) and 
homodimerizes gp130 (584). Two homodimerized gp130 molecules lead to 
phosphorylation gp130 and STAT3. IL-6 or IL-6R alone cannot activate gp130. However, 
soluble IL-6R (sIL-6R) can bind to IL-6 and form complex that can activate IL-6 
regulated signalling pathways in cells that lack cell membrane bound IL-6R but express 
gp130 (584). Binding of IL-6 to sIL-6R prolongs the plasma half-life of IL-6 (585). 
McGinnis and colleagues previously showed that, exercise preconditioning increases 
serum sIL-6R level (528). Cardiomyocytes express both gp130 (586) and IL-6R (528). 
IL-6/IL-6R complex can inhibit myocardial apoptosis and reduce MI size (587). We have 
previously demonstrated that RIPC confers cardioprotection through JAK-STAT 
pathway (321). MI also elevates IL-6 in both plasma and serum. AMI and heart 
failure patients with high serum IL-6 levels have been reported to have poor prognosis 
(588, 589). Though transient activation of STAT3 is cardioprotective (590, 591), 
Hilfiker-Kleiner and colleagues reported that, sustained activation of gp130-STAT3 is 
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associated with increased inflammation which causes adverse cardiac remodelling, 
high rupture incidents and heart failure (592). Kobara and colleagues demonstrated in 
mice MI model that, anti-IL-6R antibody reduced leukocyte and macrophage 
infiltration, attenuated MMP activation and improved LV function (593). They 
suggested a possible link between IL-6R activation and vicious circle of post MI 
inflammatory network.  However, in our study we measured plasma IL-6 15 min after 
RIPC and the rat heart was not exposed to any direct cardiac stress. Hence, the 
observed elevation of IL-6 is directly related to RIPC. Another possibility is that IL-
6/IL-6R complex may act on cell types such as leukocytes and macrophages to 
minimize the extent of I/R injury through reducing overwhelming inflammatory 
response (594, 595). Our findings are in line with the findings reported by Matsushita 
and colleagues (587). These authors reported that, a combination therapy of IL-6 and 
sIL-6R inhibited cardiomyocyte apoptosis and reduced infarct size. We demonstrated 
in chapter 5 that RIPC alone can elevate plasma IL-6 level and phosphorylate STAT3 
as early as 15 min post RIPC. IL-6 can phosphorylate STAT3. Hence, the former 
mechanism is likely to be more reasonable for our study. Although it still needs to be 
confirmed that, IL-6 is directly released by the ischaemic preconditioned skeletal tissue. 
Recently McGinnis and colleagues demonstrated that, exercise preconditioned skeletal 
tissue releases IL-6 into the blood, eliciting cardioprotection against MI (528).  
 
To translate our bench study to bedside, some important issues need to be addressed 
first. RIPC has two windows of protection: first or early window of protection opens 
within minutes of RIPC-stimulus and remains open for 4-5 h, whereas second window 
of protection opens at a later time point after RIPC stimulus and remains open for 
couple of days. Our study clearly indicates that, Egr-1 regulates the early window of 
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preconditioning-induced cardioprotection, however further investigation is required to 
define the role of Egr-1 regulation in second window of protection. It is essential to 
identify the optimum level of circulating IL-6 to propel the anti-inflammatory and 
anti-apoptotic effect of IL-6 to achieve cardioprotection. It is also important to 
address the species differences prior to applying the findings of our study into clinical 
settings. Taken together, our studies demonstrate for the first time that, Egr-1 has a 
signalling role in RIPC-induced cardioprotection. 
 
 
6.7 Limitations 
DNAzyme transfection in cardiomyocytes and rat hind limb tissue was not verified in 
this study but inferred from the selective downregulation of RIPC-induced Egr-1 
mRNA stimulation by ED5 DNAzyme. However, our group has previously validated 
the efficacy of DNAzyme transfection and the protocol used in this study to 
downregulate Egr-1 in rat model (500).   The method used in this study to deliver 
DNAzyme in the hind limb tissue is not consistent or reliable as ‘geographic miss’ or 
patchy uptake is possible.  
 
ED5 was delivered 3 h prior to RIPC and I/R followed by evaluation at 24 h post I/R.  
This method elicited an effect in vivo however, in vitro cardiomyocytes were 
transfected for 18 h prior to RIPC and it elicited an effect in vitro. It is likely that the 
DNAzyme transfects cells after 3 h to produce an effect. Earlier time points were not 
examined in this study.  
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6.8 Importance 
Despite the limitations discussed, these studies provide a proof of principle support 
for Egr-1 in the mechanism of RIPC and suggest IL-6 as a circulating mediator of 
RIPC.  
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Chapter 7.          
Future Direction 
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The work generated in this thesis has provided interesting and novel findings. 
However, complete understanding of the concept of RIPC in cardioprotection requires 
further investigation. Our observations have highlighted the relative contribution of 
the apoptotic pathways in MI settings.  
 
We suggest that, simultaneous blocking both pro-apoptotic and necroptotic cell death 
pathways may confer maximal cellular protection from myocardial tissue damage. 
However, we have carried out our study in rat model. Though there are similarities 
between rat model and human, it possesses distinctive and crucial differences. In 
particular, rat AMI lacks atheroma and thrombus which characterizes human MI. It is 
possible that these elements could confound the observations.  It is important to 
address this difference prior estimating the effect of the anti-pro-apoptotic and 
necroptotic therapy to limit MI damage.  
 
One of the limitations of RIPC as a therapeutic strategy for MI patients is the timing 
of its application. RIPC needs to be applied prior I/R injury, which makes it less 
feasible in the treatment of AMI whereas can be applied to other settings such as 
coronary artery bypass grafting (CABG) or other forms of elective cardiac surgeries. 
A better understanding of the underlying molecular process and identifying the 
circulating mediators of RIPC may aid in translating the concept of RIPC in patient 
care.  
 
This dissertation has defined a cardioprotective role of RIPC-induced autophagy. 
Further experiments are needed to establish the therapeutic window of 
cardioprotection by autophagy activation in order to clinically translate autophagy in 
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therapeutic settings. It is crucial to understand the ‘double edged sword’ effect of 
autophagy in order to achieve the optimum level of autophagy to protect the heart 
from reperfusion injury.  
 
The current studies have examined the acute effect of Egr-1 regulation in RIPC-
induced cardioprotection. A more detailed evaluation of Egr-1 regulation on longer 
term outcomes of MI such as heart failure, ventricular remodelling is essential. In this 
dissertation, only first window of preconditioning was evaluated to assess the efficacy 
of RIPC to protect the myocardial tissue from I/R injury. It is essential to assess the 
effect of Egr-1 regulation on the second window of preconditioning-mediated 
cardioprotection.  We also suggested that, IL-6 might be a potential mediator of 
RIPC-induced cardioprotection. It is important to use IL-6-/- mice to confirm the 
speculation. Dose titration will be necessary to define the optimum level of IL-6 to 
propel the anti-inflammatory and anti-apoptotic effect of IL-6 to achieve 
cardioprotection. 
 
 
As there are considerable differences between in vitro and animal model findings with 
the human model findings, it is important to translate the findings of our study in 
human. It is possible to use blood pressure measuring cuff to precondition (induce 
transient upper limb ischaemia) prior to CABG and collect blood samples and cardiac 
biopsy samples to study the effect of RIPC in human. As we have demonstrated 
through Egr-1 inhibition in rat model that Egr-1 functions as a regulator of RIPC, 
metabolomics study will help us to identify the metabolomic changes in the target 
organ which can lead to new therapeutic options to treat MI patients.  
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Diabetes is a risk factor for cardiovascular diseases. Mortality rate in diabetic patients 
after AMI is double compared to non-diabetic patients (596) (597). RIPC related 
studies to protect the heart from AMI have been performed on healthy animals. 
However, diabetic patients have an increased risk of ischaemic and cardiac events 
(598, 599). Diabetes influences oxidative stress, inflammation and endothelial 
dysfunction, all of which contribute to the exacerbation of I/R injury (600). Studies 
conducted in diabetic animal models showed varied results. Some studies reported 
increased (601, 602), decreased (603, 604), or similar (605) infarct size after I/R 
injury in diabetic model compared to non-diabetic animals. Some studies 
demonstrated a cardioprotective effect of preconditioning in diabetic animal (606) 
while others did not observe any cardioprotective effect in a similar model (607). 
Experimental design, animal model as well as the duration and the number of 
ischaemic stress all can contribute to this variation. The signalling pathways and 
mechanisms of cardioprotective preconditioning in diabetic model has not been fully 
studied. A better understanding of molecular mechanism of RIPC in diabetes is 
imperative to develop a therapeutic strategy which can be translated in patient care.   
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Chapter 8.          
Concluding remarks 
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This thesis elucidates the I/R injury mediated apoptotic pathways as well as the role 
of autophagy in RIPC-induced cardioprotection. This dissertation also evaluates the 
role of immediate-early master regulator transcription factor Egr-1 in RIPC signalling 
mechanism. 
 
Intrinsic and extrinsic pathway of apoptosis have been previously studied in a variety 
of pathological settings including vascular injury, cardiac hypertrophy, cancer, 
rheumatic diseases but its role in myocardial I/R injury has not been widely studied. 
Caspase 8 inhibitor, Z-IETD-FMK are used to explore the relative role of the 
apoptotic pathways and their cross-talk in this context.  
 
The present studies define a key role for autophagy in RIPC conferred 
cardioprotection as evidenced by abolition of RIPC-induced cardioprotection from I/R 
injury following autophagy inhibition. Furthermore, the signalling mechanism 
through which cardioprotective autophagy is stimulated are explored and found to 
include IL-6/JAK-STAT axis.  
 
In addition, effect of RIPC on MI has been explored. In particular, RIPC results in a 
decrease in myocardial pro-apoptotic proteins and an attenuation of pro-inflammatory 
mediator VCAM-1 in association with an increase in anti-apoptotic proteins in the rat 
at 24 h post reperfusion. RIPC decreases overall apoptosis and maintain 
mitochondrial membrane potential in vitro. Furthermore, RIPC in rat modifies 
cytokine expression in the preconditioned hind limb tissue and increases plasma IL-6 
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level. As IL-6 is transcriptionally regulated by Egr-1, DNAzymes selectively 
targeting Egr-1 are used to explore the relationship between Egr-1 regulation in the 
hind limb and RIPC. Egr-1 inhibition in the hind limb attenuates MI size limiting 
effect of RIPC and profoundly reduces IL-6 cytokine expression in the preconditioned 
hind limb tissue in association with reduction in plasma IL-6.  Moreover, Egr-1 
regulation prior RIPC increases apoptosis and fail to maintain mitochondrial 
membrane potential in vitro. Taken together, these findings suggest that Egr-1 acts as 
a master regulator of RIPC-induced cardioprotection and IL-6 may be the circulating 
mediator of RIPC-induced protection.  
These studies of molecular mechanism and gene modulation set the stage for future 
research and a number of areas have been identified which require detailed insight.  
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